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Malaria is the most important parasitic disease affecting man, and continues to threaten public health in 
developing countries where the disease is endemic. Within the genus Plasmodium, falciparum is responsible 
for nearly all deaths from malaria worldwide. Two symptoms that are indicative of severe disease and a high 
risk of mortality are hypoglycaemia (HG - plasma glucose below 2.2 mM) and hyperlactataemia (HL - 
plasma lactate in excess of 5.5 mM). Though multiple causes of these metabolic comorbidities have been 
identified qualitatively, there exists a dearth of quantitative evidence that can give a reliable approximation 
of which aetiological factors have the highest relative contribution to the appearance of these symptoms. 
Such a quantitative approach would not only improve our understanding of how malaria progresses to severe 
disease, but also indicate which mechanisms of host-parasite interaction would be the most amenable to 
targeting by novel antimalarial chemotherapeutics, since new anti-malarial drugs are required to combat the 
threat of acquired resistance.  
One tool that has proved useful in the process of identifying novel drug targets is mathematical modelling. In 
this study we present a whole-body model of host and parasite metabolism that can provide a quantitative 
assessment of glucose and lactate dynamics in both the healthy and infected state. This model, termed 
meyer1, combines independently published models describing separate aspects of host and parasite 
metabolism to yield an in silico platform that is subsequently used to investigate the relative quantitative 
contribution of the putative causes of HG/HL in the infected state.  
Results from model simulations and subsequent metabolic control analysis (MCA) indicated that 
heterogenous parasite sequestration within the microvasculature of organs important in mediating whole-
body glucose and lactate homeostasis has the greatest quantitative impact on the appearance of HG/HL; this 
finding agrees with qualitative statements previously made in literature. In addition, MCA identified several 
key enzymatic components of parasite and infected erythrocyte glucose metabolism that, if targeted, would 
yield the greatest contribution in preventing the appearance of hypoglycaemia in severe disease. These 
include parasite derived new permeability pathways (NPPs), the parasite glucose transporter (PHT1), and 
parasite hexokinase and phosphofructokinase.  
In addition to these findings, the final meyer1 model also provides a platform amenable to further 
development as more clinical data for model parametrisation becomes available.  New experimental studies 
would also assist in providing the data required to supersede the current phenomenological expressions with 
mechanism-based implementations representing host-parasite interactions mediating microvascular 
occlusion. This will ultimately lead to more precise identification of novel drug targets at the molecular level 
that can inhibit the process of parasite sequestration and subsequently help prevent the appearance of HG/HL 
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Chapter 1: Introduction 
1.1 Introduction 
Malaria is the most prominent parasitic disease that afflicts humans (1). Malaria is an umbrella term that 
refers to disease caused by protozoans of the genus Plasmodia. Belonging to the phylum Apicomplexa, these 
sporozoan parasites are differentiated from other eukaryotes by the possession of an apicoplast, a vestigial 
plastid that bears evolutionary homology to the chloroplasts found in plant and algal cells. Malaria parasites 
infect the red blood cells of mammals, birds, and reptiles, and are transmitted between animals via the bites 
of mosquitos. Within the genus Plasmodium, four species are known to infect humans preferentially: P. 
falciparum, P. vivax, P. ovale, and P. malariae. Errant primate malarias, such as those caused by the simian 
parasite P. knowlesi, can constitute a substantial portion of infections in certain regions of South-east Asia 
(2). Of the four species normally parasitic in humans, P. falciparum ranks highest in terms of both lethality 
and disease severity, responsible for nearly all deaths from malaria while constituting roughly only half of all 
malaria cases worldwide (3). This high mortality rate is especially prominent in Africa, the region where P. 
falciparum is most widespread (4).  
The disease itself is typically characterised by non-specific symptoms resembling influenza, with periodic 
febrile paroxysms that accompany the renewal of the parasite’s lifecycle within the infected host. Over time, 
the infection is usually controlled by the host’s immune system and eventually eliminated (4). However, a 
fraction of cases do not resolve without treatment, and proceed to severe infection. Progression to severe 
malaria is particularly likely in young children and those with compromised immune systems. In regions of 
Africa where the disease is endemic, almost twenty-five percent of childhood mortality has been attributed to 
severe malaria (4). 
Until the disease is completely eradicated there will always be a need for novel antimalarial drugs that can 
slow or halt the progression of the disease. One of the most notable advancements in the 20th century with 
regards to malaria research was the formal discovery of artemisinin, achieved through Mao Zedong’s 
directive to have several institutions and hundreds of researchers focus their efforts on finding new 
medicines to combat this disease (5). Artemisinin, derived from the Asian plant Artemisia annua, has since 
been incorporated into artemisinin combinations therapies (ACTs), a highly effective treatment regimen that 
has seen widespread deployment. The search for new drugs will continue in order to address the threat of 
acquired resistance, halt the progression of severe disease and prevent mortality, and eliminate parasite 
gametocytes to prevent further transmission (4).   
Systems biology has emerged as an important tool in the search for new anti-malarial drugs, aiding the 




approach utilised by metabolomics and metabolic modelling grants insights that would otherwise have been 
prevented by practical or ethical constraints. To date, studies utilising this methodology have yielded 
identification of the optimal drug dosing intervals to achieve full parasite clearance (6), determination of 
whether cure rate was improved with use of split drug dosage (7, 8), and a comparison of the relative degrees 
of resistance induced by two different dosages of mefloquine (9). Another recent study has extended the 
scope of the modelled organism to include the host, giving a means of predicting the changes in glucose and 
amino acid metabolism in the human host (10). Use of such theoretical modelling has improved our 
knowledge of a disease that, despite more than a hundred years of research, still remains incompletely 
understood (11). 
One aspect of the disease that continues to evade full understanding is the appearance of hypoglycaemia and 
hyperlactataemia  (HG/HL) in patients with severe malaria (12). Both of these symptoms are indicative of 
severe disease and are associated with a high risk of mortality (1, 13). Scientific literature has described 
HG/HL as having a number of different causes, including parasite metabolism, sequestration resulting in 
microcirculatory hypoperfusion, kidney and liver failure, or hypovolaemia (1, 14, 15). However, while such 
qualitative explanations have undoubtedly been useful in guiding the search for novel drugs, they lack the 
quantitative basis that would provide a more robust understanding of the aetiology underlying the metabolic 
abnormalities associated with severe malaria, as well as the means with which to improve subsequent clinical 
outcomes.  
It is this gap in understanding that the current research aims to ameliorate. A wealth of studies employing a 
systems biology approach have already provided many insights regarding metabolism (16–19), including the 
biological and biochemical networks found in P. falciparum and its human host (20, 21). Through the use of 
kinetic modelling, the overarching goal of the current research is to delineate the aetiology behind the 
appearance of HG/HL in severe malaria, improve understanding of the disease, and provide a quantitative 
basis for the pursuit of novel treatments. 
In order to obtain such quantitative evidence that can give robust indications of which biochemical targets 
are most amenable to new antimalarial treatments, an in silico platform must first be constructed that can 
serve as a framework and platform for further development. The whole-body model presented in this thesis is 
intended to serve as such a framework, whereby the phenomenological implementations of expression 
describing host-parasite interactions can be accurately parameterised with future clinical data garnered from 
experimentation specifically suited towards obtaining empirical observations of changes in host metabolism 





1.2 Research Question, Aims, and Objectives 
1.2.1 Research Question 
Can a kinetic modelling approach be used to estimate the relative contribution of suggested causes to 
hypoglycaemia and lactic acidosis in cases of severe Plasmodium falciparum malaria? 
1.2.2 Aims 
The aims of this thesis are: 
1. Construction of a whole-body model of glucose and lactate metabolism in the infected human host 
that allows examination down to and including the enzymatic level 
 
2. Implementation of in silico descriptions of aspects of Plasmodium falciparum pathophysiology that 




The research objectives are: 
1. Identify, reproduce, and test the viability of independently published models giving sufficiently 
detailed kinetic descriptions of one or more organ compartments relevant to glucose and lactate 
metabolism. 
2. Adapt and merge the selected models into a whole-body model of glucose and lactate metabolism. 
3. Validate the whole-body model by comparison of simulation outputs with both the original model's 
outputs and clinical data of patients with severe Plasmodium falciparum malaria. 
4. Test whether glycolytic parasite metabolism alone can cause hypoglycaemia and hyperlactataemia in 
the current model.  
5. In the case of model outputs failing to match clinical data; modify and extend the model with 
features, phenomenological or otherwise, to introduce host-parasite interactions that have a 
significant effect on plasma glucose and lactate, as reported in literature. 
6. Identify which components of the whole-body model have the most significant role in the 
pathogenesis of lactic acidosis and hypoglycaemia; and determine which of these would be the best 





1.3 Thesis Structure 
This thesis is divided into the following chapters: 
i. Chapter 1: Introduction  
The general introduction, as presented here. 
ii. Chapter 2: Background and Literature Review 
This chapter introduces the concepts that are discussed and explored in this thesis. This section 
includes broad overviews of malaria as a global health burden, the biology and metabolism of the 
parasite responsible for the disease, and the underpinnings of whole-body glucose and lactate 
metabolism within the human host. This is followed by more detailed discussions that converge on 
the proposed pathological mechanisms of hypoglycaemia and hyperlactataemia in cases of severe 
malaria, and the suitability of systems biology to investigate the underlying aetiology thereof. The 
chapter ends with a section intended to introduce the reader to the fields of systems biology and 
kinetic modelling. Discussion of these topics is arranged in an order that guides the reader from a 
general understanding of malaria to the specific area of research covered by this thesis. 
iii. Chapter 3: Methods 
The Methods chapter contains descriptions of the methodology employed during the construction of 
the final model. The rationale for decisions and changes made during the course of research are 
explained. An additional section is included as an appendix, briefly illustrating the software written 
as part of this research to expedite the modelling process. 
iv. Chapter 4: Results & Discussion 
The Results section contains descriptions of results obtained from model simulations as pertaining to 
the aims and objectives set out in Chapter 1. These include demonstrations of how the model was 
validated, the results of model simulations satisfying the original research objectives, and other data 
that support conclusions drawn in this chapter. 
v. Chapter 5: Recommendations, Summary & Conclusion 
Model shortcomings are discussed, together with recommendations for further development of the 






Chapter 2: Background and 
Literature Review 
This chapter introduces the concepts that are discussed and explored in this thesis. This section includes 
broad overviews of malaria as a global health burden, the biology and metabolism of the parasite responsible 
for the disease, and the underpinnings of whole-body glucose and lactate metabolism within the human host. 
This is followed by more detailed discussions that converge on the pathological mechanisms leading to 
hypoglycaemia and hyperlactataemia in cases of severe malaria, and the suitability of systems biology to 
investigate the underlying aetiology thereof. Discussion of these topics is arranged in an order that guides the 
reader from a general understanding of malaria to the specific area of research covered by this thesis. 
2.1 Epidemiology 
The most recent estimates indicate that during 2016, malaria had infected approximately 3% of the world 
population and claimed the lives of 445 000 people (22). The overwhelming majority of sufferers are young 
sub-Saharan children, typically those aged five years or younger (1). Additionally, infants born to mothers 
with malaria have an increased risk of low birth weight, anaemia, and mortality (23). In the genus 
Plasmodium, P. falciparum is responsible for nearly all cases of severe disease and subsequent mortality. 
With regards to transmission, all malaria parasites, including P. falciparum, are transmitted via mosquito 
vectors, specifically female Anopheline mosquitos. Of the several hundred Anopheline species, more than 70 
are capable of transmission (24), with approximately 25 constituting particularly effective vectors (25). 
Anopheles gambiae is thought to constitute the primary vector of P. falciparum within Africa (26). 
Malaria is found throughout the tropics of Africa, South America, South-east Asia and Oceania, and the 
Indian subcontinent. P. falciparum constitutes virtually all cases of malaria in Africa (27). Though the 
epidemiology of malaria is relatively easy to discern and interpret on a large geographical scale at low 
resolution, the situation becomes substantially more complex when considering smaller geographic areas. 
Even in regions with generally low transmission rates, small geographic regions with a combination of 
factors favourable to transmission can continue to drive malarial infection and frustrate eradication efforts.  
2.2 Parasite Biology & Lifecycle 
The process of malaria infection begins with the bite of a female Anopheline mosquito, which inoculates the 
host with plasmodial sporozoites during a blood meal (23). These sporozoites, originating from the 




number of sporozoites injected is typically small and in the range of 8 to 15, but in some cases may be on the 
order of a hundred. Post-inoculation, the circulating sporozoites that have not been cleared by splenic 
filtration rapidly proceed to invade the hepatic parenchyma. Once inside the hepatocyte, the sporozoite 
undergoes asexual reproduction, a process lasting approximately five and a half days on average in P. 
falciparum. Once this phase is complete, the infected hepatocytes rupture, releasing merozoites into the host 
circulation. During this pre-erythrocytic phase, many merozoites may be produced, but since only a few 
hepatocytes were initially invaded, no symptoms are present at this stage (23). 
The initiation of the parasite’s asexual blood-stage development begins with the invasion of erythrocytes by 
merozoites. Merozoites are small, motile, ovoid cells which are capable of attaching to the external 
erythrocytic membrane via an apical complex. The merozoite then proceeds to invade the erythrocyte in a 
wriggling or boring motion, collecting a vacuole consisting of the invaginated erythrocyte membrane. Once 
internalised, the parasite lies within the erythrocyte cytosol surrounded by both its plasma membrane and an 
enveloping parasitophorous vacuolar membrane (PVM)(28). At this point, the intraerythrocytic parasite 
begins to mature into the next stage, termed the ‘ring’ stage, due to its eponymous appearance under 
microscopic examination (21). Further maturation leads to the development of a trophozoite, with a 
characteristic signet-ring appearance. Later, the parasite further develops and matures into a schizont, a 
multi-nucleated form of the parasite produced by several cycles of karyokinesis. Each schizont will on 
average produce around 15 to 30 merozoites, which will subsequently be released into the circulation 
following rupture and lysis of the infected erythrocyte membrane. The merozoites then proceed to reinvade 
more erythrocytes, beginning the cycle anew (Fig. 2.1).  
 




The entire cycle lasts approximately 48 hours, a duration specific to P. falciparum (23). Over time, these 
reproductive cycles produce a parasite burden that grows exponentially in volume within a cycle, and in 
number of parasites over several reproductive cycles (Fig 2.2).  
 
 
Figure 2.2: Simulations of the change in volume and number of the parasite within 
and between its 48-hour lifecycle. Simulation parameters obtained from (21) 
2.3 Parasite Metabolism 
The asexual blood-stage parasite, lying within the infected erythrocyte and enveloped by the PVM, is 
dependent upon the parasitized red blood cells cytosol and membrane for the trafficking of nutrients. To this 
end, the parasite exports several hundred proteins to the infected erythrocyte cytosol through the PVM. 
These parasite-derived proteins proceed to alter the structural properties of the infected erythrocyte 
membrane, particularly its permeability to low molecular weight solutes (29). The parasite-mediated 
alteration of the host cell membrane includes the introduction of new permeability pathways, or NPPs. These 
NPPs are non-specific, integral membrane channel proteins which permit entry of nutrients into the host cell 
cytosol. Though the host erythrocyte’s existing transport functionality is sufficient for the majority of 
nutrients required by the parasite, the NPPs are necessary for the uptake of glutamate, pantothenate and 
choline from plasma (21).  
The metabolism of protozoans of the genus Plasmodium, including P. falciparum, is notable in that they are 
almost completely reliant upon anaerobic glycolysis for the synthesis of ATP during the asexual blood-stage 




to undergo catabolism by the parasite (31–33). Outside the asexual blood-stage phase of its lifecycle, the 
parasite is capable of free energy production via TCA cycle activity, with the pyruvate dehydrogenase (PDH) 
complex being able to produce acetyl-CoA from pyruvate, the penultimate metabolite of anaerobic 
glycolysis. However, in the asexual phase, the PDH complex is relegated to the apicoplast, thereby leaving 
flux through lactate dehydrogenase to produce lactate as the only remaining viable pathway for maintaining 
redox balance within the parasite compartment through pyruvate reduction (20, 34). Complete glycolytic 
catabolism of glucose by the parasite gives a net yield of approximately two moles of ATP and two moles of 
lactate per mole glucose utilised (30). Despite this dependence on glycolysis, the maturing intraerythrocytic 
parasite does not convert all of the imported glucose to lactate, with 30-40% being shuttled to anabolic 
processes required for growth and differentiation (35).  
 
Figure 2.3: Glycolysis in P. falciparum as described by Penkler (20)   
To satisfy this demand for glucose, and dispose of the lactate produced, the parasite makes use of both 
existing erythrocytic and novel parasite-derived transport mechanisms. Between the host serum and the 
parasite cytosol, three membranous barriers are present: the erythrocytic membrane, the PVM, and the 
parasite cell membrane. Transport of glucose across the host cell membrane is achieved via both endogenous 
erythrocytic hexose transporters and the NPPs previously described (21, 29). A non-selective, high-capacity 




through action of parasite hexose transporter 1 (PHT1), a passive, saturable transporter (32, 37). The 
concerted action of this series of transporters can produce a rate of glucose uptake that can equal up to 100 
times that of uninfected erythrocyte (38). Disposal of the end product of anaerobic glycolysis, lactate, is 
carried out by a lactate-proton cotransporter (39, 40), which mediates the simultaneous efflux of protons and 
lactate from the parasite cytosol. Subsequent export across the erythrocyte membrane is achieved through 
existing endogenous mechanisms, including the monocarboxylate transporter 1 (MCT1), band 3 anion 
transport protein, and diffusion across the lipid bilayer (21). 
2.4 General Pathophysiology 
The clinical presentation of malaria varies depending on the progression of the disease and the age of the 
infected individual (41). During the initial infection, a common set of non-specific symptoms appear, such as 
the appearance of fever, headache, fatigue, abdominal discomfort, muscular aches, and a general feeling of 
malaise (1). More severe symptoms that also commonly occur include nausea, vomiting, and orthostatic 
hypotension. The clinical presentation of advanced P. falciparum malaria, however, is heterogenous. The set 
of symptoms accompanying severe infection can be markedly different depending on the age of the infected 
individual (Fig. 2.4). Anaemia, hypoglycaemia, and convulsions are more common in younger patients, 
while adults are more likely to present with renal failure, jaundice and acute pulmonary oedema. Coma and 
acidosis, on the other hand, appear to not be significantly affected by age, and occur in approximately half of 
all patient populations.  
The pathophysiology for a particular symptom has been attributed to a number of different aetiologies, e.g. 
the periodic paroxysms associated with malaria infection are thought to be due to toxins released by the 
parasite upon erythrocyte rupture (23). While some research has indeed identified substances originating 
from the parasite that have a stimulatory effect on the immune system, the organ-specific pattern of severe 
malaria non-periodic pathology lends more credence to the concept of heterogenous parasite sequestration, 
whereby the particular set of symptoms present is a function of the distribution of sequestered parasites 
within the infected individual. For example, the presence of kidney or liver failure would indicate that a large 
proportion of parasites have adhered to the renal and hepatic endothelium. Conversely, the presence of 
pulmonary oedema has been linked to pathological endothelial activation of the pulmonary microcirculation. 





Figure 2.4: Relationship between patient age and clinical presentation in individuals 
infected with malaria. Adapted from (23) 
2.5 Hypoglycaemia 
In healthy individuals, blood glucose concentration is typically maintained within the range of 4.0 – 6.0 mM 
(42). This homeostatic maintenance reflects the balance between glucose provision and utilisation, mediated 
both exogenously, via dietary intake, and endogenously, via gluconeogenesis and glycogenolysis (43). 
Whole-body coordination of these processes is achieved through endocrinological means, chiefly through the 
actions of insulin, glucagon, and catecholamines (44). Hypoglycaemia, defined by the WHO as a blood 
glucose concentration less than 2.2 mM (45), is relatively common in both children (46) and adults (47) with 
severe malaria. Hypoglycaemia exhibits particularly high prevalence in children aged three years or less, 
likely owing to the increased tendency of children to become hypoglycaemic when fasting, especially when 
accompanied by fever and emesis. Hypoglycaemia is typically associated with worse clinical outcomes and 
increased mortality. This relationship is especially pronounced in paediatric cases, where hypoglycaemia has 
been found to be one of the strongest predictors of mortality (13). This association appears to hold less true 
for adults (48), where its prognostic value is mostly attributed to its co-presentation with acidosis.  
Since blood glucose concentration reflects the sum of the opposing homeostatic forces of glucose uptake and 
release, it follows that hypoglycaemia can be attributed to either a deficient rate of glucose release, an 
accelerated rate of uptake, or a combination of the two. An insufficient rate of glucose release into the 
plasma can have a number of causes, such as malnutrition, or derangements of endogenous metabolism, such 
as impaired gluconeogenesis or glycogenolysis. An abnormally high rate of plasma glucose uptake can 
possibly be attributed to accelerated carbohydrate metabolism or aberrations of the endocrinological system, 




being responsible for the appearance of hypoglycaemia. The following sections discuss the relative 
significance of these various aetiologies. 
2.5.1 Glucose utilisation 
Substantial evidence exists of accelerated glucose turnover in both children (49–52) and adults (47, 53) with 
severe malaria. The rate of glucose turnover in children is approximately five-fold that found in adults with 
severe malaria. Increased glucose utilisation is thought to occur due to features of the disease state, such as 
fever and convulsions, the systemic shift towards anaerobic glycolysis, and, to a lesser degree, glucose 
uptake by the malaria parasites (12).  
Considering the 30 to 100-fold increase in glucose uptake by infected erythrocytes in comparison to healthy 
red blood cells (38, 54), the manifestation of hypoglycaemia can, at least in part, be ascribed to the metabolic 
demands imposed by the growing parasite population. However, when compared to the rate of glucose 
consumption by the host, glucose uptake by infected erythrocytes is relatively minor.  
Contemporary literature does not feature definitive statements regarding whether glucose consumption by 
parasites and infected erythrocytes constitutes the primary cause of hypoglycaemia, or whether it should be 
considered a contributing factor together with other aetiologies. One review listed several host factors 
external to parasite metabolism that could cause or contribute to the appearance of hypoglycaemia. These 
included the Pasteur effect (an increased peripheral glucose uptake due to a shift towards anaerobic 
glycolysis), upregulated metabolism in the febrile state, and an impairment of hepatic gluconeogenesis and 
glycogenolysis (23). Some of these factors are thought to be significant in paediatric patients, owing to their 
substantially higher rates of glucose turnover in response to severe malaria, and their much smaller capacity 
for glycogen storage.  
2.5.2 Gluconeogenesis 
Impairment of gluconeogenesis has been frequently cited as one of the chief causes of hypoglycaemia in 
patients with malaria (55, 56). This consensus was reached after the consideration of two sets of observations 
from patients with malaria: low rates of gluconeogenesis in hypoglycaemic children (50, 51), and increased 
plasma concentrations of gluconeogenic precursors (57, 58). Combined with the erstwhile technological 
limitations and paucity of data, these findings seemed to imply at the time that deficient hepatic synthesis of 
glucose despite an abundance of gluconeogenic substrates is a major causative factor of hypoglycaemia in 
patients with malaria. However, there has been some contention regarding this finding as a result of more 
recent studies examining the role of gluconeogenesis in the pathology of hypoglycaemia in cases of severe 
malaria. 
More recent studies examining glucose dynamics have consistently showed that glucose production is 
increased in patients with malaria vs. healthy controls (59). Increased gluconeogenesis was found regardless 
of age, and appeared to correlate with disease severity. Children with severe malaria exhibited dramatically 




adults, glucose production was found to be upregulated by approximately 20% in those with uncomplicated 
infections (56, 60), 35% in pregnant women with uncomplicated malaria (56), and 100% in adults with 
severe malaria (53). In one notable study of adults with cerebral malaria, gluconeogenesis was found to 
account for the entirety of endogenous glucose production (61). 
Lactate, alanine, and glycerol comprise the bulk of gluconeogenic substrates; the plasma concentrations of 
these precursors are elevated in both children (62) and adults (63) with severe malaria. To investigate why 
hypoglycaemia persisted despite the abundance of gluconeogenic precursors, several studies were conducted 
to determine whether this was due to inhibition of gluconeogenesis. To this end, glucose production was 
measured after infusion with gluconeogenic substrates. While conversion of glycerol and galactose appeared 
normal (63), alanine utilisation was found to be impaired (64). These findings suggested selective 
impairment of gluconeogenesis, whereby pathways ‘proximal’ to pyruvate were inhibited, while more 
‘distal’ ones were not.  
However, contemporary studies have suggested that high plasma concentrations of gluconeogenic precursors 
in severe malaria are not due to impairment of gluconeogenesis. Instead, emphasis has been placed on factors 
such as increased anaerobic glycolysis, inhibition of alanine metabolism by hyperlactataemia, reduced 
hepatic perfusion, or impaired liver function (55, 64). One conclusion that can be drawn from this is that 
hypoglycaemia due to hepatic impairment is due to a more generalised failure of liver function. However, 
liver failure is a relatively uncommon complication, even in severe malaria (65, 66). 
2.5.3 Glycogen metabolism 
Protracted hypoglycaemia gives rise to rapid depletion of glycogen stores, as glycogenolysis is continually 
upregulated by elevated levels of glucagon. The speed of glycogen depletion is especially pronounced in 
children, owing to smaller glycogen stores (67). This reduced capacity for glucose provision through 
glycogenolysis has often been cited as a contributing factor for the sustained presence of hypoglycaemia in 
children with severe malaria (68). Additionally, endogenous glucose production in response to glucagon 
infusion is diminished in both children (69) and adults (58), giving further evidence of extensive glycogen 
depletion in patients with malaria. 
However, the hypothesis that hypoglycaemia is exacerbated by impaired glycogenolysis due to diminished 
glycogen stores has been contradicted. A recent study examined the relative rates of glycogenolysis in fasted 
adults with or without uncomplicated malaria. Though the rate of glycogenolysis was substantially lower in 
the malaria patients, the rate of decline of glycogenolysis was slower than that observed in the healthy 
controls (70). In other words, the rate of glycogenolysis did not appear to be limited to the same degree by 
reduced substrate availability, implying that glycogen metabolism is altered to guarantee glucose output and 
maintain euglycaemia. This suggests that glycogen depletion does not contribute to hypoglycaemia in 
malaria, a notion further supported by the presence of unutilised hepatic glycogen in hypoglycaemic patients 




2.5.4 Quinine-Induced Hyperinsulinaemia 
Owing to quinine’s ability to stimulate insulin secretion by pancreatic beta-cells, hyperinsulinaemia and 
subsequent hypoglycaemia has been associated with quinine administration (23, 71). While this relationship 
has been confirmed in adults suffering from severe malaria, a study has concluded that there is no evidence 
of hypoglycaemia occurring as a result of quinine administration in African children (72). 
However, since the effect of antimalarials are beyond the scope of the current research, the utility of this 
information is relegated to interpretation of clinical data obtained from adults, where measurements of blood 
glucose concentrations should be given closer scrutiny if quinine administration was present. 
2.6 Overview of Lactate Metabolism 
2.6.1 Lactate production 
Lactate is produced as part of the final step of anaerobic glycolysis in humans, where pyruvate is reduced to 
form lactate via catalysis by cytosolic lactate dehydrogenase (LDH, Fig. 2.5)(73). Under normal 
physiological conditions, this reversible reaction favours lactate production with an approximate 10:1 lactate-
pyruvate ratio (74). Like all preceding steps in glycolysis, this process does not require the presence of 
oxygen. Lactate production by the LDH catalysed reduction of pyruvate serves as a useful proxy for 
monitoring anaerobic metabolism.  
 
Figure 2.5: The reaction catalysed by lactate dehydrogenase   
To produce ATP, glycolysis requires not only glucose, but also a readily available supply of oxidized 
nicotinamide adenine dinucleotide (NAD+). Provision of NAD+ is mediated, in part, by the action of LDH. In 
a healthy, normoxic individual at rest, approximately 10% of cytosolic pyruvate is reduced to lactate by LDH 
(75). The reduction of pyruvate is facilitated by NADH, which is oxidized to NAD+ (76).  
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Hence, cytosolic lactate concentration is influenced not only by pyruvate concentration, but also by pH and 
the ratio of NADH/NAD+ (77).  
In humans, the bulk of cytosolic pyruvate will be transported into the mitochondria for use by the 
tricarboxylic acid (TCA) cycle. The TCA cycle, in turn, provides NADH for use by oxidative 
phosphorylation, a process that requires oxygen. Thus, should an oxygen deficit accrue, LDH activity will 




generating capacity of glycolysis is preserved by lactate production as NAD+ is replenished and the 
concentrations of pyruvate and H+ are simultaneously decreased (79–81). 
Plasma lactate is principally derived from two sources: glucose and alanine (82). Glucose contributes 
approximately 65% of plasma lactate, following its catabolism via anaerobic glycolysis. Alanine contributes 
approximately 16-20% of plasma lactate by virtue of its ability to be converted to pyruvate, as catalysed by 
alanine aminotransferase (83). The remainder is constituted by the catabolism of other amino acids, which 
include serine, threonine and cysteine (84). 
Anaerobic glycolysis produces a maximum of two molecules of ATP per molecule of glucose catabolised; 
this figure rises to 36 ATP per molecule of glucose in the case of aerobic glycolysis (78, 85). While the 
shuttling of pyruvate into the mitochondria for the ultimate purpose of oxidative phosphorylation does result 
in a greater overall net energy yield, the reduction of pyruvate to lactate as part of anaerobic glycolysis is 
necessitated in some cases. These include insufficient tissue oxygen delivery (DO2) during intense exercise, 
or simply the absence of mitochondria, as is the case in erythrocytes. Despite its apparent inefficiency, 
homolactic fermentation can produce ATP at a rate up to 100 times faster than aerobic glycolysis. (86, 87). 
The production of lactate is partitioned amongst various tissues. These include muscle (25%), skin (25%), 
the brain (20%), intestines (10%) and erythrocytes (20%)(88). Erythrocytes, leukocytes and platelets 
contribute 80, 13 and 7% of lactate production within the blood, respectively (89, 90). These values are 
subject to change, especially during illness. In addition to the thermogenic energy expenditure levied by 
fever, lactate production by leukocytes (particularly neutrophils) increases dramatically as part of the 
immune response.  
Organs that are typically considered net consumers of lactate, such as the liver and kidneys, can become net 
producers of lactate if microvascular perfusion becomes sufficiently compromised (91–93); this phenomenon 
becomes especially pertinent in the case of severe malaria, as is discussed in this thesis. 
2.6.2 Lactate clearance 
Lactate is cleared from the circulation primarily via oxidation to pyruvate, primarily in hepatic, renal, and 
cardiac tissues. This pyruvate can experience two metabolic fates: oxidative catabolism in the mitochondria, 
or conversion to glucose as part of gluconeogenesis. Both of these processes begin with the same two steps: 
oxidation to pyruvate by LDH, and subsequent transport into the mitochondria (94). 
2.6.2.1 Oxidative catabolism of pyruvate 
The oxidative metabolism of pyruvate within the mitochondria to ultimately yield ATP is a complex process 
that involves sequential action of the pyruvate dehydrogenase (PDH) complex, the TCA cycle, and the 
mitochondrial electron transport chain (ETC). The process begins with the oxidative decarboxylation of 
pyruvate to produce acetyl-CoA, accompanied by the reduction of NAD+ to NADH (95, 96). This reaction, 
catalysed by the PDH complex, is irreversible. Acetyl-CoA subsequently proceeds through the TCA cycle, 




In the inner mitochondrial membrane, NADH and FADH2 are re-oxidized as part of the ETC, providing 
reducing equivalents used to reduce molecular oxygen, and protons that give rise to a chemiosmotic gradient. 
This chemiosmotic gradient is harnessed by ATP synthase to catalyse the oxidative phosphorylation of ADP 
to finally yield ATP (99, 100).  
2.6.2.2 Gluconeogenesis 
Gluconeogenesis, an anabolic pathway present primarily in tissues such as the liver and kidney, mediates the 
endogenous production of glucose, and contributes substantially to lactate clearance (Fig. 2.6)(101). 
Mitochondrial pyruvate carboxylase (PC) catalyses the carboxylation of mitochondrial pyruvate to form 
oxaloacetate (102).  
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Mitochondrial oxaloacetate can then be converted to phosphoenolpyruvate (PEP) via catalysis by 
phosphoenolpyruvate carboxykinase (PEPCK).  
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Alternatively, mitochondrial oxaloacetate can be converted to malate, as catalysed by malate dehydrogenase 
(MDH) and transported to the cytosol. 
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Cytosolic malate is converted back to oxaloacetate, which can then be converted to PEP by the cytosolic 
isoenzyme of PEPCK (103). The reactions catalysed by pyruvate carboxylase and PEPCK are irreversible 
and therefore play a significant role in determining the overall rate of gluconeogenesis (104). 
The remainder of gluconeogenesis is effectively glycolysis in reverse, with PEP being sequentially converted 
through the same set of glycolytic intermediates. Enzymes catalysing the reversible reactions similarly 
remain unchanged. The two glycolytic enzymes catalysing irreversible reactions, phosphofructokinase-1 and 
hexokinase, are replaced by fructose-1,6-bisphosphatase 1 and glucose-6-phosphatase, respectively. Like 
pyruvate carboxylase and PEPCK, they are also irreversible and important in determining overall 
gluconeogenic activity (87).  
Gluconeogenesis, with lactate or pyruvate as the initial substrates, is an endergonic process that results in a 
loss of free energy. The reactions catalysed by pyruvate carboxylase and 3-phosphoglycerate kinase each 
involve the hydrolysis of one molecule of ATP; one molecule of GTP is also consumed during the 
conversion of oxaloacetate to PEP by PEPCK (105). Since two molecules of lactate or pyruvate are required 
to synthesise one molecule of glucose, a total of six ATP equivalents is consumed. Given that the glycolytic 
conversion of one molecule of glucose to two molecules of pyruvate yields two molecules of ATP, the net 
energetic cost of glycolysis followed by gluconeogenesis (i.e. glycolytic conversion of glucose to pyruvate 
and then back again) is four ATP equivalents (87). Thus, the rate of gluconeogenesis will be impaired should 





Figure 2.6: Generalised metabolic schema of whole-body glucose metabolism in the fasted 
state. The liver is responsible for the bulk of glucose provision, with approximately equal 
fractions originating from glycogenolysis and gluconeogenesis. The approximate 
percentage contributions of gluconeogenic substrates by other organs are shown adjacent to 
the orange arrows. The diagram shows a cyclical pattern whereby the catabolic products of 
glucose metabolism released by peripheral tissues is converted back into glucose by the 
liver, with the complete oxidation by the brain representing a net loss of glucose and 
glucose equivalents from the body. Lipid oxidation not shown. Figure adapted from (43) 
2.6.2.3 Renal Lactate Excretion 
The kidney is capable of the urinary excretion of small organic acids, including lactate (106). Given lactate’s 
metabolic utility, it is typically not excreted by healthy individuals. However, should plasma lactate 
concentration exceed the renal threshold of approximately 5 mM, the kidney will begin to contribute to 
lactate clearance via excretion in the urine (88). 
2.6.2.4 Organ-specific Lactate Clearance 
Exact estimates of the relative contribution of each organ to lactate clearance have been difficult to 
determine. This has been due to not only technical and methodological limitations (107), but also biological 
factors, including nutritional status, recent exertion, and the prevailing lactate concentration within the 
plasma (79, 82). 
However, despite these challenges, the literature does contain some approximations of the relative 
contribution of each organ to lactate removal from circulation. The liver and kidneys, two major sites of 
gluconeogenesis, account for approximately 60% and 30% of total whole-body lactate clearance respectively 
(88, 108), with the remainder mediated by the heart and skeletal muscle (109). The predominance of the liver 




considered to be the dominant gluconeogenic substrate used by these organs in healthy postprandial humans 
(110).  
Of the lesser gluconeogenic tissues, the myocardium appears to be the most important (111, 112). Isotopic 
studies have estimated that approximately 5% of systemic lactate uptake is mediated by the heart (113). The 
majority of lactate taken up by the myocardium is oxidized as a source of energy (114). 
The pattern of partitioning of lactate uptake amongst these organs is, however, subject to change, depending 
on the prevailing physiological conditions. For example, lactate uptake and release by skeletal muscle can 
vary substantially based on the degree of exertion or the plasma lactate concentration. Resting skeletal 
muscle exhibits simultaneous uptake and release of lactate, with a net release in healthy humans in the 
postabsorptive state (115). However, when only considering the absolute rate of lactate uptake, skeletal 
muscle can account for up to 27% of total removal of lactate from the circulation (116). Additionally, the 
unidirectional uptake of lactate by skeletal muscle has been found to be closely associated with arterial 
lactate concentrations (117). Resting skeletal muscle readily oxidizes lactate for the purposes for oxidative 
metabolism or glycogenesis (118). Taken together, these observations provide an explanation for the 
phenomenon where skeletal muscle displays a net uptake of lactate under sufficiently high plasma 
concentrations at rest. 
Considering the myriad of different ways lactate clearance is managed by the several different pathways 
described here, the appearance of HG/HL despite these becomes a point of interest. A number of questions 
arise when considering the seemingly paradoxical co-presentation of excess plasma lactate and deficient 
blood glucose when lactate itself is a prime gluconeogenic substrate for the synthesis of glucose. Is the rate 
of parasite glycolysis so high that it can overcome the entirety of the host’s metabolic homeostasis? Does the 
parasite modify the host’s metabolism in a way that prevents it from carrying out gluconeogenesis? Does the 
parasite perhaps accelerate the host’s glycolytic metabolism in such a way that the upregulated conversion of 
glucose to lactate can account for these symptoms? These questions form part of what initially drove the 
interest to pursue this research topic, and will form several of the main points discussed in the remainder of 
the thesis. 
2.6.3 Malaria and Hyperlactataemia 
2.6.3.1 Clinical significance 
Acidosis in severe malaria is associated with a high risk of mortality. Several studies have concluded it to be 
one of the most powerful, if not the most powerful, prognostic indicator of death in both adults and children 
(13, 15, 119–121). Acidosis in patients with malaria is determined using measurements of base excess (>8 
meq/L), plasma carbonate (<15 mM) or venous plasma lactate (>5 mM)(45). The presence of deep (acidotic) 
breathing has also gained acceptance as a diagnostic tool for acidosis in settings where laboratory facilities 
are unavailable (45, 122). Large-scale analyses, combining data obtained from studies in diverse patient 




the range of 40-50% (123–126). The prevalence of acidosis appears to be similar in both adults and children 
(124).  Having discussed normal lactate metabolism in the healthy individual, the possible causes of lactic 
acidosis in severe cases of P. falciparum malaria will now be examined. 
Lactate plasma concentration is determined by the rate of production versus the rate of removal. Therefore, 
hyperlactataemia occurs when the rate of lactate production exceeds the rate of removal for an extended 
period of time. The aetiology of hyperlactataemia within the context of severe P. falciparum malaria can thus 
be divided into increased lactate production, diminished lactate clearance, or a combination of the two. 
2.6.3.2 Increased Production by Parasites 
During the asexual blood-stage phases of the parasite lifecycle, P. falciparum is completely dependent upon 
glycolysis for free energy production (20). The parasite satisfies this metabolic demand by an up to 100-fold 
acceleration of glucose uptake by the infected erythrocyte. The intraerythrocytic parasite subsequently 
converts approximately 60-70% of this glucose to lactate, with the remainder committed to anabolic 
pathways, such as the synthesis of nucleic acids and the glycosylation of proteins and lipids required for 
parasite growth (21). The lactate produced by the parasite is exported to the infected erythrocyte’s cytosol, 
from where it is released into the circulation. 
The amount of lactate produced by the parasitized erythrocyte population is not insignificant, especially at 
higher percentage parasitaemias. However, multiple sources have stated that when taking into account the 
host’s capacity for lactate clearance, parasite lactate production alone cannot account for sustained 
hyperlactataemia (12, 77, 93).  
2.6.4 Microvascular Obstruction: A Unifying Aetiology 
Though parasite lactate production itself is generally not considered quantitatively sufficient for the presence 
of hyperlactataemia, the ability of the parasite to adhere to the capillary endothelium has been routinely cited 
by recent literature as having significant implications for host lactate metabolism. The observed phenomenon 
whereby P. falciparum infected erythrocytes sequester in the peripheral microcirculation, and subsequently 
compromise capillary perfusion, has been considered to be the central mechanism underlying the 
development of pathologies associated with severe P. falciparum malaria (15, 127–130). Lactic acidosis in 
particular has been attributed to the changes in host lactate turnover mediated by microvascular obstruction 
within specific organs. The following sections will first examine the causes of this phenomenon, followed by 
the changes in host metabolism that subsequently occur. 
2.6.4.1 Microvasculature 
The term ‘microvasculature’ refers to the microcirculation within the capillaries and postcapillary venules, 
which contain erythrocytes, leukocytes and the endothelial lining, as well as the chemical effectors therein, 




Reduced microcirculatory blood flow, within the context of severe P. falciparum malaria, has many causes, 
but the end result is the same: reduced luminal diameter of capillaries and postcapillary venules with 
subsequently diminished oxygen and nutrient delivery to tissues (4, 15). The causes of disturbed 
microcirculatory blood flow and their involvement in the pathogenesis of severe malaria are discussed 
below. 
2.6.4.2 Cytoadherence and sequestration 
The phenomenon whereby parasitized erythrocytes adhere to and accrue within the blood vessels was first 
observed over a century ago by Italian pathologists Marchiafava and Bignami (131). Since then, the 
sequestration of infected red blood cells within the microvasculature of vital organs has been deemed the 
defining pathological characteristic of severe falciparum malaria (127).  
Cytoadherence refers to the increased propensity for infected erythrocytes to adhere to the endothelial lining, 
while sequestration refers to the permanent adherence of parasitized red blood cells to the endothelium in 
capillaries and postcapillary venules (23), thereby removing them from the circulation and preventing their 
destruction by the spleen. Among the species of Plasmodium known to cause malaria in humans, increased 
cytoadherence and sequestration is unique to P. falciparum. Whereas mature parasites are readily visible on 
blood smears of other malaria types, they are rarely observed in P. falciparum malaria and are considered 
indicative of serious infection (23).  
The process of sequestration begins with the parasite’s expression of a family of proteins termed 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1)(127). Subsequent interactions between 
these parasite-derived molecules and the host cell cytoskeleton lead to the appearance of “knobs”: 
protrusions of the erythrocytic membrane which mediate attachment to vascular endothelial ligands. 
Intracellular adhesion molecule 1 (ICAM-1) and the cluster of differentiation 36 (CD36) protein are 
considered the most important endothelial receptors mediating attachment within and outside the cerebral 
microvasculature, respectively.  
The timeline of infected erythrocyte adherence parallels the parasite’s progression through its 48-hour 
asexual life cycle. In the febrile host, cytoadherence manifests approximately 12 hours after merozoite 
invasion, reaches half-maximal levels between 14-16 hours, and is virtually complete by 24 hours. 
Accordingly, cytoadherence is relegated to the mature stages of the parasite; ring-form parasites also exhibit 
adherence, albeit to a lesser degree (132, 133). The parasite thus spends the majority of its 48-hour life cycle 
sequestered within the peripheral circulation, explaining its absence from blood smears. Parasite adherence is 
terminated following erythrocyte rupture during merogony (schizogony) at the conclusion of the parasite life 
cycle, whereupon remnants of the erythrocyte membrane, complete with the attached pigment body, can still 
be found attached to the vascular endothelium (23). 
Parasite sequestration is not distributed uniformly throughout the macro- or microvasculature: the 
distribution and extent of sequestration can differ both within and between organs. The degree of 




the liver, kidneys, heart, eyes, intestines, and adipose tissue (134). Within these tissues, the degree of 
sequestration and subsequent luminal occlusion is distributed heterogeneously, where hypo- and 
normoperfused regions can be found lying adjacent to one another (127). 
 
Figure 2.7: Electron microscope image showing cytoadherence and sequestration within a 
cerebral blood vessel in a case of cerebral malaria. Inset: Possible rosette formation shown 
by uninfected red blood cells surrounding a parasitized red blood cell. Legend: PR, 
parasitized red blood cell; R, uninfected red blood cell; arrows, parasitized erythrocyte 
ghosts; arrowheads, parasitized red blood cell surrounded by healthy erythrocytes, 
representing possible rosette formation. Image adapted from (135) 
The study of parasite sequestration has provided not only etiological insights into P. falciparum 
pathophysiology, but also its major role in determining treatment outcome. Strong correlations have been 
observed between the degree of parasite sequestration and the three major independent predictors of 
mortality: cerebral malaria, metabolic acidosis, and acute kidney injury (127, 128, 134, 136, 137). General 
scientific consensus considers parasite sequestration to be the primary cause of microvascular obstruction 
and endothelial activation (Section 2.6.4.5), which lead to tissue hypoperfusion and acidosis. It should be 
noted, however, that some authors have disputed the order of this cause-and-effect relationship, arguing 
instead that parasite sequestration lies distal to acidosis and endothelial activation in the causal chain (138, 
139). 
2.6.4.3 Rosetting, agglutination and aggregation 
Following cytoadherence of the parasitized erythrocyte to the endothelial lining, subsequent luminal 
occlusion can be compounded through rosetting, agglutination and aggregation. These processes encompass 
phenomena whereby clumps of cells are formed within the capillary or postcapillary venule lumen, as 




platelets and infected red blood cells (aggregation); and attachments between infected red blood cells only 
(agglutination)(130). 
Rosette formation is a phenomenon whereby uninfected erythrocytes adhere to parasitized red blood cells 
(Fig. 2.8). Like cytoadherence, rosette formation begins at approximately the 16-hour mark after merogony. 
There are, however, several key differences. Rosetting in P. falciparum is not a ubiquitous phenomenon: 
while all fresh isolates of P. falciparum exhibit cytoadherence, not all rosette. This could be mediated by the 
variability in blood group antigens between individuals, as evidenced by the protective effect against 
rosetting conferred by blood group O (23). 
 
Figure 2.8: Cytoadhesion of infected erythrocytes to the luminal surface of the capillary 
endothelium impedes microcirculatory blood flow. To maintain blood flow, healthy 
erythrocytes must squeeze past the immotile parasitized erythrocytes, a process made 
difficult by the reduced deformability of infected erythrocytes and the propensity for 
healthy red blood cells to become trapped in nascent rosettes. Diagram adapted from (23) 
Approximately five times as much force is required to separate a rosette when compared to the force required 
to separate a parasitized cytoadherent cell from the endothelium (23). Rosette formation typically occurs in 
post-capillary venules, likely facilitated by the obstruction of flow in proximal capillaries by cytoadherent 
infected erythrocytes. This suggests a scenario whereby cumulative luminal occlusion, as mediated by 
cytoadherence and rosetting, gives rise to ever-increasing degrees of obstruction of microvascular perfusion. 
Agglutination (sometimes termed auto-agglutination) describes the formation of crosslinks between infected 
erythrocytes due to the parasite-induced expression of similar antigens on infected erythrocytic membranes 
(140). Similarly, aggregation involves adherence between infected erythrocytes, this time mediated by 




severity, and, in addition to rosetting and agglutination, likely contribute to reduced perfusion of the 
microvasculature (23). 
2.6.4.4 Red cell deformability 
The diameter of erythrocytes is slightly larger than the luminal diameter of capillaries; this size discrepancy 
is overcome by the ability of red blood cells to undergo deformation, allowing them to ‘squeeze’ through the 
capillaries in single-file. The term red cell deformability (RCD) has thus entered the scientific nomenclature 
to describe the ability of erythrocytes to pass through the narrow capillaries. The properties of the 
erythrocyte that determine RCD are its shape, cytoplasmic viscosity, and membrane rigidity (130). 
Progression of P. falciparum through the trophozoite and schizont stages within the infected erythrocyte is 
associated with a transition from the normal biconcave disc shape to that more resembling a sphere; this 
change is accompanied by increased cytoplasmic viscosity and membrane rigidity (130). Thus, all three 
determinants of RCD are negatively affected by the growing parasite, which itself becomes more spherical 
and increasingly rigid (23). Additionally, the rigidity of uninfected erythrocytes has also been observed to 
increase during severe P. falciparum infection.  
The pathophysiological implications of reduced RCD are readily apparent: rigid erythrocytes, unable to 
squeeze past parasitized, cytoadherent red blood cells, become trapped in the microvasculature. Loss of 
motility in close proximity to nascent rosettes likely facilitates the process of rosette formation, thereby 
further impeding microcirculatory perfusion in a positive-feedback fashion (130). 
Diminished RCD is not unique to cases of P. falciparum malaria, and can also be observed in sickle cell 
disease and thalassemia, where elevated plasma lactate is not a typical manifestation (141). This indicates 
that reduced RCD alone cannot cause sufficient obstruction of the microcirculation to bring about acidosis. 
However, it remains an important contributing factor when combined with cytoadherent infected 
erythrocytes and associated phenomena.   
2.6.4.5 Endothelial activation 
A discussion of the microcirculation is incomplete without a description of the endothelium. Endothelial 
cells are present in all blood vessels, especially capillaries, where the lumen is enclosed by a layer of 
endothelium one cell thick. Adjacent endothelial cells are joined by tight junctions, ensuring barrier integrity 
and maintenance of vascular permeability. Nitric oxide (NO), synthesised by nitric oxide synthase (NOS), is 
an important signalling molecule within the endothelium; among its many functions are the induction of 
vasodilation, the prevention of platelet aggregation within the capillary lumen, and averting unnecessary 
adhesion of leukocytes to the endothelial wall (142). Should leukocytes be required to cross the endothelial 
barrier to move into the tissues, the binding of the leukocyte to the endothelium is facilitated by ICAM-1, a 
membranous glycoprotein expressed by both endothelial cells and leukocytes. Parasitized erythrocytes can 




The endothelium can respond to disease states through a process called endothelial activation. Endothelial 
activation is an immune process that heightens the propensity for inflammation and coagulation (144), and is 
commonly observed in diseases such as sepsis (145). Within the context of severe P. falciparum malaria, 
alterations in microvascular structure by endothelial activation play an important role in disease 
pathogenesis.  
NF-ΚΒ is a protein signalling complex central to the process of inflammation. NF-ΚΒ expression is 
indirectly stimulated by glycosylphosphatidylinositol, a molecule released by lysed infected red blood cells 
(iRBCs), and by binding of cytoadherent iRBCs to ICAM-1 (4). Furthermore, NF-ΚΒ upregulates the 
expression of adhesion molecules, including ICAM-1, thereby providing additional binding sites for 
parasitized erythrocytes. An additional downstream effect of upregulated NF-ΚΒ is cytoskeletal retraction, 
whereby cytoskeletal rearrangements within the endothelium disrupt intercellular tight junctions, thereby 
compromising endothelial barrier integrity and permeability. Parasitized erythrocytes thus induce a positive-
feedback cycle, whereby intravascular haemolysis and iRBC adherence, acting through NF-ΚΒ, further 
upregulate the propensity for cytoadherence.  
Adherence of infected erythrocytes to the endothelium induces endothelial activation, and endothelial 
activation is generally inhibited by NO (146). Nitric oxide generally acts to oppose the inflammatory 
responses inherent to pathological endothelial activation, not least in part due to its inhibitory effects on NF-
ΚΒ (4, 146, 147). Functional NO signalling can promote survival by slowing the expression of adhesion 
molecules and preventing the breakdown of the endothelial barrier; these ameliorative effects are 
complemented by its vasodilatory activity, particularly in post-capillary venules. Conversely, its absence 
contributes to deterioration of microvascular function. Deficient NO signalling has been correlated with 
disease severity in both children and adults suffering from malaria (148–150).  
When infected erythrocytes burst, intravascular haemolysis releases free haemoglobin and arginase. 
Haemoglobin can react with NO to form inactive nitrate, while free arginase degrades plasma arginine, one 
of the substrates utilised by NOS. NOS is further inhibited by Rho kinase, a downstream effector of NF-ΚΒ 
(4), therefore forming a cycle whereby the ameliorative effects of NOS are inhibited by increased NF-ΚΒ 
expression. Disruption of NO signalling by the parasite is thus a multifaceted process, encompassing 
inactivation, substrate depletion, and inhibition of NO synthesis.  
In addition to increased inflammation and impaired NO signalling, parasite-induced endothelial activation 
also includes increased propensities for thrombosis (4), whereby endothelial cells upregulate the release of 
procoagulatory substances into the plasma, triggering the formation of blood clots within the lumen of small 
blood vessels, contributing to further deterioration of microvascular perfusion. 
Endothelial activation thus plays a critical role in the pathogenesis of malaria, particularly in the severe 
disease state. In recognition of the pathological importance of endothelial dysfunction, ongoing research 




2.6.4.6 Microvascular Obstruction and Lactate Metabolism 
When discussing how microvascular obstruction alters the balance of host lactate turnover, two related but 
functionally distinct terms warrant explanation: ischemia and hypoxia. Ischemia is defined as inadequate 
perfusion of tissue, while the insufficient supply of oxygen to respiring tissue is termed hypoxia. While 
localised microvascular hypoperfusion due to parasite sequestration will likely result in ischemia, there is 
ambiguity in the literature as to whether the subsequent pathology is due to hypoxia. 
Tissues capable of oxidative carbohydrate metabolism that become hypoxic as a result of local microvascular 
obstruction will display a shift towards anaerobic glycolysis (77). As explained in Section 2.6.1, low oxygen 
tension accelerates anaerobic glycolysis, as pyruvate is unable to complete oxidative catabolism through the 
TCA-cycle due to impairment of the mitochondrial respiratory chain, likely due to inhibition of pyruvate 
dehydrogenase. The growing pyruvate and NADH concentrations drive increased flux through LDH, 
resulting in the intracellular accumulation of lactate, which is subsequently transported into the circulation. 
The brain, an organ wholly reliant on aerobic glycolysis, is particularly vulnerable to hypoxia caused by 
parasite sequestration within the cerebral microvasculature.  
The liver is one of the major organs mediating uptake of lactate from blood plasma and converting it to 
useful molecules such as glucose through gluconeogenesis. The host’s apparently reduced capacity for 
lactate clearance has generally been attributed to hepatic ischemia, with multiple studies revealing an inverse 
relationship between liver blood flow and plasma lactate concentration (12, 93). Reduced hepatic perfusion 
limits the provision of lactate as a substrate for gluconeogenesis, while concomitantly decreasing the amount 
of synthesized glucose that can be transported into the general circulation. A smaller body of evidence has 
pointed towards the possible deleterious effects of hepatic hypoxia on gluconeogenesis. An oxygen deficit 
within the hepatic microcirculation has been reported to cause inhibition of both pyruvate dehydrogenase and 
pyruvate carboxylase (108, 152), which catalyse the first step in pyruvate’s metabolism through the oxidative 
and gluconeogenic pathways, respectively. 
Renal pathology, resulting from accumulation of infected erythrocytes and immune cells within the 
glomerular and peritubular capillaries, is also relatively common in adult severe malaria (106). The kidney is 
an important gluconeogenic organ, and is capable of excreting organic acids during acidosis. Therefore, the 
appearance of acute kidney injury during malaria carries a worsened prognosis for the sustained presence of 
hyperlactataemia.  
2.6.5 Other Pathologic Factors Related to Lactate Metabolism 
Systemic oxygen delivery through the general circulation is determined by the combination of cardiac 
output, blood haemoglobin content, and arterial oxygen saturation (77). Indices of cardiac function are 
altered in severe P. falciparum malaria, but not to such a degree that it would explain the manifestation of 
hypoxia; this is reflected by the relatively low incidence of shock (127). Lung abnormalities such as 




metabolic acidosis, severe anaemia, pneumonia coinfection, or clinical use of fluid resuscitation (124, 153). 
This leaves diminished blood haemoglobin content as a remaining possible cause of systemic hypoxia. 
Haemoglobin, found in red blood cells, is responsible for the uptake of oxygen in the lungs and its 
subsequent release throughout the body. Destruction of erythrocytes thus releases haemoglobin into the 
blood, which is later excreted in the urine; haemoglobinuria is accordingly used as a diagnostic measure of 
pathological haemolysis. Severe anaemia (blood haemoglobin <5 g/dL or haematocrit <15%) is commonly 
observed in severe malaria, though this declines with age (124). Anaemia is caused not only by haemolysis 
by the proliferating parasite, but also by the spleen, which has been shown to exhibit upregulated removal of 
both parasitized and uninfected erythrocytes (154). This indiscriminate filtering of both healthy and infected 
red blood cells is thought to be caused by the changes in red blood cell deformability mediated by asexual 
blood-stage parasites. Red blood cell count decline in severe malaria is further exacerbated by impaired 
erythropoiesis after repeat infections (154, 155). 
Severe malarial anaemia (SMA) thus seems to provide a reasonable and intuitive explanation for parasite-
induced hypoxia: as haematocrit decreases, so too does blood haemoglobin content, and the capacity of the 
macrovasculature to deliver oxygen to the tissues is compromised, thereby resulting in hypoxia. However, 
such an explanation is rendered unlikely by a number of observations. SMA, though common (particularly in 
children), is not associated with an increased risk of mortality, and carries a substantially less severe 
prognosis when compared with other features of severe malaria (124). Furthermore, SMA does not translate 
into a comparative incidence of pathologically low (<92%) blood oxygen saturation, thereby casting doubt 
on a possible cause-and-effect relationship between anaemia and systemic hypoxia. This can be explained by 
the phenomenon whereby patients are able to tolerate SMA reasonably well, provided that the decline in 
haematocrit occurs slow enough for a compensatory right-shifted change in the oxygen dissociation curve 
(proportion of saturated haemoglobin versus prevailing oxygen tension)(23, 77). Thus, while the contribution 
of SMA to hypoxia should not be considered negligible, it remains an unlikely candidate for the primary 
cause of hypoxia-induced hyperlactataemia. 
Generalized convulsions, a feature of severe malaria and characterised by rapid, repeated contraction and 
relaxation of skeletal muscle, can also elevate the contribution to blood lactate within clinical settings (23). 
Mean plasma lactate values of up to 13 mM have been measured in adults following the relatively brief 
episodes of intense muscular exertion that characterize generalized convulsions (12). 
2.7 Modelling of Biochemical Systems 
Mathematical modelling is, as the name implies, a means of describing observed phenomena using 
mathematical equations. Such phenomena can include the motion of planets around the sun, the flow of 
traffic, or the sound emitted by a plucked string. A model would include one or more functions accompanied 
by numerical parameters that match the phenomenon under study. Such a model could be defined, in a 




The form and complexity of a mathematical model should match the question it is intended to answer. For 
example, the rate of a reaction catalysed by an enzyme in solution is the result of a myriad of factors with 
seemingly interminable complexity. A ‘truly realistic’ mathematical model would include descriptions for 
the random motion of substrate molecules within the solution, the intermolecular interactions between the 
substrate and enzyme, transient changes in enzyme conformation, and so on. However, the Michaelis-
Menten equation describing the reaction velocity of an irreversible enzyme-catalysed reaction, shown below, 
achieves this with only two parameters and a single variable. For a substrate s and a product p, 
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This equation allows the rate of an enzyme-catalysed reaction to be predicted based on the substrate 
concentration, maximum reaction velocity (VMAX), and the substrate’s equilibrium dissociation constant to the 
enzyme (KM). Since the reaction velocity is expressed as the change in concentration over time, it follows 









The parameters governing this reaction can be determined with relative ease using standard enzymatic assay 
methods. If the objective is to simply describe and predict the concentration of substrate and product over 
time, then such a compact model can successfully answer this question, despite not including detailed 
descriptions at the molecular level. Such a minimalist description satisfies the “Minimum Description 
Length” principle that essentially states that the most accurate and useful model is usually also the smallest 
(157, 158).  
Of course, the biochemical processes present in nature are rarely so straightforward. A biochemical reaction 
can be reversible, involve a number of substrates or products each with its own associated kinetic 
parameters, or be catalysed by different enzymes which may be subject to different modes of regulation. 
Furthermore, while it is certainly useful to examine a single reaction in isolation, this only involves a single 
component of what is usually a much larger reaction network. The biochemistry of a living organism is 
characterised by a highly organised set of reactions occurring simultaneously, where one product could be 
the substrate for many other reactions, and vice versa. These networks can occur in different compartments, 
whether this be on the level of the organelle, cell, or organ. A single organism could contain millions of 
reactions and chemical species that are subject to constant change. 
However, such considerations do not prevent each reaction being characterised in a manner similar to the one 
shown above. Once a sufficient number of reactions have been described mathematically and equipped with 
the suitable parameters, the activity of the pathway as a whole can be described and predicted. For example, 
if the properties of glycolysis in a microorganism have been characterised experimentally and expressed 




concomitant production of molecules such as ATP. This is typically achieved using computational methods, 
whereby the system is simulated with a given set of conditions and parameters. The answer to broader 
questions, such as which component of the pathway is most important in determining the rate of glucose 
consumption, can also be answered by analytical techniques carried out computationally. Such modelling 
and analytical techniques are the mainstay of systems biology. 
The modelling of biochemical systems spans several domains of biology, with applications including the 
prediction of a protein’s function from its structure, the investigation of the constituent parts of signalling 
networks, or the analysis of gene regulatory networks (156). The work described in this thesis falls under the 
auspice of molecular systems biology, which involves the modelling of biochemical pathways to examine the 
emergent properties of a system as a function of its smaller, constituent parts. As described previously, these 
smaller components could be on the scale of a single compartment, a pathway, an enzyme, or a parameter. 
The utility of kinetic modelling in this regard is the ability to discern properties and outcomes of a large-
scale biochemical system that could otherwise not be derived analytically from first principles. The ability to 
construct and simulate ever larger and more complex biological phenomena is enabled by the perpetual 
advancements in sophistication of software platforms and the processing power of the hardware on which 
they operate. 
2.7.1 Metabolic Control Analysis 
A skilled biochemical systems biologist could likely make intuitive deductions about the properties of a 
simple, straightforward biochemical network following cursory inspection. However, once more complicated 
pathways are considered, such as the complex, branched, and intricately regulated biochemical networks so 
ubiquitous in cellular metabolism, a more sophisticated and systematic approach is required. 
Metabolic control analysis, or MCA, is a powerful tool that can yield both qualitative and quantitative 
insights concerning biochemical networks that exhibit stationary properties, such as steady-states. It involves 
the mechanistic examination of enzyme pathways to determine how the kinetic behaviour of the sequence as 
a whole varies with the properties governing the activity of each individual enzyme. In other words, MCA is 
used to discern the relationship between the parameter components of a model and its steady-state properties, 
thereby revealing the sensitivity of the system at steady-state to a change in a particular parameter. 
Though these relationships are expressed in terms of different coefficients, the fundamental relationship is 
the same. MCA coefficients are effectively the ratio of fractional changes in a model parameter x, and a 




















If x is perturbed by a fractional amount and y changes by the same fractional amount, then the coefficient can 
be said to be 1; in other words, there is a one-to-one ratio in the fractional change in x and the fractional 










An extension of this approach is a double perturbation, whereby x is both increased and decreased by a 




()↑ 	−	)TU) 	−	()↓ 	−	)TU)	
2	 ⋅ 	∆?	 ∙ 	?TU
 
 
Figure 2.9: Graphical representation of positive (left) and negative (right) sensitivity 
coefficients. 
These coefficients yield two very useful pieces of information: whether the dependent quantity y is directly 
or inversely proportional to the value of the independent quantity x, and the magnitude (or slope) of this 
relation. Thus, should a comprehensive sensitivity analysis be conducted on an entire model, one could 
ascertain not only which components increase or decrease a property of interest, but also which of them 
influence it the most. 
2.7.2 The Coefficients of MCA 
When examining the effects of changes within a biochemical system, the level of analysis can lie either 
locally or globally. In other words, if we are interested in the changes of a component on the local level, such 
as the rate of a single reaction, then local coefficients would be utilised. If, however, the change in the global 
state is to be determined, such as the change in the system’s steady state, then global coefficients would be 
used.  
To illustrate, consider the example of the elasticity coefficient, a local coefficient used to quantify the 
fractional change in a specific rate upon a fractional change in the concentration of a metabolite (substrate 
elasticity) or the value of a parameter (parameter elasticity), while the concentrations of all other remaining 
intermediates are kept constant at a value corresponding to a given reference state (Table 2.2)(160). This 
allows the properties of the specific reaction to be analysed locally and in isolation.  
Mathematically, substrate elasticity, or the sensitivity of a reaction rate vk to the change in the metabolite 





















Global coefficients, as their name implies, pertain to the system as a whole. There are two types of global 
coefficient: control coefficients and response coefficients (Table 2.1). 
Table 2.1: The coefficients of MCA 
















Control and response coefficients differ only in the independent variable used in their calculation: reaction 
rates or parameters, respectively. This can be illustrated considering the finite perturbation method: in the 
former case, an entire rate expression is increased or decreased by a fraction, the example below using 1%: 
,↑
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]										 ; 										,↓
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] 
in the latter case, a fractional change would be introduced to a specific parameter instead, here chosen to be 
KM: 
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One can thus form distinct definitions for the two types of coefficients, shown here using up and down 
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This section has discussed the meaning and derivation of the coefficients of MCA. Illustrative examples of 
how these coefficients are used to examine biological networks can be found in Table 2.2. 





Notation Schematic Representation 
Substrate elasticity Yes cdw
fw 
 
Parameter elasticity Yes cDx(fy)
fy  
 
Flux control No pfy
qw 
 
Concentration control No pfy
dw 
 
Flux response No vDx(fy)
qw  
 
Concentration response No vDx(fy)
dw  
 
Red arrows indicate the perturbed entity (variable, reaction rate, parameter); blue arrows indicate the entities the 





Chapter 3: Building the Model 
The previous chapter described how severe malaria is a complex disease involving multiple organs and cell 
types within the blood. Further discussion dealt with the changes in metabolism observed in the host as a 
result of infection by the malaria parasite, with specific examination of the associated pathophysiology of 
hypoglycaemia and metabolic acidosis. The chapter was concluded with an introduction to the concepts of 
kinetic modelling and metabolic control analysis, and how use of these methodologies is suitable in 
answering the research question of how severe P. falciparum malaria can give rise to these metabolic 
aberrations. This chapter goes on to discuss how these methodologies were applied to satisfy the research 
aims and objectives. 
Section 3.1 details the underlying rationale of constructing a multi-compartment model, explaining the 
choice of constituent models which were merged to yield the final whole-body model. This section also 
describes how this merging process was carried out, with particular attention paid to how the original, 
independently-published models were modified to be compatible and give reasonable descriptions when 
compared to clinical data.  
In Section 3.2, we discuss which components were added to the model as part of the current research, and 
why they were considered suitable for incorporation with regards to answering the research question. Section 
3.2.1 describes additions made at the whole-body level to ensure that the individual compartments 
functioned congruently and exhibited reasonable behaviour when connected through the common plasma 
compartment. Section 3.2.2 goes on to describe the novel components introduced to specifically address the 
host-parasite interactions that could contribute to the development of hypoglycaemia and metabolic acidosis, 
as discussed in Chapter 2. A summary of these changes and additions is provided in Section 3.2.3. 
Finally, Appendix A outlines the in silico methodologies employed during model construction and analysis. 
This section gives an overview of how the model was structured in a computational environment, as well as 
the software written to discern model structure, view simulation outputs, and efficiently conduct metabolic 
control analysis. 
3.1 Model Construction and Validation approach 
In the first chapter of this thesis, the aims and objectives of the current research were stated, all of which 
depended on the construction of a whole-body model of glucose and lactate metabolism, which could 
subsequently serve as an in silico platform for investigating the causes of hypoglycaemia and lactic acidosis 
in severe P. falciparum malaria. To achieve this goal, contemporary scientific literature was reviewed to 




lactate in both healthy and diseased states. The suitability of mathematical modelling to provide answers to 
the research question was explained, as well as the practical considerations and limitations of this approach.  
Glycolysis is embedded in a network of reactions, which may provide or consume substrates, products, or 
intermediates, the precise structure of which is dependent on the particular needs of the organ in question. 
For example, the brain displays a strong preference for glucose, utilising the majority for the free energy 
production required to sustain neural activity. By contrast, the liver may catabolise glucose for energy, 
synthesise it through gluconeogenesis, or store it as glycogen, depending on the prevailing metabolic needs 
of the body. Furthermore, some organs, such as adipose tissue, may only take up glucose from circulation 
following stimulation by insulin, subsequently converting it to lipids for storage as fat. The relative 
contribution of each organ to plasma glucose concentration will thus vary depending on the metabolic and 
endocrinological state of the body at a particular point in time.  
Since all tissues are capable of catabolizing glucose (42), a whole-body model of glucose metabolism would 
ideally include compartments describing each and every organ, tissue, and cell in the human body. Such a 
‘complete’ model would not only describe pathways pertaining to carbohydrate metabolism, but also those of 
fat and protein, since these possess a plethora of intermediates that can be used by the processes of glycolysis 
or gluconeogenesis. Of course, such an exhaustive model has yet to be constructed, and is the subject of 
ongoing research by teams across the world. Furthermore, even if such a model did exist, its interminable 
size and complexity would undoubtedly be beyond the scope of this thesis, not to mention the computational 
burden of simulating such a model.  
However, the most detailed model is not necessarily the best model to answer a specific research question; 
the level of detail is dependent upon the answers being sought.  
These practical limitations thus necessitate a different approach. Fortunately, there exists a wealth of 
independently published models describing the metabolism of one or more compartments with varying 
degrees of detail and complexity. Examples include a whole-body model constructed for the purpose of 
examining glycogen regulation, with a more detailed hepatic compartment geared towards investigating the 
role of substrate cycling (161). Conversely, another model investigating skeletal muscle energy metabolism 
features only a single compartment, but includes detailed and comprehensive kinetic descriptions of both 
cytosolic and mitochondrial pathways (17). A common feature of these models is the inclusion of a blood or 





Figure 3.1: Diagram depicting a possible whole-body model limited to dynamic 
descriptions of glucose, pyruvate, and lactate metabolism. The plasma compartment 
provides a common framework to which other compartments can be freely connected or 
removed via their respective transporters. The direction and specificity of metabolite 
transport can be specified on a per-compartment basis. The level of detail in each 
compartment can also vary. For example, the liver may feature detailed descriptions of 
glucose metabolism involving bidirectional exchange of multiple metabolites with plasma, 
while less significant organs can be relegated to a lumped compartment termed “Other” that 
mediates only glucose uptake from plasma.  
The plasma compartment common to different models can therefore be thought of as a unifying vessel to 
which other compartments can be ‘plugged’ into in a modular fashion (Fig. 3.1). The majority of the 
research in this thesis was conducted in this manner, whereby each compartment was added sequentially and 
evaluated to identify any discrepancies that resembled anomalous or unexpected behaviour. These 
discrepancies could include errors in reproduction, unit incompatibilities, or unforeseen interactions between 




simple matter of simply ‘disconnecting’ it from the master plasma compartment by removal of its rate 
equations from the plasma ODEs. Details of such model development methodology are given in Section 
3.3.1. 
The first step in integrating the independently published models was to confirm that they had been 
reproduced accurately. This was done after the models had been reconstructed in Wolfram Mathematica, and 
was achieved by comparing the outputs produced with those shown in the original independent publications. 
In each case, the model was reproduced and its results compared in isolation i.e. it was not combined with 
other models prior to comparison of outputs. In cases where the published and reproduced results differed 
substantially despite exhaustive troubleshooting efforts, reasonable attempts were made to understand why 
the discrepancies persisted, and to keep their presence in mind when proceeding with further model 
development. Simulation outputs of the final model were compared to data from clinical studies, specifically 
the plasma concentrations of glucose and lactate in both the healthy and diseased state. Such comparison is 
necessary not only to check the veracity and plausibility of model outputs, but ultimately to confirm the 
model’s ability to answer the research question. 
The final model, hereafter referred to as meyer1, contains ten compartments adapted from three publications, 
with additional changes, modifications, and additions from other sources where noted. The models and their 
respective compartments are detailed in the following sections. 
3.1.1 Erythrocyte and Parasite Compartments 
The model presented in this thesis has its foundation in green1, a model published by Kathleen Green in 
2017 as part of her thesis titled ‘Whole body modelling of glucose metabolism in malaria patients’(162). The 
green1 model was based on previous work conducted by Francois du Toit, published in 2015 (21). This latter 
model (dutoit3) describes glucose metabolism in infected erythrocytes. The model constructed by du Toit 
was, in turn, based on pioneering work by Gerald Penkler, who published a kinetic model of glucose 
catabolism in Plasmodium falciparum (penkler1) in 2013 (20). The parasite glycolytic pathway in penkler1 
is comprised of detailed kinetic descriptions with parameters obtained from experiments characterising each 
enzyme within the Embden-Meyerhof-Parnas pathway, yielding a system of eighteen coupled ODEs.  
Following this, du Toit proceeded to construct a multi-compartmental model that could simulate the 
metabolic behaviour of an infected erythrocyte (Fig. 3.2); this was done by adapting a previous model of 
erythrocyte metabolism published by Mulquiney and Kuchel (163–165). The work published by du Toit 
described not only the process of adapting and merging these models, but also the results of experimental 
validation, whereby the volume of the growing intraerythrocytic parasite, as well as extracellular substrate 





Figure 3.2: Compartments and pathways present in the combined P. falciparum-infected red blood cell 
model. Reactions are grouped in a modular fashion: A, Glycolysis; B, pentose phosphate pathway; C, 
Rapoport-Leubering shunt; D, haemoglobin complexes; E, glutathione metabolism; F, magnesium 
complexes; G, parasite compartment. Reproduced from (21) 
Green (162) built upon this model to investigate how the accelerated glycolytic flux of infected erythrocytes 
contributed to the pathogenesis of hypoglycaemia and lactic acidosis, two of the metabolic comorbidities 
characterising severe malaria that are associated with a high risk of mortality. This research yielded a whole-
body model of glucose metabolism that utilised the model published by du Toit and combined it with another 
independently published whole-body model by Xu et al. (161). This latter model, originally used for the 
purpose of examining substrate cycling within the context of glycogen turnover and whole-body glucose 
homeostasis, was merged with the infected erythrocyte model of du Toit. This process required extensive 
modification and adaption to ensure the compatibility of the different units of mass and concentration 
between the femtomole amounts present in the infected erythrocyte model and the millimolar concentrations 
present in the model published by Xu et al. Addition of both an infected and uninfected erythrocyte 
compartment to the Xu model necessitated numerous changes to accommodate the introduction of a 
sophisticated red blood cell compartment to an otherwise generalised, coarse-grained model. Further changes 
and replacements were also made to glucose and lactate transporters in the erythrocyte and liver 
compartments, respectively. Finally, the model was validated with simulation outputs from both the existing 
models, as well as clinical data obtained from studies measuring blood glucose and lactate concentrations in 




Four compartments were obtained from this model and subsequently incorporated into meyer1, namely that 
of the uninfected erythrocyte, infected erythrocyte, and blood plasma. The remaining hepatic, skeletal 
muscle, and adipose compartments from the original Xu model were not utilised in the current study. 
3.1.2 Hepatic Compartment - Overview 
A model describing hepatic glucose metabolism (hereafter referred to as H1) was published by 2012 by 
Matthias König, Sascha Bulik, and Hermann-Georg Holzhütter (18). The authors set out to construct a 
detailed mathematical model describing the metabolism of glucose by the liver. Additional features included 
descriptions of hormonal control by insulin, glucagon, and epinephrine, as well as incorporation of allosteric 
regulation (Fig. 3.3). The model was subsequently used to simulate experimental data corresponding to four 
physiological phenomena: (i) the relative quantitative contributions levied by hepatic glycolysis, 
gluconeogenesis and glycogen metabolism under varying concentrations of external plasma glucose; (ii) the 
timecourses of hepatic glycogen concentration under fed and fasting states; (iii) the switching between net 
hepatic glucose production and utilization as a function of hypo- and hyperglycaemia, and (iv) the effect of 
varying hormone concentrations on liver glucose metabolism.  Procurement of model parameters in the 
original study was done either through literature review, or fitting to multiple experimental data sets.  
Several features of H1 made it particularly attractive for incorporation into the current model. The model 
features a detailed description of both glycolysis and gluconeogenesis. Additionally, glycogen turnover is 
comprehensively described, with expressions denoting not only the activity of glycogen synthase and 
glycogen phosphorylase, but also glucose-1-phosphate 1,6-phosphomutase (G1PI) and UTP-glucose-1-
phosphate uridylyltransferase (UGT). A rudimentary description of mitochondrial metabolism is included to 
account for initial gluconeogenic flux of pyruvate through pyruvate carboxylase and phosphoenolpyruvate 
carboxykinase. Finally, hormonal regulation is incorporated throughout the model, supplementing 





Figure 3.3: Structure of the reaction networks in H1. Reactions unique to hepatic glucose 
utilisation are shown in green, and those unique to glucose production indicated in red. 
Enzymes regulation by hormonal or allosteric mechanisms are marked with a yellow P and 
red A, respectively. Reactions that have been added to the original model in this work are 
indicated in blue. Reactions and species that were disabled or absent in the original model 
have been removed. Abbreviations: ANT: ADP/ATP translocase; NDX: NAD+/NADH 
exchanger; OxPhos: oxidative phosphorylation; PYRT: pyruvate transporter. Figure 
adapted from (18) 
H1 also features descriptions of hepatic exchange of glucose and lactate with the plasma compartment, 
which were considered highly valuable after taking into account the primary role these two metabolites play 




simulating the dynamics of hepatic glucose metabolism under varying plasma concentrations of glucose and 
lactate, thereby making it wholly suitable for incorporation into a model investigating the metabolic 
underpinnings of hypoglycaemia and hyperlactataemia associated with severe malaria.  
However, as with all in silico descriptions of biological phenomena, the model was limited by the need to 
make assumptions and simplifications. While not all of these were necessarily prohibitive for use within the 
current model, those that were significantly problematic did need to be addressed, and are thus mentioned 
here. First, H1 does not allow for changing concentrations of energy carriers and reducing equivalents, in 
particular the concentrations of NAD+/NADH and ATP/ADP. To quote the original paper, “[t]he model is 
limited to physiological states where changes in the energy- and redox state can be neglected, […] 
consequently, the model is not able to simulate conditions where this assumption of energy decoupling is not 
valid, for example, under hypoxic or ischemic conditions” (emphasis added)(18). Thus, while including a 
basic description of mitochondrial metabolism, the model does not include descriptions of oxidative 
phosphorylation or translocation and exchange of energy carriers and reducing equivalents between the 
cytosol and mitochondrion. Given the substantial role that parasite-mediated microvascular occlusion and the 
resulting ischemia plays in malaria pathogenesis, the lack of detailed mitochondrial oxidative metabolism 
was considered to be an important issue. 
Second, while transport of glucose and lactate between the hepatic and plasma compartments is described, 
that of pyruvate is not. Within the context of the current model this constitutes a significant issue, because 
the erythrocyte model previously described exhibits significant levels of pyruvate export (in addition to 
lactate), and there will thus be an interminable accumulation of pyruvate within the plasma compartment if 
an accompanying method of uptake from the plasma is not included. Physiologically, the liver would 
constitute the chief organ responsible for removal of plasma pyruvate via monocarboxylate transporters. 
However, a description of hepatic pyruvate transport between the cytosol and plasma compartments was not 
originally present. 
Third, the model is limited to glycolytic metabolism with lactate constituting the only metabolic terminus 
free to leave the hepatic compartment. Other metabolic fates of glycolytic intermediates, such as conversion 
to alanine, entry into lipogenic pathways, or metabolism by the tricarboxylic acid cycle are not considered. 
However, this limitation only becomes pertinent if the model is to be expanded to encompass the entirety of 
gluconeogenesis with the inclusion of amino acid and glycerol pathways, an endeavour that was beyond the 
scope of this research. It should be noted, however, that the authors have recently released an updated, 
expanded version of the model, named HEPATOKIN1 (166), that addressed most, if not all, of the issues and 
limitations described above. The authors have graciously made a copy of the model available through 
personal correspondence, though it was regrettably unable to be utilised due to time constraints.  
In meyer1, one compartment was incorporated from this model to represent the liver, consisting of the 




3.1.3 Hepatic Compartment - Modifications 
3.1.3.1 Reducing equivalents 
In König’s original model (18), the cellular redox and energy states were kept constant. This meant that the 
concentrations of NAD+, NADH, ATP and ADP remained unchanged in both the cytosolic and 
mitochondrial compartments. Additionally, since the concentrations were kept fixed, no transport equations 
were included that described the movement of these molecules across the mitochondrial membrane.  
The decision to omit this additional complexity was likely made due to both its minimal relevance to the 
research objectives, and the lack of impact on the model’s predictive power. However, within the context of 
the current model, the lack of a dynamic system of reducing equivalents and energy carriers severely limits 
the ability to produce plausible simulations of hepatic metabolism under conditions of cellular hypoxia, 
hypoglycaemia, and high extracellular concentrations of lactate.  
To address these issues, a number of changes were made. First, the concentrations of the hepatic metabolites 
ATP, ADP, AMP, NAD+ and NADH were unclamped, thereby allowing them to vary as a function of their 
respective fluxes. For ATP, ADP, NAD+ and NADH, this included the introduction of separate variables for 
their respective cytosolic and mitochondrial concentrations. These variables were defined with initial values 
identical to the original clamped concentrations used for reproduction of the published results. 
Next, two rate equations were introduced that allowed the movement of ATP, ADP, NAD+ and NADH 
between the cytosol and mitochondria. First, the activity of adenine nucleotide translocase, an antiporter 
mediating the exchange of free ATP and ADP across the inner mitochondrial membrane, was modelled using 
a facilitated transport flux expression based on one previously described by Li et al. (17) for skeletal muscle. 
Note the use of the compartmental phosphorylation state (PS) in lieu of a substrate concentration variable. 
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Since the original H1 model lacked the required metabolites and kinetic descriptions, the incorporation of 




deemed practically viable. In the current model, using the same approach of Li et al. (17), the effective 
exchange of NADH and NAD+ between the cytosol and mitochondria was modelled using an expression 
similar to that described above, again with compartmental redox state supplanting substrate concentration 
variables. 
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While these transporters operate only across the inner mitochondrial membrane in a physiological setting 
(exchanging metabolites between the mitochondrial intermembrane space and matrix), for the purposes of 
this model, movement of these molecules across the outer mitochondrial membrane was considered to be 
instantaneous, effectively making these transporters operate between the cytosolic and lumped mitochondrial 
compartments. 
Following the implementation of these changes, an additional rate equation was introduced to model the 
process of oxygen utilisation and oxidative phosphorylation within the mitochondria, whereby ADP and 
NADH could be recycled into ATP and NAD+. To maintain consistency and compatibility, this expression 
was incorporated verbatim from an earlier paper published by Dash et al. (167) where it was employed in 
their model for muscle cell metabolism . In the current model, the concentrations of oxygen and phosphate 
are kept fixed, and the values of the remaining parameters are left unchanged. 
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Finally, the kinetic expression of adenylate kinase, present but disabled in the original model, was enabled in 
H1. Adenylate kinase itself is important in mediating cellular energy homeostasis via ongoing 
interconversion of the adenine nucleotides ATP, ADP, and AMP, a role that was judged to be significant 




3.1.3.2 Pyruvate transporter 
The liver contains multiple isoforms of monocarboxylate transporters (MCTs), several of which are capable 
of transporting lactate and pyruvate (168). H1 did not originally contain a description of pyruvate transport to 
and from the plasma compartment. The decision to add such a description was made based on both its 
physiological plausibility, and the tendency of infected erythrocytes to export pyruvate into plasma (20), 
which would subsequently be taken up by the liver. Thus, without a means for the pyruvate to be cleared 
from the plasma, such as through hepatic uptake, the model would show an unrealistic accumulation of 
pyruvate within the plasma compartment. The option of keeping the plasma pyruvate concentration fixed and 
not introducing a pyruvate transporter term into the hepatic compartment was not pursued for several 
reasons. First, the ratio of lactate to pyruvate in the plasma is often used as a diagnostic measure in clinical 
studies when determining the degree of metabolic acidosis (93, 130). This was interpreted as a indicating that 
both the levels of plasma lactate and pyruvate were important when modelling lactic acidosis. Second, a 
constant pyruvate concentration would have ‘upstream’ effects with regards to (infected) erythrocyte 
metabolism, whereby pyruvate export from red blood cells would not be subject to dynamic equilibrium with 
the plasma compartment. Third, with the exception of glycerol, pyruvate constitutes the immediate product 
of gluconeogenic conversion of alanine and lactate, and as such stands as a focal point of gluconeogenic 
metabolism. To abstain from introducing a dynamic relationship between this focal point of hepatic 
gluconeogenesis and the plasma compartment therefore seemed unreasonable. This decision was further 
encouraged by the fact that both lactate and pyruvate are transported by the same MCTs, and that a lactate 
transporter equation was already present in H1. The dynamic relationship could thus be easily implemented 
by using the existing rate equation with different parameters obtained from literature (168–171). 
The kinetic rate expression for the pyruvate transporter was adapted from H1’s existing description of lactate 
transport; this approach was substantiated by the knowledge that pyruvate and lactate are both transported by 





















3.1.3.3 Sub-compartment volume scaling 
Hepatocytes contain mitochondria, which mediate several metabolic pathways relevant to the scope of the 
overall model. Thus, during the process of integrating H1 with the rest of the model, particular attention was 
paid to ensure that the hepatocyte’s cytosolic and mitochondrial compartments functioned in a manner 
congruent to the rest of the model. The primary aspect of this congruency was ensuring that the 
mitochondrial subcompartment was effectively defined as its own entity within the hepatic cytosol, similar to 
how the parasite compartment was defined as a subcompartment within the infected erythrocyte cytosol. 
Such an implementation was further indicated by the aforementioned conversion of hepatic cytosolic and 
mitochondrial ATP/ADP and NAD+/NADH to dynamic variables. To distinguish between the concentrations 
of these metabolites, separate volume denominators would have to be implemented with their molar 
amounts. Such an approach would also allow the transport of absolute molar amounts between the cytosolic 
and mitochondrial compartments to satisfy stoichiometric constraints and mass conservation.  
Subsequent changes were made with the purpose of (i) defining two separate compartments with distinct 
volumes, metabolites, and reactions, and (ii) scaling these compartments according to the existing H1 
parameters, while still keeping their relative magnitudes physiologically plausible. Using this approach, the 
liver would be represented by two separate compartments, with one comprising the entirety of hepatic 
cytosol, and the other all of hepatic mitochondria. This methodology parallels that used by other independent 
authors for the remaining compartments featured in the current model, where the metabolism of a single cell 
is scaled up to represent an organ (162). 
Changes began with determining the overall dimensions of the hepatic compartment. First, the total volume 
of the liver was estimated to be approximately the same as its weight, assuming unitary density (172). For a 
normal adult male, this would be approximately 1.5 litres. Estimation of total liver volume was made due to 
discovery of an existing parameter in the original H1 model defining the hepatic parenchymal volume 
fraction. Thus, the value for total liver volume was multiplied by the H1 parameter defining the hepatic 








This process was repeated with two other existing parameters, which were interpreted to indicate the 




















These expressions for hepatic cytosolic and mitochondrial volume were subsequently used both as 
denominators for the mass-based metabolite variables (redefining them in terms of concentration for use in 
rate equations), and as coefficients of reactions, to scale the enzymatic activity according to the size of the 











3.1.4 Inclusion of Extra-hepatic Compartments 
Having reproduced and validated the parasite, erythrocyte, infected erythrocyte and hepatic compartments 
(see Chapter 4), it was considered whether or not these compartments, in combination with the plasma 
compartment, would be sufficient to achieve the research aims and objectives. It was decided to extend the 
model to include several additional compartments involved in glucose and lactate metabolism, with the 
implementation described in Section 3.1.5. The rationale for this decision is outlined below. 
i. Existing descriptions were found to be inadequate. The original green1 model did feature 
rudimentary implementations of skeletal muscle and adipose compartments, but these were found to 
be lacking in the detail required to allow them to respond in a physiologically plausible manner 
when subject to the extremes of blood glucose and lactate concentrations that are associated with 
severe malaria. The skeletal muscle compartment, adapted from Xu et al. (161), was effectively a 
very coarse-grained compartment that converted glucose to lactate through a series of three 
reactions. The adipose compartment, also adapted from Xu et al., simply imported glucose and, 
through another series of three reactions, converted it to free fatty acids, the latter of which was 
clamped and had no subsequent interaction with the model. It was decided to adapt a different 
independently published model entirely, ideally one that could more realistically simulate the 
metabolic behaviour of these organs under a range of blood glucose and lactate concentrations. 
ii. Malaria affects the metabolism of multiple organs. As described and explained in Section 2.6.4, 
only the immature forms of the parasite remain motile in the circulation, with the remainder adhering 
to the microcirculatory capillary endothelium during sequestration prior to schizont rupture. The 
tissue distribution of sequestered parasite is heterogenous both within affected tissues, and between 
infected individuals, giving rise to a range of possible clinical presentations affected by multiple 
factors, including the age of the host (Fig. 2.4). The literature presented in Chapter 2 suggests that 




the liver, could be an important causative factor in mediating the appearance of HG/HL in severe P. 
falciparum malaria. If the current model is to address this, then the incorporation and inclusion of 
sufficiently detailed compartments outside of the liver and erythrocytes is a necessity. 
iii. Modular descriptions of whole-body glucose and lactate metabolism are available and could be 
easily incorporated. A cursory search for independently published models yielded discovery of one 
published by Kim et al. that had a particular focus on the dynamics of whole-body lactate 
metabolism during exercise (16). Examination of this model showed that it did not contain excessive 
detail, was defined in a modular fashion that would expedite the addition or removal of 
compartments as necessary, and would be wholly compatible with the existing model under 
construction. The methodological approach taken when incorporating this model is detailed in the 
following sections. 
3.1.5 Muscle, Brain, Cardiac, Adipose, and GIT Compartments - Overview 
A multi-compartmental model of fuel homeostasis during exercise (here referred to as K1) was published in 
2007 by Jaeyeon Kim, Gerald Saidel, and Marco Cabrera (16). K1 features seven tissue compartments, 
namely the brain, heart, liver, gastrointestinal tract, skeletal muscle, adipose tissue, and an umbrella 
compartment, termed ‘Other’, that denotes the remainder of compartments that collectively have an effect on 
plasma glucose levels. The kinetic behaviour of each compartment is drawn from a base template of lumped 
pathways and reactions that encompasses the anabolism and catabolism of the glucogenic substrates glucose, 
glycogen, lactate, pyruvate, alanine, glycerol, fatty acids, and triglycerides (Fig. 3.4). Each compartment has 
a unique subset of reactions appropriate to its metabolic role (see Figs. 3.4, B.3 & B.8 for examples of 
different implementations between compartments). For example, direct glyceraldehyde-3-phosphate 
reduction to glycerol-3-phosphate (lumping in the dihydroxyacetone intermediate) is only present in the 
adipose compartment, alanine synthesis from pyruvate is only present and skeletal muscle, and glycogen 
metabolism is present in all compartments save for the gastrointestinal tract and adipose tissue. All organ 
compartments include a complete description of glycolysis, that, while lumped, is subject to both hormonal 
and allosteric regulation, as well as intermediate and terminal branch points that carry flux into glycogenic, 
lipogenic, and tricarboxylic acid cycle pathways. A summary of the compartments with their accompanying 





Figure 3.4: Schema illustrating the template of reaction pathways present in the different tissues of K1. 
Cyan and blue circles represent the exponent of reducing equivalent controllers, while orange and red 
indicate those of energy carrier controllers (see text). Grey arrows and metabolites indicate clamped 
fluxes and species. Figure adapted from (16) 
Reaction parameters are specific to each compartment, in line with its relative contribution to overall fuel 
homeostasis. Additionally, hormonal regulation of key reactions by insulin, glucagon and epinephrine is 
incorporated on a per-compartment basis, as a function of an integral-rein controller (see Section 3.1.8) 
simulating plasma hormone concentrations. 
With H1 already providing a suitably comprehensive model to describe hepatic glucose metabolism, K1’s 
consistent, modular, multi-compartmental description of whole-body glucose metabolism was found to 




lumped and simplified reaction networks are not particularly desirable when attempting to model an organ so 
crucial to whole-body glucose turnover as the liver, they are very expedient when modelling ‘lesser’ non-
gluconeogenic organs that, within the scope of this model, are essentially ‘glucose-in-lactate-out’ 
compartments. For this purpose, and for contributing to the ability to answer the research question outside of 
the hepatic and erythrocyte compartments previously described, the K1 model has several features that make 
it suitable for addition to the current whole-body model. 
Table 3.1: Reactions present in the K1 model that are not common to all compartments 
 Brain Heart Muscle GIT Liver Adipose 
Gluconeogenesis    I PYR → GAP       
II GAP → G6P       
III G6P → GLC       
Glycogenesis G6P → GLY       
Glycogenolysis GLY → G6P       
Fatty acid synthesis ACoA → FFA       
Fatty acid oxidation FFA → ACoA       
Lipolysis TG → 
FFA + 
GLR 
      
Triglyceride synthesis FFA + GRP → TG       
Glycerol phosphorylation GLR → GRP       
GAP reduction GAP → GRP       
GRP oxidation GRP → GAP       
Alanine transamination ALA → PYR       
Alanine synthesis PYR → ALA       
Phosphocreatine hydrolysis PCR → CR       
Phosphocreatine synthesis CR → PCR       
Shaded blocks are reactions that are included; blank blocks are not included in the respective compartment column. 
Abbreviations: ACoA, acetyl-CoA; ALA, alanine; CR, creatine; FFA, free fatty acids; G6P, glucose 6-phosphate; GAP, 
glyceraldehyde 3-phosphate; GLC, glucose; GLR, glycerol; GRP, glycerol phosphate; GLY, glycogen; PCR, 
phosphocreatine; PYR, pyruvate; TG, triglyceride 
K1 also features dynamic descriptions of energy carriers (ATP/ADP) and reducing equivalents 
(NAD+/NADH), the respective ratios of which are incorporated into the relevant rates as controllers, which 
serve as dynamic terms that regulate reaction rate in lieu of more complex substrate binding constant terms: 
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In accordance with its approach of lumped reactions, K1 does not feature reversible reactions, but rather 
pairs of irreversible reactions acting in opposition, and coupled with controller energy metabolite pairs 
(PS/RS) where appropriate. To illustrate, let us use the example of lactate dehydrogenase (LDH), which is 
implemented differently between H1 and K1. In H1, the rate equation is expressed as follows: 


















Whereas in the corresponding metabolic process in K1’s hepatic compartment, 
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K1 considers nine substrates to be capable of transport between the blood and tissue compartments: glucose, 
pyruvate, lactate, glycerol, alanine, free fatty acids, triglycerides, oxygen and carbon dioxide. The net uptake 
or release of substrate mass si and concentration Ci in compartment x is expressed in the original paper by 
Kim et al. with the dynamic mass balance 
ΔåB
Δt
	= 	≥Y 	 ⋅ 	 rpjçÄé|Ä,B 	−	µY,B	pY,Bt 
Where Qx denotes the rate of blood flow through compartment x in litres per minute, σx,i represents the 
partition coefficient of substrate si in compartment x, and Cplasma,i and Cx,i the plasma and compartmental 
millimolar concentrations of substrate si, respectively (16).  
The advantages and disadvantages of K1 generally contrast with those of H1. Where H1 has fewer overall 
rates and metabolites with more complex and detailed individual descriptions, K1 has an abundance of 
variables and kinetic expressions that attempt to encompass the entirety of whole-body glucose turnover with 
generalised, generic descriptions that feature no enzyme mechanistic detail and little to no modification 




certainly preferable to a dearth thereof, the additional pathways and metabolites not immediately consequent 
upon the glycolytic/gluconeogenic pathway between glucose and pyruvate/lactate (e.g. alanine, glycerol, free 
fatty acids and triglycerides) introduces another problem: are they to be included as free, dynamic variables, 
clamped and kept constant, or removed?  
3.1.6 Muscle, Brain, Cardiac, Adipose, and GIT Compartments - Modifications 
As stated in the previous section, K1 includes several metabolites that are not present in H1, namely alanine, 
glycerol, free fatty acids (FFAs) and triglycerides. In the original K1 model, all of these metabolites are 
present in the hepatic compartment, and undergo exchange with the blood compartment. Thus, since K1’s 
hepatic compartment has effectively been supplanted by H1, these variables pose a problem in that they 
either require incorporation into H1, or need to be removed from the model.  
Initial research for this thesis using different models pursued the former option by attempting to introduce 
the ‘missing’ reactions and metabolites into the hepatic compartment using kinetic expressions and 
parameters from other models or online databases, effectively employing a ‘mix-and-match’ approach. 
However, this approach was discontinued for several reasons. First, and perhaps foremost, the introduction 
of previously unconsidered reactions into a model that was parameterised in their absence invariably 
produces anomalous and unrealistic results that are difficult to rectify. Second, if one were to add species and 
reactions for the purpose of comprehensiveness and modelling the physiological reality as closely as 
possible, it becomes difficult to decide where to set the arbitrary limit of complexity. An illustrative example, 
encountered in much earlier versions of the multi-compartmental model, is that of amino acid metabolism. 
Of the amino acids, alanine is the prime gluconeogenic substrate in the liver, but glutamine is a very close 
second. However, unlike the simple, reversible reaction carried out by alanine transaminase, glutamine must 
first undergo hydrolysis by glutaminase, followed by conversion to α-ketoglutarate, subsequent flux through 
the TCA cycle to oxaloacetate, after which it can enter the gluconeogenic pathway by eventual conversion to 
phosphoenolpyruvate. While the inclusion of such descriptions would indeed increase how ‘realistic’ the 
model is, it adds additional complexity, computational burden, and errors or anomalous results that are 
exceedingly difficult to troubleshoot. Furthermore, the decision to include an additional amino acid, but not 
the remaining eighteen glucogenic amino acids, can be criticised as unreasonable and arbitrary. Finally, such 
additions and the resulting model are impossible to validate without the appropriate data.  
Following consideration of these issues, it was subsequently decided that the aforementioned variables 
present in K1, but not H1, would be clamped and kept constant at their original concentrations as published 
by Kim et al. (16), who used values at steady-state that reflected a normal overnight fasted human at rest. 
These concentrations would serve as an starting point that was validated previously by the original authors. 





Table 3.2: Implementation in meyer1 of metabolites present in the K1 model that are clamped (kept 
constant), variable, or are not common to all compartments 
 Brain Cardiac Muscle GIT Adipose 
Alanine N/A N/A N/A N/A N/A 
Glycerol N/A Clamped Clamped N/A N/A 
FFA N/A Clamped Clamped Clamped Clamped 
Triglycerides N/A N/A N/A N/A N/A 
Glycogen Variable Variable Variable N/A N/A 
GRP N/A Clamped Clamped Clamped Clamped 
PCR Variable Variable Variable Variable N/A 















N/A indicates that the metabolite was either not originally present, or removed due to all relevant reactions being 
clamped.  
Abbreviations as in Table 3.1. 
While this was relatively straightforward to implement, it then raised the question of how to define the 
reactions that featured both clamped and unclamped metabolites as substrates and products. While the 
clamped metabolites are assigned constant concentrations reflecting the healthy, rested state, the unclamped 
metabolites are free to vary and respond to the metabolic changes associated with malaria infection. If some 




creates the situation where the capacity of the model to give accurate descriptions is impaired, because 
portions of the model are unresponsive to changes in whole-body metabolism. To illustrate, let us consider 
the following examples. In both the cardiac and skeletal muscle, glycerol (GLR) undergoes phosphorylation 
to form glycerol-3-phosphate (GRP), using the hydrolysis of ATP to ADP for the provision of a phosphoryl 
group.  
C"v	 + 	49(	 → 	Cv(	 + 	45( 
While both GLR and GRP are clamped, ATP and ADP are not. Three other reactions had such a combination 
of clamped and unclamped variables: triglyceride synthesis, present in all compartments except for the brain,  
Cv(	 + 	3	ññ4	 + 	6	49(	 → 	9C	 + 	6	45(	 + 	7	(B 
GAP reduction, present only in adipose tissue, 
C4( + 	3456 → 	Cv(	 +	3457 
And fatty acid oxidation, present in cardiac, skeletal muscle and adipose tissue: 
ññ4	 + 	8	4pA4	 + 	2	49(	 + 	14	3457 	→ 	8	4pA4	 + 	2	45(	 + 	2	(B 	+ 	14	3456 
Following metabolic control analysis of the erstwhile iteration of the model, it was discovered that these 
reactions, particularly cardiac and muscular glycerol phosphorylation and triglyceride synthesis, exhibited 
very high control over plasma glucose (Fig. 3.5) and lactate concentrations (Fig. 3.6), which at the time 
appeared anomalous. Further investigation confirmed these suspicions, as both these reactions involve ATP 
hydrolysis (Fig. 3.4). Since glycerol, glycerol phosphate, and triglyceride concentrations are clamped, this 
effectively translates to a constant, significant level of ATP hydrolysis that substantially overshadows the 







Figure 3.5: Rates exhibiting control over plasma glucose concentration, ranked in terms of 
absolute value in descending order. Green bars indicate positive coefficients, while red bars 









Figure 3.6: Rates exhibiting control over plasma lactate concentration, ranked in terms of 
absolute value in descending order. Green bars indicate positive coefficients, while red bars 
indicate negative coefficients. 
In other words, this relatively high rate of ATP hydrolysis would overshadow the comparatively low flux 
through other ATP-consuming reactions under conditions of hypoglycaemia and hyperlactataemia. The high 
control exhibited by these reactions was not judged as a scientifically meaningful finding or an emergent 
property of the model, since they display these high degrees of control while some of their constituent 






this section, to unclamp them would involve changes to the model that are beyond the scope of the current 
research. 
Further investigation showed that, by decreasing the clamped concentration of GRP in the cardiac 
compartment by factor of 10 and doubling it within the muscle compartment, the control of these reactions 
on plasma glucose and lactate levels was drastically reduced, as well as substantially improving the ability of 
the model to describe clinical data. It is possible that these changes brought the system closer to a state that 
represented equilibrium during malaria infection. These changes were, however, admittedly biased and made 
in order to have simulation outputs match clinical data, and not to predict in vivo concentrations. However, 
considering that only two clamped metabolites were changed, and that this measure was much more viable 
than a more comprehensive reworking of the entire model that would be impractical in terms of time, such 
modifications were judged to be permissible. 
Additionally, the definition of some clamped variables, such as triglyceride, are not present or declared in the 
current model at all. This is due to a custom optimisation function written to remove any rates, assignments, 
or parameters that are not present in the final model submitted for numeric solving. Since some of the rates 
in K1 have only clamped variables as substrates and products, and thus do not affect the fluxes of the model 
in any meaningful capacity, they were removed, so as to minimise the information submitted for computation 
(Table 3.2).  
3.1.7 Hormonal Compatibility Changes 
Models H1 and K1 utilised different approaches with regards to describing the concentrations of insulin, 
glucagon, and epinephrine, the chief hormones regulating glucose metabolism across multiple compartments.  
K1 adapted a method previously described by Saunders et al. (173, 174) to describe the dynamic plasma 
concentrations of insulin and glucagon. This method involves use of an integral rein controller, composed of 
a system of coupled ODEs that determine hormonal concentration over time. This controller uses as input not 
only blood glucose concentration, but also the concomitant concentrations of insulin and glucagon, as the 
level of one hormone inhibits the rate of secretion of the other. Given K1’s particular focus on exercise, the 
level of plasma epinephrine is not dictated by any metabolic inputs, but an empirical relation whereby 
epinephrine levels rise as a function of the degree of physical exertion. 
With hormonal concentration dynamics so described, K1 has further descriptions whereby the maximum rate 
coefficients of reactions known to be hormonally regulated are stimulated as a function of plasma hormone 
concentrations. For reactions considered to be affected by glucagon and insulin, the model utilises a 
hyperbolic function with the plasma glucagon-insulin ratio (GIR) as input. 
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Note that these descriptions describe only stimulation of the relevant reactions; no descriptions for inhibition 
are present. This is understandable when considering the purpose of the original model, which sought to 
simulate the changes in fuel homeostasis during exercise, and was not intended to be used for description of 
metabolic changes during the majority of the day when the individual is not subject to exertion.  
Conversely, H1 makes use of a different approach, using phenomenological functions termed glucose-
hormone responses (GHR). These sigmoid functions describe the plasma concentration of a given hormone 
between its minimum, basal concentration and maximum concentration. The function for insulin increases 
monotonically with increasing blood glucose concentration: 




A similar function is applied in the original H1 model to glucagon (and epinephrine, with its corresponding 
set of parameters), this time monotonically decreasing with increasing blood glucose concentration: 









With these functions in place, their relative contribution to the cell’s overall phosphorylation state is 
calculated by applying a Michaelis-Menten like transformation to each, converting each to a hyperbolic 
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Note that the expression for epinephrine contains an additional coefficient that scales its effectiveness down 
by 20%. 
The fraction of hepatic enzymes currently phosphorylated (denoted γ) is subsequently expressed as 
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During the combination of these models, the issue of how to incorporate their respective hormonal regulatory 




concentration outputs, it would simply have been a matter of implementing one model’s hormonal controller 
and having it control all compartments. Unfortunately, this was not the case (Fig. 3.7). 
 
Figure 3.7: Hormone concentration vs glucose concentration plots for the original H1 
(dashed line) and K1 (solid line) models. 
A possible solution would have been to include both controllers, and have each govern its respective 
compartment, as per the original models. However, several drawbacks make this approach impractical. First, 
inclusion of K1’s insulin and glucagon variables, in addition to the variables already present in H1, would 
have added computational load, model complexity, and hinder troubleshooting. Second, as mentioned before, 
K1 was not designed to simulate hyperglycaemic states, which have been observed in some malaria patient 
subpopulations (175). Additionally, it lacks a dynamic description of plasma epinephrine concentration, a 
limitation absent in H1. Third, attempts to reproduce and validate K1’s original descriptions were met with 
limited success (Figs. 3.5 & 3.6), limiting the confidence with which its hormonal controller could be 
applied to H1. Finally, the bulk of K1’s hormonal modifiers occur in its hepatic compartment, which has 
already been supplanted by H1.  
With these considerations in mind, the decision was made to utilize H1’s descriptions of hormone 
concentrations. K1’s remaining non-hepatic hormonal modulation terms (located in the cardiac, skeletal 
muscle, adipose, and GIT compartments) were adapted to accept H1’s plasma hormone concentrations as 
input. In the case of epinephrine-mediated regulation, this was achieved by simply replacing the input to the 
hyperbolic function with the normalized hormone concentration (concentration above baseline) originally 
described in H1 (see second equation within Section 3.1.7): 
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3.2 Model Construction – Novel Additions 
One of the research objectives described in Section 1.2.3 was to modify and extend the model with features, 
phenomenological or otherwise, to introduce host-parasite interactions that have a significant effect on 
plasma glucose and lactate, as reported in literature, to prepare for the contingency that, without these 
changes, the model would fail to describe the clinical data. When this indeed did prove to be the case, 
multiple modifications and additions were implemented in the interest of improving the descriptive capacity 
of the model. In an ideal model, these additions would be based on scientific studies, where the novel 
components are parameterised via processing of numerical sets of input and output data. In this way, the 
changes, modifications and additions would be able to describe unknown phenomena while still having a 
quantitative basis in reality. 
In the current research, however, such changes and additions were made without the aid of quantitative data 
to guide the process of deriving and parameterising phenomenological functions governing phenomena such 
as host-parasite metabolic interactions. At the time of writing, the situation is one where a consensus has 
been reached by multiple independently published sources stating that a particular cause-and-effect 
relationship exists between parasite infection and host metabolism, but such statements are wholly limited to 
the qualitative realm. A good example of this is the causal chain that has been established between parasite 
sequestration within the hepatic microvasculature, impedance of liver function, and the contribution of this 
compromised hepatic metabolism to the appearance of hypoglycaemia and hyperlactataemia in severe 
malaria (12, 49, 63, 93, 108, 176). The few studies that have measured quantitative data demonstrating the 
positive relationship between the degree of microvascular obstruction and plasma lactate levels have limited 
applicability in the current research, as the data was collected through orthogonal polarization spectral 
imaging of capillaries in the rectal mucosa (128). The authors of this paper noted that the changes in 
microcirculatory blood flow through the rectal mucosa could also be present in other organs, including the 
liver, where compromised tissue oxygenation could have a deleterious effect on lactate metabolism, citing 
the heterogeneity in the degree of sequestration between organs observed in autopsy studies (132, 135).  
These findings thus necessitated the use of a ‘top-down’ modelling approach, which is typically less 
preferable than the ‘bottom-up’ method used when deriving other novel additions made to the model. For 
example, when parameterising features such as scaling organ compartment weight by age or choosing a 
value for a glucose input function, decisions are made based on numerical data and quantitative observations. 
In other words, these components are built upon empirical observations, and are extended and adapted ‘up’ 
towards description of the clinical data of plasma glucose and lactate concentration in severe malaria. 
Conversely, the ‘top-down’ method is effectively the opposite approach, where in the absence of such 
empirical data, the values of parameters are chosen based on the quality of the descriptions they yield, 
irrespective of how closely they resemble physiological values, the latter of which remain to be determined.  
This ‘top-down’ approach was thus necessitated for the derivation, parameterisation and implementation of 




modulation of host metabolism, due to the relative abundance of published qualitative statements and the 
paucity of quantitative data. 
It could be argued that the model features presented here, particularly those related to modelling 
microvascular disturbances, are not applicable, since they are not derived from detailed mechanistic 
interpretations of physiological processes or fitted to quantitative measurements. Since such quantitative data 
simply is not available at the time of writing, the next course of action would be to base these functions on an 
in-depth model derived from the biophysics of blood flow in the microcirculation. However, considering that 
this model is concerned with metabolic phenomena that manifest at the whole-body level, and that the 
dynamics of luminal capillary blood flow would constitute an entire research project on its own, the work 
presented below constitutes what was judged to be the most reasonable and practical implementation 
considering the time and means available. Ample effort has been given to substantiate these changes with 
references to the existing literature, and the mechanistic basis of novel additions are explained where 
possible. A summary of these changes with their accompanying rationale is provided at the end of Section 
3.2 in Tables 3.5 & 3.6. 
3.2.1 Plasma Compartment 
3.2.1.1 Compartment Age and Weight Scaling 
Recent literature has emphasised the role of age in the presentation and prognosis of severe malaria, 
highlighting not only differences in disease severity, but also the relative incidence of pathological 
manifestations (23, 124). While syndromes such as coma and metabolic acidosis do not appear to be 
associated with age, hypoglycaemia and anaemia are found to be more prevalent in children, with adults 
typically being more prone to hepatic and renal failure (Fig. 2.4). 
Thus, the ability to scale the model compartments with the age of the individual being simulated became an 
appealing prospect, and was subsequently implemented. The decision to add this feature was made for a 
number of reasons: simple, expedient formulae that estimate body weight from age are already in use in the 
clinical setting (177, 178); the volume of individual organ compartments can be directly inferred and scaled 
from total body weight; and the mass-based units of the model mean that the absolute mass of metabolites 





Figure 3.8: Plots of simulated weight, blood volume, and organ compartment volume 
normalization factors as a function of age. Top-left panel corresponds to formulae shown in 
Table 3.3, while the top-right panel corresponds to those shown in Table 3.4. Bottom-left 
panel shows the normalisation factor (bodyweight/bodyweightadult) used to potentially scale 
individual organ volumes 
Calculation of weight as a function of age was done using a modified version of a previously established 
method (177), with additional formulae added for adolescents and adults (Table 3.3). An individual aged 18 
or older was assumed to have a bodyweight of 70 kilograms. 
Table 3.3: Formulae for simulated weight as a function of age 
      Weight (kg) 
0 ≤ Age < 1  0.5	 ×	((4ã&	 × 	12) + 9) 
1 ≤ Age < 5  2	 ×	(4ã& + 5) 
5 ≤ Age < 14  4	 × 	4ã& 
14 ≤ Age < 18  3.5	 ×	(4ã&	 − 	14) 	+ 	56 
18 ≤ Age    70 
Additionally, the total blood volume was estimated using a formula adapted from anaesthesiology (Table 





Table 3.4: Formulae for total blood volume as a function of age 
       Blood Volume (L) 
Neonates (<28 days old) 0 ≤ Age < 
28
365




 ≤ Age < 1   &Éãℎ%	(¿ã)	× 	0.08	"/¿ã 
Adults 1 ≤ Age     &Éãℎ%	(¿ã)	× 	0.072	"/¿ã 
 
Finally, since the H1 and K1 models were originally designed to simulate adults weighing 70 kg, 
compartment volumes and other scalable components are multiplied by the normalised ratio of age-
determined bodyweight to adult bodyweight. 




Where (ORGAN)_COMPARTMENT_WEIGHT_DEFAULT is the typical weight of the given tissue in a 70 
kg adult male.  
It should be noted that, while this scaling was implemented successfully and produced reasonable simulation 
outputs, this functionality was not utilised in a meaningful capacity during further research. Instead, all 
simulations were conducted at a constant simulated age of 18 and body weight of 70 kg. While the 
investigation of how simulation outputs with regards to steady-state plasma glucose and lactate 
concentrations would differ as a function of age could possibly yield useful insight into malaria 
pathophysiology (Section 2.4), development of this feature was discontinued due to the time required to both 
collect data with which to parameterise the relative growth of individual compartment volumes through 
various stages of life, and to implement and test such functionality. Furthermore, the greater relevance of 
other novel model components (such as host-parasite interactions, Section 3.2.2) also placed further 
development of age and weight scaling at a lower priority. This functionality has, however, been 
incorporated into the model for future investigations. 
3.2.1.2 Volume scaling 
The volume of the ‘blood’ compartment was defined as consisting of several distinct sub-compartments, 
namely the plasma, uninfected erythrocyte cytosol, infected erythrocyte cytosol, and the parasite cytosol. The 
volume of each of these compartments is a fraction of the total blood volume, which, in turn, is defined by a 
function estimating total blood volume from age.  
("4LK4_p>K(4v9KF39_N>"ïKF_"9FvL → Ã4ã& &Éãℎ%ûN[("4LK4_4ïÑ_4CF] 
The subsequent total erythrocytic cytosolic volume is derived as a subfraction of the total blood compartment 
volume (‘plasma’ indicating the volume of the blood not taken up by cells): 




Where RBCu_MISC_AlphaCellWaterFraction indicates the free liquid cytosolic volume portion of the 
erythrocyte, BLOOD_HAEMATOCRIT indicates the volumetric fraction of the blood taken up by 
erythrocytes, and BLOOD_TotVolmL the volume of the blood compartment in millilitres.  
This erythrocyte cytosol compartment is then further divided into infected and uninfected sub-compartments: 
vûp+_N>"ïKF	 →	 (1 − (ñ_4ïÑ_(L	) 	 ⋅ 	vûp_pÅ9>L>" 
vûpÉ_N>"ïKF	 → 	(ñ_4ïÑ_(L	 ⋅ 	vûp_pÅ9>L>" 
Where PF_AUX_PS indicates percentage parasitaemia. Finally, the infected erythrocyte compartment is 
again separated into the infected erythrocyte cytosol, and the parasite cytosol: 




Where the fraction PF_MISC_volPFTroph/RBCu_MISC_volRBCDefault indicates the fraction of the 
erythrocytic volume taken up by the parasite. The parameter volPFTroph represents an averaged volume of 
the parasite across all intraerythrocytic lifecycle stages. Thus, the total infected erythrocyte volume can be 
calculated by multiplying the infected erythrocytic volume portion by the total volume of infected 
erythrocytes, parasites included: 
vûpÉ_CELL_N>"ïKF → 	vûpÉ_pF""_N>"ïKF_ñv4p9>3	 ⋅ 	vûpÉ_N>"ïKF_ñv4p9>3 
A similar approach is used to calculate the volume of the parasite compartment, by multiplying the 
percentage parasitaemia by the total infected and uninfected erythrocyte volume to obtain the fraction of 
erythrocytes that are infected, and subsequently multiplying this again by the volume fraction of the 
erythrocytic volume taken up by the parasite: 





Figure 3.9: Parasite and infected erythrocyte compartments volumes as a function of percentage 
parasitaemia obtained from the equations for PF_VOLUME and RBCi_CELL_VOLUME, 




3.2.1.3 Renal lactate excretion 
Implementation of renal lactate excretion (clinically observed above 5 mM plasma concentration)(88) was 
done using an extended hyperbolic tangent function. This function bears close resemblance to the activation 





	 ⋅ 	 (1	 +	tanh[#	 ⋅ 	 (?	 − 	$)]) 
With gradient proportional to a and inflection point at c (Fig 3.10). 
 
Figure 3.10: The tanh ‘switch’ function 
This function was defined following difficulties using a piecewise function. Within the context of computing 
numerical differential solutions for the model, the piecewise function introduces numerical and 
computational instability, likely owing to its Boolean processing of model variables which leads to 
problematic stiff equations. Usage of a piecewise function as part of a controller function can become 
problematic if the input variable continually oscillates around the piecewise threshold. To illustrate, let us 
consider a possible piecewise implementation of a renal excretion function, which is only active at or above 
a plasma lactate concentration of 5 mM: 
Ã(?) = “
0, ["#$%#%&:çÄé|Ä] < 5.0
¿ùë¬ 	 ⋅ 	 ["#$%#%&:çÄé|Ä], ["#$%#%&:çÄé|Ä] ≥ 5.0
 
While such a straightforward function can be readily implemented using Mathematica’s built-in 
functionality, it poses several problems. First, it is not physiologically plausible; the kidney does not 
completely halt all excretory function when the plasma lactate concentration falls below 5 mM. Second, if 
the plasma lactate concentration happened to reach a steady-state at 5 mM, computation would be slowed by 
the task of having to switch between two mathematical definitions at each time step.  
Having encountered these problems, a ‘switch function’ was implemented in the trigonometric form 
described above. Like the piecewise function, this function can still give near-absolute outputs of ‘true’ and 




3.10). This switch function was used to rapidly ramp up (‘switch on’) renal lactate excretion as it neared and 
exceeded a threshold value of plasma lactate concentration.  
This function was subsequently implemented in the rate equation denoting renal lactate excretion from the 
plasma compartment. Parameters were determined according to the values which gave descriptions that best 
agreed with the clinical data (Section 4.1.3) based on visual inspection (see Section 4.3.4 and Fig. 4.12 for 
an example of how parameter values were chosen according to congruence with clinical data upon visual 
inspection). 
3.2.1.4 Glucose feed function 
Since the model is an open system, where species such as lactate are removed from the plasma compartment 
through means such as renal excretion, a corresponding function had to be implemented for glucose entry 
into the plasma. Implementation of such a glucose ‘feed’ function was necessitated for steady-state analysis, 
since, without a constant input of glucose, the model would eventually evolve to equilibrium as all 
glucogenic stores, such as glycogen, became depleted.  
The most realistic way to model the intake of nutrients (specifically glucose) in an individual would likely be 
the introduction of a stomach and/or gastrointestinal compartment(s), which would receive a predefined 
influx of nutrients at times of the day that correspond to meals. While this approach was successfully 
implemented, the nature of a steady-state model precludes any kinetics that do not equilibrate with time. 
This therefore leaves the introduction of a constant, zero-order rate of glucose influx into the plasma 
compartment as the most practical option. This method is also representative for the clinical setting where a 
constant intravenous infusion of glucose is provided, to prevent hypoglycaemia in children with severe 
malaria who are incapable of ingesting meals (49, 180).  
Therefore, a relatively straightforward function was introduced, comprised simply of a constant rate of 
glucose influx, defined in units of milligrams per kilogram bodyweight per minute. This input parameter is 
subsequently converted to millimoles per minute via division by the molar mass of glucose and 
multiplication with bodyweight.  
The magnitude of the glucose influx rate was chosen to be approximately 2 mg/kg/min, to align with the 
intravenous infusion given to unconscious, hypoglycaemic children with severe malaria (62). This could 
potentially be increased to 5 mg/kg/min, as is the case in emergency settings (65), although this would likely 





,_F3’_("4LK4_C"ïp>LF_ñFF5	 → 	("4LK4_C"ïp>LF_ñFF5_KK	 ⋅ 	û>5Å FC69_/C	
Here, PLASMA_GLUCOSE_FEED_MM represents the rate of glucose infusion, expressed in millimoles per 




3.2.1.5 Glucose utilization function 
To account for the remainder of glucose utilisation not specified by other compartments, two 
phenomenological functions were implemented to account for glucose uptake by the renal and splanchnic 
organs. These functions were parameterised in the current research, based on previous literature describing 
glucose usage on a per-compartment basis (181–184). They were further adapted to increase glucose 
consumption at a rate proportional to the plasma glucose concentration as an indirect, phenomenological 
inclusion of the effect of insulin release. The phenomenological rate equation for renal glucose utilisation is 
shown below. 
,_("4LK4_C"ïp>LF_ï9"_vF34" = 	("4LK4_C"ïp>LF_ï9"_vF34"_¿	 ⋅ 	("4LK4_N4v_ã@+$Aå&:´OdGO_ª´÷;◊d0_÷í¡´_ä0©O´_©	 
Where PLASMA_GLUCOSE_UTIL_RENAL_k represents a first-order rate coefficient, 
PLASMA_VAR_glucose represents the millimolar concentration of plasma glucose, and 
PLASMA_GLUCOSE_UTIL_RENAL_N represents an exponential modifier. This rate equation is of the 
exponential form y = a·x2 to accommodate a higher rate of glucose uptake by ‘other’ tissues (i.e. those not 
explicitly assigned a compartment) at higher plasma concentrations of glucose, thereby giving a proxy, 
phenomenological description of insulin’s effect on glucose uptake as blood glucose concentration increases. 
Parameter values were chosen based on how well the corresponding simulation outputs of glucose utilisation 
of the whole model in the healthy state resembled the results published in the references (181–184). 
3.2.2 Parasite-Mediated Modulation of Host Metabolism 
3.2.2.1 Uninfected Erythrocytes 
One of the most striking examples of parasite-mediated changes in host metabolism was illustrated by a 
series of experiments performed by Mehta et al. (185). Exposure of healthy, uninfected erythrocytes to 
culture medium (CM) conditioned by P. falciparum-infected erythrocytes showed an almost complete 
inhibition of key glycolytic enzymes in the healthy red blood cells. The enzymes in question were 
phosphofructokinase (PFK) and pyruvate kinase (PK). The activity of glucose 6-phosphate dehydrogenase 
(G6PDH), a component of the pentose phosphate pathway, remained relatively unaffected.  
To incorporate this inhibitory effect into the model, a phenomenological function was implemented using a 
hyperbolic inhibitory function (Fig. 3.11), defined as follows: 




In the absence of data describing how the degree of inhibition varies with parasitaemia, both the hyperbolic 
form of the function and the accompanying inhibition constant were initially chosen arbitrarily and 




This inhibition component was introduced as a coefficient to the rate expressions of PFK and PK in 
uninfected erythrocytes. This marked the first phenomenological implementation of host-parasite metabolic 
interaction in the combined meyer1 model.  
 
Figure 3.11: Plot of the numerical inhibition value vs 
percentage parasitaemia 
3.2.2.2 Hepatic microvascular occlusion 
To model the effects of heterogenous microvascular occlusion on whole-body glucose and lactate 
metabolism, phenomenological functions and modifiers were introduced to various compartments, which 
altered the properties of specific rates as a function of percentage parasitaemia (similar to the PK and PFK 
inhibition discussed in Section 3.2.1). Due to the lack existing mathematical descriptions in literature, these 
functions and modifiers were novel additions derived phenomenologically as part of the current research. 
The hepatic perfusion and hypoxia modulation parameters were the third and fourth to be introduced, 
respectively. 
3.2.2.2.1 Perfusion 
Obstruction of microvascular flow has been observed in blood vessels supplying and draining the liver; 
based on the results examined in Section 2.6.4, it is assumed that this is due at least in part to the presence of 
infected erythrocyte aggregates and membrane remnants. Additionally, disruption of endothelial barrier 
integrity would also be a likely confounding factor. 
The existing mathematical framework describing the rates of transporters of glucose, lactate, and pyruvate 




exchange chemical species with plasma. First, a phenomenological hyperbolic function was used to 





Initial implementations used this function to decrease the maximal velocities of transporters. However, this 
method was discarded following the reasoning that the parasite altered the endothelial milieu and not the 
hepatocyte membranes; in other words, the maximal velocity of the transporter enzymes would not be 
affected, since neither the conformation of the enzymes themselves nor their effective concentration is 
altered. Instead, the sequestered parasites that adhere to the luminal surface of the endothelial capillary 
surface impede diffusion of metabolites to and through the endothelial wall. Attached to the inside of the 
capillary, they take up the volume of plasma available for metabolites to diffuse to the adjacent capillary 
wall. In the current study this effect was implemented as an increased affinity binding constant, or KM. 
Furthermore, since the sequestered erythrocytes adhere to the luminal side and do not penetrate to the 
hepatocyte parenchyma, this inhibition would be limited to the affinity binding constant of the plasma 
metabolites only. Finally, the function was defined as hyperbolic and saturable both to match the general 
trend of the clinical data, and the reasoning that there exists a limited luminal capillary surface for the 
parasites to adhere to, and a finite intraluminal capillary volume for the parasitized and infected erythrocytes 
to rosette and agglutinate within. 
Thus, another approach was employed, which involved an increase in the dissociation constant of the hepatic 
transporters for the extracellular species (Fig. 3.12). This was implemented as shown below, with the form 
of the rate equation being the same as that published in the original paper by König et al.: 
/GG{ù 	= 	/G 	 ⋅ 	 (1	 + 	6F(49p_(ñ_36û_(FvñïL>3) 
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Parameter values optimised on the basis of how closely the corresponding simulation outputs resembled 





Figure 3.12: Plot of increase in the plasma-side affinity 
binding constants for the hepatic glucose, lactate, and 
pyruvate transporters. 
3.2.2.2.2 Hypoxia 
Among the varied sequelae consequent upon microvascular obstruction, lack of tissue oxygenation is the 
most readily apparent and often the most cited. Though blood oxygenation has consistently been found to not 
be reduced by malaria infection, it stands to reason that, if a tissue becomes ischemic due to parasite-blocked 
capillaries, localised hypoxia would be an almost certain outcome. Furthermore, much of the literature 
reflects a consensus that the appearance of glycaemia with concomitant hyperlactataemia is due to 
accelerated generalised anaerobic glycolysis, of which the cause is usually insufficient oxygen supply. 
Incorporation of this phenomenon into the hepatic compartment of the model was implemented using 
separate descriptions from those utilised to model perfusion. This was done based on the reasoning that (i) 
oxygen diffuses between the blood and the tissues, and is not actively transported, (ii) H1 does not include 
any description of oxygen transport or turnover, and (iii) hypoxia affects the functions of enzymes mediating 
metabolic turnover, not transport.  
The function relating plasma percentage parasitaemia to tissue hypoxia was of the hyperbolic type (Fig 
3.13). Inhibition was limited to approximately 60% of normal, based on how well the model described 
steady-state plasma glucose and lactate concentrations when compared with clinical observations (Section 
4.1.3) of these metabolites. 








Figure 3.13: Plot of the hypoxia-mediated inhibition 
coefficient vs percentage parasitaemia.  
 
This inhibition term was then applied as a rate multiplier for fluxes known to either require oxygen, or that 
have been observed to be inhibited by the presence of parasitaemia. The enzymes in question are 
v_ENZ_HEPATIC_O2_H2O (oxidative phosphorylation), 
v_ENZ_HEPATIC_PYRUVATE_CARBOXYLASE, 
v_ENZ_HEPATIC_PYRUVATE_DEHYDROGENASE and 
v_ENZ_HEPATIC_TRANSPORTER_MITOCHONDRIAL_PYRUVATE, these enzymes were chosen 
based on literature reports (108, 152). Given that the literature in question gave only qualitative statements 
regarding the involvement of the aforementioned enzymes, inhibition of the reactions catalysed by these 
proteins was parameterised according to how well the resulting outputs matched clinical data in the presence 
of varying malaria parasite burdens. 
3.2.2.3 Cerebral perfusion inhibition 
Sequestration of P. falciparum within the microvascular beds of the brain causes occlusion of these vessels, 
reducing blood flow to the brain and causing inhibition of cerebral perfusion (135, 186). To model this 
process, a phenomenological function was implemented that would reduce the normal, basal blood flow as a 
function of increasing parasitaemia. This constituted the fourth modulation parameter introduced to the 
model. 







The inhibition term was used as a coefficient when calculating the blood flow to the brain (see Section 3.1.5 
for definition of blood flow rate equation). 
ûv43_û">>5_ñ"> _≥	 = 	ûv43_û">>5_ñ"> _≥_û4LF	 ⋅ 	("4LK4_ FC69_Lp4"4v	 ⋅ 	ûv43_(ñ_36û_(FvñïL>3 
Parasite-mediated changes in brain metabolism were limited to inhibition of perfusion, due to the relative 
dearth of discussion in the literature of aberrations of brain metabolism versus the effect of cerebral 
microvascular obstruction. 
3.2.2.4 Muscle metabolic upregulation 
Modulation of muscle metabolism by parasitaemia was implemented based on reasoning that (i) plasma 
lactate has been observed to rise after generalised convulsions (23), and (ii) basal muscle activity would be 
raised as part of pyretic thermogenesis (187). Generalized convulsions in particular would likely involve a 
transient shift towards greater usage of anaerobic glycolysis, owing to the intensity of the muscular 
contractions and the associated increased demand for rapid ATP supply. Introduction of a component 
describing this behaviour would thus allow the model to emulate the increased glycolysis that is expected to 
occur.  
This was subsequently modelled using a phenomenological Michaelis-Menten type function that would 
upregulate the activity of muscle ATPase activity with parasitaemia as input. This term was subsequently 
implemented as a rate multiplier to muscle ATPase flux as the final modulation parameter incorporated into 
the model. 









Figure 3.14: Plot of disease-mediated activation 
coefficient for skeletal muscle ATPase activity 
3.2.3 Summary of Changes and Additions 
A summary of the changes and additions made to the constituent models during the development of meyer1 
is given in Table 3.5. Modifications and extensions are listed by compartment, with each component 







Table 3.5: Compartments and the models they were based on; additions and changes and the rationale thereof 
Plasma; green1 (162) 
 Glucose feed function Provision of a constant input of glucose into the plasma compartment; 




 Glucose utilization function Accounts for glucose uptake by remaining compartments  (181–184) 
 Renal lactate excretion Simulation of renal lactate excretion during hyperlactataemia; indirectly 
accounts for renal gluconeogenic activity 
(88, 106) 
 Volume scaling Allowed plasma compartment volume to scale with age; reworked 
implementation of plasma/erythrocyte compartments to share a finite 
volume as defined by haematocrit 
* 
Hepatic; König et al. 2012 (18) 
 Unclamped reducing 
equivalents 
Extends functionality to include simulation of cellular hypoxia, 
hypoglycaemia, and hyperlactataemia 
(17) 
 Transport of reducing 
equivalents across the 
mitochondrial membrane 
 
 Oxidative phosphorylation 
activity 
 
 Pyruvate transporter Provides physiologically realistic means for plasma pyruvate uptake  
 Sub-compartment volume 
scaling 
Scaling of enzyme fluxes absolute masses of metabolites by relative 
volumes of cytosol and mitochondria; allows hepatic function to scale 
with liver size/volume 
 
 Parasite-mediated inhibition 
of liver function 
Phenomenological additions to simulate effects of parasite sequestration 
within the hepatic sinusoids, divided into perfusion inhibition 
(extracellular effects) and hypoxia (intracellular effects) 
 
Parasite; penkler1 (20)  Redefined how compartment volume was determined; no functional changes were 
made 
Erythrocyte; dutoit3 (21) 
 Modified transport rate 
coefficients 
Unit compatibility with plasma compartment  
 Parasite-mediated inhibition 
of PFK and PK function 
Simulation of healthy erythrocyte enzymatic inhibition by bloodborne 
parasite-derived substances 
(185) 
Infected erythrocyte; dutoit3 (21) 
 Modified transport rate 
coefficients 
Unit compatibility with plasma compartment  
Brain, Heart, Muscle, GIT, Adipose; Kim et al. 2007 (16) 
 Parameter adjustment Adjusted to accommodate clamped fluxes  
 Clamping of metabolites Compatibility with hepatic compartment  
 Adaption of hormonal 
controllers 
Compatibility with hepatic compartment and creating a unified global 
hormonal regulatory system 
 
 Addition of insulin controller 
to muscle glucose import 
Prevented excessive muscle glucose import at low plasma glucose 
concentrations; improved descriptions of plasma glucose 
 
 Parasite-mediated stimulation 
of muscle ATPase activity 
Phenomenological addition to simulate and account for increased muscle 
activity during generalised convulsions 
 
 Addition of limiting saturation 
term to cardiac glycogen 
synthase activity 
Prevented glycogen build-up to physiologically unrealistic levels during 
extended normo- or hyperglycaemia 
 
 Parasite-mediated inhibition 
of cerebral perfusion 
Phenomenological addition to simulate and account for parasite 
sequestration within cerebral microvasculature 
 





A description of the novel parasite-mediated host modulation terms is shown below in Table 3.6. Note that, 
because each modulation term could be enabled, disabled, and varied independently, the initial parameters 
for the respective modulation terms were first chosen based on their effect alone, with the final parameters 
being determined based on their effects on the plasma glucose and lactate vs. parasitaemia curves plotted 
against clinical data (viz. Fig. 4.4, Appendix C) with all modulation terms acting in concert. 
Table 3.6: Novel host-parasite metabolic interaction terms with descriptions, listed in the order they were introduced 
1. Inhibition of uninfected erythrocyte metabolism Section 3.2.2.1 
  Hyperbolic inhibition of uninfected erythrocyte phosphofructokinase and pyruvate 
kinase as a function of increasing parasitaemia 
 
2. Hepatic perfusion inhibition Section 3.2.2.2.1 
  Hyperbolic increase in the dissociation constant in the rate equations mediating 
transport of glucose, lactate and pyruvate between the hepatic and plasma 
compartments, as a function of increasing parasitaemia 
 
3. Hepatic hypoxia Section 3.2.2.2.2 
  Decrease in the maximum velocities of the hepatic reactions catalysed by pyruvate 
carboxylase, pyruvate dehydrogenase, and the mitochondrial pyruvate transporter, as a 
function of increasing parasitaemia 
 
4. Cerebral perfusion inhibition Sections 3.1.5 
(description of blood 
flow) & 3.2.2.3 
  Inhibition of the rate of transport of all metabolites being exchanged between the 
plasma and brain compartments via a hyperbolic decrease in the common parameter Q, 
as a function of increasing parasitaemia 
5. Muscle metabolic upregulation Section 3.2.2.4 
  Hyperbolic increase in a rate multiplier affecting skeletal muscle ATPase reaction 
velocity, as a function of increasing parasitaemia 
 
For a visual representation of the effects of varying the parameters mediating each modulation term, the 
reader is referred to Appendix C.  
Although many of the effects are currently implemented in a phenomenological way, the model now 
represents a modular framework for future studies where the different effects can be reparametrized based on 
clinical data and the parameter values updated, or the modules can be improved if more mechanistic 






Chapter 4: Results & 
Discussion 
In Chapter 3 the structure of the model was described, discussing the individual compartments that together 
form the whole-body model, as well as the modifications and additions that were made to ensure 
compatibility between the different constituent models and how these compartments were repurposed to 
specifically address the research question posed in this thesis.  
This chapter presents a demonstration of the types of analyses that can be performed on the complete meyer1 
model framework, accompanied by discussion of how these findings could contribute to the research aims 
and objectives. Due to the fact that the complete model contains a number of phenomenological processes 
with estimated parameters, no conclusive evidence can be gathered by such analyses at this stage. Although 
the model goes some way toward a more realistic description of the process involved in whole-body glucose 
metabolism and its response to malaria infection, model fitting and validation procedures are precluded by 
the lack of independent, empirical data.  
In Section 4.1, the results pertinent to research objectives 1 through 3 (identification and merging of 
independently published models describing separate components of glucose and lactate metabolism, and 
subsequent validation of this combined whole-body model) are discussed. First, simulation outputs given by 
meyer1 in the healthy state are compared with those published for the original constituent models. This was 
done to ensure that the whole-body meyer1 model still gave reasonable metabolic descriptions for each 
individual compartment. This is followed by an examination of how well the meyer1 model can describe 
steady-state plasma glucose and lactate concentrations over a range of parasitaemias, when compared with 
clinical data.  
Section 4.2 examines the results obtained from the model pertaining to research objective 4, namely to test 
whether glycolytic parasite metabolism alone can cause hypoglycaemia and hyperlactataemia in the infected 
state. Model simulation results indicating the degree to which parasite metabolism contributes to the 
development of each of these symptoms is discussed in turn. 
The results and discussion featured in Section 4.3 examine the role that hepatic metabolism plays in 
influencing the appearance of hypoglycaemia and metabolic acidosis in the diseased state, to address 
research objective 5. Several components of hepatic metabolism as depicted in meyer1 are discussed, 
including the dynamics of metabolite transport fluxes into and out of the hepatic compartment, the behaviour 




upon implementation and manipulation of the phenomenological host-parasite interactions introduced into 
the hepatic compartment. 
Finally, Section 4.4 demonstrates how the sixth and final research objective was addressed, by discussing the 
results of metabolic control analysis and how these can be interpreted to determine which components of 
parasite and host metabolism can be targeted by novel chemotherapeutics to ameliorate the disease, with 
particular emphasis on prevention and reversal of malaria-associated hypoglycaemia and hyperlactataemia. 
The results accompanying discussion featured in this chapter was limited to those findings judged to be most 
significant with regards to the research question, aims and objectives. The remainder of the results and 
discussion can be found in Appendices B & C. 
4.1 Model Results and Comparisons with Published Data 
Before using the combined meyer1 whole-body model as an investigative tool, we first obtained outputs for 
healthy and infected states, and compared these results with published data obtained both from the original, 
unchanged models, as is the case from green1 and K1, and clinical data obtained from literature measuring 
the plasma glucose and lactate concentrations in malaria patients over a range of parasitaemias. Comparison 
of the meyer1’s results with those of the models it was built upon helps to ascertain the extent to which it 
resembles the original models, and highlight any differences in outputs, and whether such discrepancies 
produced anomalous behaviour indicating that the models were merged erroneously or additional effects 
included incorrectly. Additionally, and perhaps more importantly, comparison of model outputs with clinical 
data gives an indication of the model’s descriptive capacity with regards to the physiological reality of 
malaria infection. If the model were not able to satisfactorily describe the appearance of hypoglycaemia and 
hyperlactataemia as a function of increasing parasite burden, then further analysis and conclusions would 
have little veracity. 
4.1.1 Model Reproduction 
Comparison of outputs of the reproduced model with those published for the original was carried out 
repeatedly to confirm both that the independently published models (dutoit3 (21), green1 (162), König 2012 
(18), Kim 2007 (16)) had been faithfully reproduced, and that the final model was able to give accurate, or at 
least reasonable descriptions of plasma concentrations of glucose and lactate in both the healthy and diseased 
state. Note that this section covers reproduction of the constituent models in isolation i.e. prior to 
incorporation into the merged whole-body model. 
Accurate reproduction  (construction of reproduced models that produced results closely resembling those 
published for the original) of the parasite, erythrocyte, and infected erythrocyte models was successful and 
achieved with minimal effort. This was likely due to the extensive validation that these models had already 
undergone by the original authors, and that the availability of these models in Mathematica format obviated 




reproduction of the K1 model was also achieved with relative ease, with simulation outputs in isolation and 
as part of the combined meyer1 model remaining approximately similar to those shown in the original 
publication. However, the process of validating accurate reproduction of the hepatic H1 model proved to be 
substantially more challenging, both in isolation and after incorporation into the final model. 
It is our understanding that the H1 model, originally published in 2012, was still subject to ongoing 
improvement during the course of the current research. Attempts to reproduce all of the originally published 
results verbatim were unsuccessful. While smaller components of the model such as the hormonal integral 
rein controllers were able to be reproduced accurately (Fig. 4.1), the remainder of the results shown in the 
paper proved difficult to reproduce.  
 
Figure 4.1: Validation plots comparing the reproduced H1’s results (dashed lines) with 
those published by König et al. (Fig. 2 in the original publication, solid lines). 
Validation efforts were primarily focused on reproducing the plots depicting the change in enzyme activity 
over time for several enzymes that represented key junctions of overall flux through hepatic glucose 
production or utilisation as a function of plasma glucose concentration (Box 4.1). Considerable effort was 




differing plasma glucose concentrations (Fig. 4.2). While such extensive testing and examination did yield a 
greater understanding and familiarity with the model, validation was marred by ambiguous parameter 
specifications in the published appendices and incomplete descriptions present in the SBML version of the 
model.  
 
Figure 4.2: Validation plots comparing the modified, extended H1 results (dashed lines) with 
those published by König et al. (Fig. 3 in the original publication, solid lines). Red lines indicate 
results obtained with a clamped plasma glucose concentration of 3.6 mM, while green indicates 
4.6 mM. Simulations were initiated with the same initial conditions (not shown). (A) hepatic 
glucose production (HGP), represented by flux through the hepatic glucose transporter (B) 
gluconeogenesis (GNG), represented by G6P isomerase flux (C) glycogenolysis (GLY), 
represented by glucose-1-phosphate 1,6-phosphomutase flux, (D) relative percentage contribution 






Ultimately, the pursuit of an exact reproduction was discontinued after the realisation that the model would 
have to undergo substantial changes and extensions in order to provide the function required within the scope 
of the current research in any case. The results of comparing the simulation results of the modified, extended 
hepatic compartment with those of the original paper are shown in Figures 4.2 and 4.3. All remaining 
components of H1 that were not modified, including the initial values, remained the same. 
While the general shapes of the curves appear to be reasonably similar (Fig. 4.2 A-C, Fig 4.3), the values of 
the graphs differ, with the current model showing substantially smaller variation in outputs when simulated 
at different plasma glucose concentrations. It can be argued that the initial timecourse discrepancies are 
inconsequential, since this model is intended to provide results only at steady-state.  Even so, some plots still 
differ even at steady-state (Fig. 4.2 A & B).  
 
Figure 4.3: Validation plots comparing the modified, extended H1 results (dashed lines) with 
those published by König et al. (Fig. 4 in the original publication, solid lines). Clamped glucose 
concentrations are (A, red) 3.6 mM; (A, green) 5.0 mM; (B, red) 5.5 mM; (B, green) 8.0 mM   
Full resolution of this issue was ultimately prevented by time constraints, and the finding that, despite these 
discrepancies, the modified hepatic compartment, functioning in tandem with the rest of the model, was able 





Box 4.1: The Problem of Hepatic Pyruvate Kinase 
The extremely low PK flux in both the infected and uninfected states was noticed during the analysis 
stage of H1 in isolation, and it was thought that this implausibly low level of activity in such an important 
component of the glycolytic pathway was due to an error during reproduction of the original model. 
However, upon further investigation it was discovered that the rate expression for pyruvate kinase had 
indeed been reproduced verbatim, and that it displayed low steady-state concentration of its substrate, 
phosphoenolpyruvate (PEP). This low PEP concentration is likely due to the absence of PEP provision by 
gluconeogenic flux through malate. As shown in the original model schema presented below, the authors 
had possibly intended to include kinetic descriptions of mitochondrial oxaloacetate flux through malate 
dehydrogenase to form malate, the latter subsequently being able to cross the mitochondrial membrane to 
form cytosolic oxaloacetate.  
 
Cytosolic oxaloacetate, in turn, can subsequently be converted to cytosolic PEP, thereby providing an 
adequate substrate pool for PK activity. But, as with the decision to utilize clamped energy carriers and 
reducing equivalents, the authors possibly chose to omit such descriptions due to their inclusion being 
unnecessary in achieving the research objectives the original model was built to achieve. However, while 
simplified or disabled components such as energy and reducing equivalents or cytosolic PEPCK activity 
were still present in the model, complete with parameters and rate equations, no mention or description of 
malate dehydrogenase kinetics were present outside of the published model schema. Since it had already 
been decided during development of the current model that the de novo introduction of pathway 
components to an established model was ultimately not conducive to producing a reliable model, malate 
dehydrogenase activity was not included. In the final version of the model, this results in PEP turnover 
being dominated by its release from the mitochondrion and subsequent utilization by enolase, to the near-




This concludes the section devoted to reproduction of the original models in isolation. The subsequent 
section examines the results given by simulations of the combined model, meyer1.  
4.1.2 Comparison of the Combined meyer1 Model with Previous Models 
The results shown here were obtained from simulations using the combined whole-body meyer1 model, 
which includes the constituent compartments detailed in the previous section, as well as the modifications 
and additions summarised in Table 3.5. As these are the results of simulations in the healthy state, the 
modulation terms listed in Table 3.6 were disabled as a consequence of the lack of parasitaemia. 
Simulation outputs for the steady-state transport fluxes of glucose (Table 4.1) and lactate (Table 4.2) 
between somatic compartments and the plasma compartment obtained from meyer1 were compared with 
those published by previous models, where applicable. These were conducted at 0% parasitaemia, i.e. in the 
uninfected state.  
Differences between model results were noted for the rates of glucose transport mediated by the hepatic and 
skeletal muscle compartments. While the current model’s result for hepatic glucose uptake displays 
approximate agreement with that shown by green1, it differs substantially from that obtained by the original 
K1 model. The skeletal muscle compartment also shows a much higher rate of glucose uptake than both the 
K1 and green1 models. No reversal of uptake or release was observed. 
Table 4.1: Comparison of steady-state uptake and release rates of glucose between models in the 
healthy state 
Compartment Kim 2007 (16) green1 (162) meyer1 
Brain -0.380 - -0.416 
Heart -0.040 - 0.000 
Liver 0.731 0.0053 0.041 
GIT -0.076 - -0.080 
Muscle -0.165 -0.053 -0.283 
Adipose -0.038 -0.053 -0.049 
Others -0.062 -0.077 -0.168 
Negative values indicate uptake, positive values indicate release of glucose  






Smaller differences were observed when comparing the current model’s results with those of K1 and green1 
with regards to lactate transport. The brain displayed a relatively small amount of lactate release in the 
healthy state, when compared with the reported value of zero in K1. This result is consistent with 
experimental observations showing a small net lactate release by the brain (188). 
Conversely, the current model also displayed negligible lactate transport between the cardiac and plasma 
compartments, contrasting with a rate of 0.04 mmol/min reported for the K1 model. Negligible lactate 
transport by the cardiac compartment in the resting, healthy state contradicts experimental studies showing 
the heart to mediate approximately 5% of whole-body lactate uptake (Section 2.6.2.4)(113). This finding 
could be explained by the clamping of the glycerol, free fatty acid, and glycerol phosphate variables in the 
cardiac compartment (Table 3.2). Keeping these variables constant may have resulted in the need for 
lactate’s use as a supplemental fuel being obviated at steady-state. Clamping of these same variables in the 
adipose compartment may also account for the reversal in lactate transport shown by the adipose 
compartment. 
Other notable differences include an approximately 50% decrease in lactate release by the skeletal muscle 
compartment when comparing the values of K1 and the current model, as well as a reversal from lactate 
release to uptake for the adipose compartment.  
Table 4.2: Comparison of steady-state uptake and release rates of lactate between models in the 
healthy state  
Compartment Kim 2007 (16) green1 (162) meyer1 
Brain 0 - 0.030 
Heart -0.040 - 0.000 
Liver -0.270 -0.042 -0.238 
GIT 0 - -0.006 
Muscle 0.112 0.0078 0.065 
Adipose 0.056 - -0.020 
Others 0.142 -0.0011 0.129 
Negative values indicate uptake, positive values indicate release of lactate  
All values in mmol/min 
The skeletal muscle compartment of meyer1 exhibiting a higher rate of glucose uptake combined with a 
lower rate of lactate release may indicate that either more glucose is being stored as glycogen, or that a 
greater portion of glycolytic intermediates are entering pathways other than anaerobic glycolysis, such as 
oxidative phosphorylation. In either case, these results indicate that the skeletal muscle compartment in 
meyer1 occupies a metabolic state more representative of the resting, anabolic state. 
4.1.3 Comparison with Clinical Data 
Clinical data specifying both percentage parasitaemia and plasma glucose or lactate concentrations was 
obtained from literature for both children (14, 123, 189–196) and adults (53, 63, 64). These measurements of 
plasma concentrations of glucose and lactate were subsequently used as a guide for model calibration. (Fig. 
4.4). Additionally, simulation outputs were compared with those obtained by the green1 model (162), the 




construct a model that could give accurate descriptions of clinical data, the green curves represent data 
obtained from the final meyer1 model with all changes and additions (as listed in Tables 3.5 & 3.6) active. 
The results shown in Fig. 4.4 are an extension of those published by Green (162), and reflect the research 
aims and objectives set out at the beginning of this thesis: to construct a model that can be used to explore 
malaria metabolic abnormalities while still producing results that fall within the bounds of real-world 
examples. Visual inspection of Fig. 4.4 shows that the more sophisticated and in-depth descriptions of 
glucose metabolism in organs external to erythrocytes yielded significantly improved descriptions over a 
range of parasitaemias.  
 
 
Figure 4.4: Percentage parasitaemia vs simulated steady-state 
concentrations of plasma glucose (A) and plasma lactate (B). Red line: 
simulations obtained from green1 model. Green line: simulations 
obtained from the current meyer1 model. Dot symbols: data points 
obtained from adults (53, 63, 64).. Cross symbols: data points 




The descriptions given by the current model showed good agreement overall with the clinical data, with the 
exception of plasma glucose concentration at parasitaemias exceeding 5%. The similarity between simulated 
and measured plasma glucose and lactate concentrations varied according to both the range of percentage 
parasitaemia, and whether the data was obtained from children or adults. An initial rise in plasma glucose 
can be seen between 0-1% parasitaemia. Plasma glucose results approximate the data well between 0-5% 
parasitaemia, but proceed to exhibit a bias towards hypoglycaemia at higher parasitaemias. This bias was 
tolerated with the rationale that the model was constructed with the purpose of simulating hypoglycaemia in 
severe malaria, a symptom that, while occurring in a subset of the population, is still indicative of poor 
clinical outcomes. Furthermore, it could not be ruled out that the apparent bias was due to the lack of data 
available (N = 37) as well as the specificity of the data itself (e.g. publication of population means versus 
individual patient measurements). 
Results for plasma lactate appear to coincide significantly more closely for data obtained from children, 
although the initial curve does not describe that hyperlactataemia will occur until approximately 3% 
parasitaemia, in contrast to the clinical data, which shows multiple data points indicating metabolic acidosis 
(greater than 5 mM blood lactate (45)) in the 0-3% parasitaemia range. Nevertheless, the curve displays a 
good general approximation of plasma lactate levels for children with malaria up to the 15% parasitaemia 
mark. 
4.2 The Contribution of Parasite Metabolism to 
Hypoglycaemia and Hyperlactataemia 
To determine the degree to which parasite metabolism is responsible for the appearance of hypoglycaemia in 
cases of malaria infection, the rate of glucose uptake by infected erythrocytes was examined within the 
context of whole-body glucose metabolism. This was done by examining the relative contribution of each 
compartment to the steady-state plasma glucose concentration by calculating the percentage of the absolute 
flux of each compartment at a given parasitaemia.  
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Since all fluxes affecting a given variable sum to zero at steady state, the total of the absolute value of the 
fluxes at steady state was used as a denominator instead. Although this precludes the ability to distinguish 
between positive and negative fluxes during further calculations, it nevertheless gives an indication of the 
relative ‘share’ that individual fluxes have over a variable at steady state. 
The results of these simulations are shown in Figure 4.5. Since the PLASMA_GLUCOSE_FEED function 
was considered as representing glucose absorption from the phenomenological gastrointestinal compartment, 





Figure 4.5: Relative contributions of fluxes to plasma glucose flux at steady state in the meyer1 model. Percentages are calculated from a rate’s 
absolute flux over the sum of absolute fluxes at a given percentage parasitaemia. Simulation points for positive (glucose release) and negative 





The glucose feed function appears to account for both the majority of glucose influx into the compartment, 
and the majority of glucose flux overall, with its values remaining in the range of 40-50%. Glucose export by 
the liver into the plasma compartment rises in a hyperbolic trend from approximately 2% at zero 
parasitaemia to around 8% at 14% parasitaemia. Glucose removal from plasma by the remaining 
compartments consistently decreases with increasing parasitaemia, except for the infected erythrocyte 
compartment, which shows an almost linear increase from zero percent to over 25% at 14% parasitaemia. 
Note that, above parasite burdens of approximately 1%, no other negative flux increases in magnitude, while 
that of infected erythrocytes shows a perpetual climb.  
These results support the notion that the appearance of hypoglycaemia is due to plasma glucose uptake by 
infected erythrocytes overwhelming the host’s ability to maintain blood glucose homeostasis. Considering 
both Figs. 4.4 & 4.5, it appears that this relationship holds only at higher percentage parasitaemias in excess 
of 10%, where the curve for plasma glucose crosses the threshold value of 2.2 mM that marks entry into 
hypoglycaemia. This threshold also coincides with the percentage parasitaemia where infected erythrocytes 
account for 20% or more of plasma glucose flux. Below this parasitaemia threshold, the model shows that 
the body would still be able to compensate for the increased glucose demand through gluconeogenic means. 
One of the chief gluconeogenic substrates is lactate, a metabolite often found to be at exceedingly high 
plasma concentrations in cases of malaria infection. 
As for lactate fluxes: simulation results from this model show that lactate efflux by the infected erythrocyte 
compartment and, by proxy, the parasite compartment, is insufficient to overcome the host’s capacity for 
lactate clearance. Hepatic lactate uptake is able to exceed infected erythrocyte (RBCi) lactate export until 
approximately 5% parasitaemia; this has been established under conditions where the liver function is 
inhibited by the presence of infection (Fig 4.6). Furthermore, if the second major organ displaying 
significant lactate uptake were to be included, which in the case of this model is the brain, then the additive 
hepatic and cerebral rate of lactate clearance substantially exceeds the rate of RBCi lactate efflux. 
 
Figure 4.6: Steady-state fluxes at varying parasitaemias for infected erythrocyte 
lactate release (black), hepatic lactate uptake (red), and the sum of brain and liver 




4.3 The Role of Hepatic Function in Severe Malaria 
As the only compartment within the model equipped with gluconeogenic kinetics, the liver is the only organ 
capable of directly reversing the concomitant syndromes of hypoglycaemia and lactic acidosis present during 
severe P. falciparum infection. As described in Section 3.1.3, the original model published by König et al. 
(18) did not feature kinetic descriptions of non-carbohydrate metabolism, and it was decided during adaption 
and incorporation of this model into the current whole-body framework that expansion to include the 
gluconeogenic contributions of alanine and glycerol would be beyond the scope of the current research. 
Significant changes were however made to other components of the hepatic compartment, a process that was 
expedited by an existing, but disabled, framework already being in place. These modifications centred on the 
implementation of a dynamic system of reducing equivalents that could be exchanged between the cytosol 
and mitochondria, the addition of a pyruvate transporter, and the incorporation of parasite inhibition terms. 
To ascertain the role that liver function plays in the pathogenesis of metabolic syndromes associated with 
severe P. falciparum infection, several facets of the hepatic compartment will be examined. These are (i) the 
net transport fluxes of glucose, pyruvate and lactate, (ii) the relative fluxes through the 
glycolytic/gluconeogenic substrate cycles, and (iii) the overall energy and redox state of the hepatic 
compartment. Together, these three sections encompass the examination of how innate hepatic function 
changes during the transition from a healthy state through nascent and severe malaria infection, and whether 
these changes indicate that impaired hepatic gluconeogenic function can be considered a primary cause of 
HG/HL in severe malaria. 
An additional fourth and final section examines in greater detail the effects of phenomenological parasite-
liver interactions modelled after literature reports on hepatic function, and the subsequent influence that such 
interactions have on the pathogenesis of HG/HL in severe malaria infection. 
Note that the results presented within this section were obtained from the final meyer1 model with all 
modifications and parasite-host modulation terms (listed in Tables 3.5 & 3.6) active. 
4.3.1 Hepatic Transport Fluxes 
The liver appears to export glucose and import pyruvate and lactate at all levels of parasitaemia; for glucose 
and lactate, a hyperbolic relationship is seen, and for pyruvate, a linear trend appears that slightly decreases 
at parasitaemia levels above 6% (Fig 4.7). The hepatic compartment at steady state generally imports lactate 
twice as fast as it does pyruvate, although this apparent preference is likely due to pyruvate’s comparatively 
low plasma concentration. An increase in net hepatic gluconeogenic activity can be seen (Fig. 4.7, bottom-






Figure 4.7: Metabolite transport fluxes for the hepatic compartment and the hepatic gluconeogenic 
ratio in the meyer1 model. TRNSP (L+P)/G is calculated as [½(Lactate Influx + Pyruvate 
Influx)/Glucose Efflux] 
Here we have demonstrated that, across the entire range of parasitaemias used as input, model simulations 
show a net import of lactate and pyruvate with a concomitant net release of glucose into the circulation. 
These results unambiguously indicate that, from a purely input/output perspective, the liver functions as a 
wholly gluconeogenic organ within the context of the malaria disease state as simulated in this model.  
4.3.2 Hepatic Glycolytic/Gluconeogenic Substrate Cycling 
Recall that the pathways of hepatic glycolysis and gluconeogenesis are identical, save for three irreversible 
steps. First, the phosphorylation of glucose to form G6P is catalysed by glucokinase (GK) and reversed by 
glucose 6-phosphatase. Second, the conversion of fructose 6-phosphate to fructose 1,6-bisphosphate, 
catalysed in the forward direction by 6-phosphofructo-1-kinase (PFK1) and in the reverse by fructose 1,6-
bisphosphatase (F16BP). Finally, pyruvate kinase (PK) catalyses the conversion of phosphoenolpyruvate 
(PEP) to pyruvate, a reaction reversed by the sequential action of pyruvate carboxylase (PC) and 
phosphoenolpyruvate carboxykinase (PEPCK). For each substrate cycle, the ratio of the two fluxes will 
determine the flow of metabolites at that juncture, and the overall ratio of these flux pairs will ultimately 
determine whether the hepatic compartment is in a glycolytic or gluconeogenic state.  
With this in mind, the fluxes of these reactions within the hepatic compartment were determined at steady 
state over a range of parasitaemias, as well as the flux ratios of these opposing processes to ascertain the 
degree to which gluconeogenesis is favoured at each respective junction (Fig. 4.8).  
In accordance with the observations regarding the liver’s net glucose export across a range of parasitaemias, 




Both the ratios of G6Pase / GK and F16BP / PFK1 increase rapidly above 7% parasitaemia, from an initial 
ratio of 1.11 and 1.25 to a final value of 5.95 and 36.28, respectively. Pyruvate kinase activity, however, 
shows only a single symmetrical peak centred on 2% parasitaemia, the value of which is effectively 
negligible.  
Hepatic PC and mitochondrial PEPCK, the gluconeogenic counterparts to PK, parallel one another with 
hyperbolic trends, increasing from 0.0827 mmol/min and 0.0794 mmol/min to 0.5297 mmol/min and 0.3910 
mmol/min, respectively.  
 
Figure 4.8: Steady-state reaction ratios of hepatic substrate cycle reactions (A, B, F) in the meyer1 
model. The steady-state flux values for PK (C), PC (D) and mitochondrial PEPCK (E) are shown 
for clarity. Abbreviations: G6Pase, glucose 6-phosphatase; GK, glucokinase; F16BP, fructose 1,6-
bisphosphatase; PFK1, 6-phosphofructo-1-kinase; PK, pyruvate kinase; PC, pyruvate carboxylase; 
PEPCK, mitochondrial phosphoenolpyruvate carboxylase 
Of note is the observation that, for percentage parasitaemias leading up to approximately 5%, flux ratios of 
G6Pase/GK and F16BP/PFK1 remain approximately unitary, but increase rapidly thereafter, reaching 
respective ratios of 6 and 35 at 15% parasitaemia (Fig. 4.8). These steep increases parallel plasma lactate 




hyperlactataemia. Conversely, while flux through the reactions catalysed by PC and PEPCK also increase in 
proportion to parasitaemia and appear to share the same approximate inflection point, the ratio of their 
combined flux vs PK activity is difficult to ascertain. Nevertheless, when also considering the transport flux 
behaviour described in Section 4.3.1, these results clearly indicate that the enzymatic machinery of hepatic 
gluconeogenesis remains functional, and the failure thereof can thus be ruled out as a primary cause of 
circulatory hyperglycaemia and hyperlactataemia within the scope of this model.  
4.3.3 Hepatic Energy and Redox States 
As explained in Section 3.1.3.1, the clamped set of phosphoryl donors and reducing equivalents was 
converted to a dynamic system whereby they are consumed and recycled through the cytosolic and 
mitochondrial compartments. Had the change not been made, the hepatic compartment would effectively 
possess an infinite supply of energy, and the system as a whole would be completely unresponsive to 
reductions in substrate supply. However, with the new dynamic implementation in place, the energy and 
redox state of the hepatic compartment is open to examination. 
Within the context of this model’s hepatic compartment, the reducing equivalent pair NAD+/NADH forms 
part of four enzyme-catalysed reactions, viz. those catalysed by GAPDH and LDH within the cytosolic 
compartment; PDH within the mitochondrion, and the phenomenological NAD+/NADH exchanger 
mediating antiport transport of these species between cytosol and mitochondria. 
Since gluconeogenesis depends both directly and indirectly on the activity of these reactions, the presence of 
appropriate concentrations of reducing equivalents is thus essential for gluconeogenesis to proceed. It was 
thus investigated whether the presence of malaria infection had any deleterious effects on the rates of these 
reactions and thereby the magnitude of the flux through gluconeogenesis. Additional consideration is also 
given to the dynamics of energy carriers, considering their direct (kinase activity) or indirect (oxidative 
phosphorylation, glycogen turnover) effect on hepatic glucose metabolism. 
Within the cytosolic compartment, oxidized NAD+ constitutes the near entirety of the redox pair across all 
parasitaemias, including the uninfected state (Fig. 4.9). These values parallel those found in both König et 
al.’s (18) and Li et al.’s (17) original published models (Table 4.3). NAD+ is abundant in the cytoplasmic 
compartment regardless of parasitaemia, maintaining the redox degree at near zero. In the mitochondrial 
compartment, the fraction of NADH increases with growing parasitaemia, reaching a maximum of 0.4 at 4%, 
which steadily declines to 0.25 at 10%, at which it remains for further increases in parasitaemia. 
Table 4.3: Comparison of reducing equivalent concentrations between models in the healthy state 
 [NADHcyto] [NAD+cyto] [NADHmito] [NAD+mito] 
König 2012 (18) 0.00056 1.22 0.24 0.98 
Li 2009 (17) 0.0002778 0.15 0.4975 3.15 






Figure 4.9: Phosphorylation and redox states for the hepatic cytosolic and mitochondrial 
compartments as simulated in the meyer1 model. PDx = ATPx / (ATPx + ADPx); RDx = NADHx / 
(NADHx + NADx) 
Analysis of percentage flux partitioning shows a trend whereby NADH production in the cytosolic 
compartment is dominated by LDH activity (Fig. 4.10). LDH activity mediates the entirety of positive flux 
for hepatic cytosolic NADH, and half overall. GAPDH and NADH/NAD+ exchanger activity both mediate 
negative cytoplasmic NADH flux, with GAPDH activity overtaking NADH/NAD+ exchanger flux as 
parasitaemia rises and hepatic gluconeogenesis increases. The NADH produced by LDH is either consumed 
by GAPDH, or exchanged for NAD+ with the mitochondrial compartment. In the mitochondrial 
compartment, the NADH produced by PDH and imported by the NADH/NAD+ exchanger is consumed by 
oxidative phosphorylation activity (Fig. 4.11).  
 
Figure 4.10: Percentage flux contributions to steady-state hepatic cytosolic NADH in the meyer1 
model. Values were calculated according to the individual absolute flux over the absolute flux total. 
Relative percentage flux contributions were calculated in the same method as described for Figure 4.5. 





PDH and NADH/NAD+ activity is responsible for positive NADH flux in the mitochondrial compartment, 
having approximately equal fractions overall (Fig 4.11). Oxidative phosphorylation activity, which 
consumes NADH, constitutes half of all flux overall. 
 
Figure 4.11: Percentage flux contributions to steady-state hepatic mitochondrial NADH in the meyer1 
model. Green and red data points correspond to percentages calculated from positive and negative 
fluxes, respectively  
The mitochondrial NAD+ produced by oxidative phosphorylation is subsequently transported back into the 
cytosolic compartment, where it provides substrate for lactate oxidation via LDH. Thus, a cycle is 
established whereby gluconeogenic activity is sustained through constant maintenance of cytosolic NAD+ 
concentration, which enables continued lactate oxidation and subsequent gluconeogenesis.  
The relative fractions of hepatic ATP and ADP show different trends depending on the sub-compartment 
under consideration (Fig. 4.9). ATP makes up almost the entirety of the adenosine phosphate pool within the 
cytosolic compartment (Table 4.4). In the mitochondrial compartment, approximately only 20% of the 
adenosine phosphate pool consists of ATP in the infected state; this is down from approximately 60% in the 
uninfected state. In the mitochondrial compartment, ATP synthesized by oxidative phosphorylation is used 
either by PC, or by NDK-GTP, which provides the GTP required by mitochondrial PEPCK; both of these 
enzymes constitute essential parts of the mitochondrial gluconeogenic pathway.  
Table 4.4: Comparison of adenosine phosphate concentrations between models in the healthy state 
 [ATPcyto] [ADPcyto] [ATPmito] [ADPmito] 
König 2012 (18) 2.8 0.8 2.8 0.8 
Li 2009 (17) 5.924 0.0178 8.68 7.84 
meyer1 5.983 0.0035 14.02 2.50 
The consideration of these observations as a whole give a clear indication that hepatic gluconeogenic 
function is not obstructed by deficient levels of energy carriers or reducing equivalents. Flux partitioning of 
these metabolites in the infected state reflects a state of active, continued gluconeogenesis. Thus, these 
results support the notion of the hepatic compartment being entirely geared towards sustained 





4.3.4 Parasite-Liver Interaction 
One of the chief research objectives of this thesis was to delineate the causes of hypoglycaemia and lactic 
acidosis in the event that parasite metabolism per se was found to not be able to account for these 
phenomena. Simulations of the meyer1 model that included effect of parasite metabolism but not parasite-
mediated modulation of host metabolism (see Section 4.2) supports this notion. Although the metabolic 
effects mediated by the parasites could cause hypoglycaemia, results suggest that they are insufficient to 
explain hyperlactatemia. Further investigation was orientated towards examining if and how the possible 
diminished capacity of hepatic gluconeogenesis through other effects was the causative factor. As shown 
above, hepatic fluxes and species concentrations are fully in favour of gluconeogenesis (Fig. 4.8); thus, the 
innate capacity of the liver to convert imported lactate (and to a lesser extent, pyruvate) into glucose and 
export it to the circulation is not saturated. This leaves the aetiology of hypoglycaemia and lactic acidosis to 
factors external to native hepatic metabolism, specifically those belonging to parasite-mediated modulation 
of hepatic function, such as impairment of hepatic blood flow and metabolite delivery to the liver 
parenchyma. 
When modelling the putative mechanisms of parasite-liver interactions, two phenomenological functions 
were implemented: inhibition of oxygen-requiring processes, such as oxidative phosphorylation, and 
inhibition of perfusion i.e. blood flow through the hepatic circulation (Section 3.2.2.2). Perfusion inhibition 
was included in the model to allow an in silico assessment of the possible effect of microvascular occlusion 
rendered by parasite sequestration, as described in the literature (12, 64, 127). Reduced perfusion was 
modelled by decreasing the affinity of hepatic transporters for plasma glucose, lactate and pyruvate as a 
function of increasing parasitaemia. For each of the two parasite-mediated inhibition terms introduced into 
the hepatic compartment, two parameters specifying the percentage parasitaemia producing half-maximal 
effect (KM), and the maximum magnitude of effect (MAX) were used.  
Of the novel parasite-host interactions introduced as part of the current research, the inhibition of hepatic 
perfusion by increasing parasite burden appeared to have the most dramatic effect on plasma lactate 
concentrations (a full description of the effects of parasite-host interactions is given in Appendix C). To 
ascertain the effects of varying degrees of maximum parasite-mediated perfusion inhibition (Section 
3.2.2.2.1), the value of the MAX parameter was varied between 0 (no inhibition) to 50 (its default value) (Fig 
4.12). The absence of perfusion inhibition prevented the appearance of lactic acidosis entirely, while 
delaying the onset of hypoglycaemia. In other words, if parasite-mediated inhibition of hepatic lactate uptake 
was lifted, then plasma lactate concentrations do not rise above the 5 mM threshold considered as 
constituting lactic acidosis, even at the maximum percentage parasitaemia simulated (due to the capacity of 
hepatic gluconeogenesis). These results indicate that glycolytic parasite metabolism alone cannot cause 
hyperlactataemia in cases of severe P. falciparum infection, a conclusion that parallels that expressed by 
previous literature. While still providing evidence for parasite metabolism as a contributory factor, a clear 
indication is given that the primary aetiology of metabolic acidosis could lie within parasite-mediated 





Figure 4.12: Changes in selected meyer1 model outputs with variation of the maximal perfusion 
inhibition parasite modulation parameter. Glucose, lactate and pyruvate fluxes refer to influx or 
efflux into or out of the hepatic compartment. Details presented in information box, top-left. The 
colour of each curve corresponds to simulations conducted with the matching parameter value. 
Data as presented in Fig 4.4. 
In contrast to the dramatic changes seen in steady-state plasma lactate concentrations observed upon variance 
of the maximal perfusion inhibition parasite modulation parameter, implementation of parasite-mediated 
hepatic mitochondrial hypoxia yielded minimal improvement in the descriptive capacity of the model. The 
results of the introduction of this host-parasite interaction, as well as the remainder of those described in 





4.4 MCA and Potential Drug Targets 
One of the advantages of metabolic control analysis is that it allows a large-scale biochemical network to be 
searched for components that have the strongest influence over a particular outcome, whether this be the 
concentration of a metabolite, or a particular steady-state flux. One of objectives of the current research was 
to identify which components of the whole-body model have the most significant role in mediating the 
appearance of hypoglycaemia and hyperlactataemia as part of malaria infection, and would therefore be 
expected to yield the greatest improvement in clinical outcome if targeted by specific treatments. To achieve 
this, metabolic control analysis was conducted on all reactions to identify the rates exhibiting the greatest 
control over steady-state plasma glucose and lactate concentration. 
Since the current model allows us to obtain steady-state data for any given parasitaemia, MCA was 
conducted over a range of parasitaemias that included both uncomplicated and severe infection. For a range 
of parasitaemia values, control coefficients with regards to plasma glucose and lactate were calculated for all 
rates. Thereafter, the integral of each rate’s control coefficients versus percentage parasitaemia was 
determined, to give an indication of which rates had the greatest overall control across the range of 
parasitaemias simulated. These integrals were subsequently ranked in descending order, the results of which 
are shown below in Figs. 4.13 & 4.14. 
 
Figure 4.13: Eight rates showing significant control 
coefficients with regards to plasma glucose, integrated over a 
range of parasitaemias from ~0% to 15%. Green bars indicate 
positive values, red bars indicate negative values. Rates for 





The significant control coefficients with regards to steady-state plasma glucose concentration are dominated 
by rates located in the infected erythrocyte and parasite compartments, particularly those mediating the 
uptake of glucose into the infected erythrocyte and its subsequent catabolism within the parasite. The data 
presented here indicates three possible junctures where novel chemotherapeutics could have the greatest 
impact on improving plasma glucose concentrations: entry of glucose into the infected erythrocyte, uptake of 
glucose into the parasite from the infected erythrocyte cytosol, and glycolytic catabolism within the parasite, 
as mediated by parasitic hexokinase (HK) and phosphofructokinase (PFK). 
Uptake of glucose from the infected erythrocyte cytosol into the parasite itself presents another potential 
target for chemotherapeutic interventions, an avenue of research that has already undergone exploration 
(197). Of the possibilities described here, this would likely constitute one of the options least disruptive to 
host metabolism, since it would theoretically allow the infected erythrocyte’s native metabolism and 
physiological function to continue while simultaneously starving the parasite of glucose. The specific 
enzymes that would be targeted to prevent uptake of glucose by the parasite would likely either be the non-
selective, high-capacity channel mediating transporting of glucose across the parasitophorous vacuolar 
membrane (197), or parasite hexose transporter 1 (PHT1). 
The significant control coefficients with regards to plasma glucose shown by parasitic HK and PFK activity, 
in addition to that exhibited by parasite glucose uptake, parallel the results obtained from the green1 model 
in the author’s original thesis (162). The enzymes HK and PFK mediate the first and third reactions of 
glycolysis within the parasite compartment and are both irreversible (PFK was characterised as irreversible 
in the original published model)(20). Both exhibit significant negative control over plasma glucose 
concentration, indicating that targeted inhibition of these enzymes would help slow the appearance of 
hypoglycaemia in cases of malaria infection. These interventions would, however, need to be specific for 





Figure 4.14: Twenty rates showing the most significant control coefficients with regards to 
plasma lactate, integrated over a range of parasitaemias from ~0% to 15%. Green bars indicate 
positive values, red bars indicate negative values. Rates for brain and muscle compartments are 
denoted as COMPARTMENT_SUBSTRATE_PRODUCT. 
 
Interpretation of the control analysis with regards to plasma lactate indicates that the concentration of this 
metabolite is more strongly influenced by rates external to the infected erythrocyte milieu. While strong 
control over plasma lactate by the infected erythrocyte lactate transporter is still present, targeting the 




lactate itself is capable of diffusion of the protonated form across the parasite plasma membrane bilayer (21). 
Furthermore, such an intervention would likely not ameliorate the development of hypoglycaemia due to 
parasite glucose uptake. However, two other rates with substantial negative control over plasma lactate are 
worthy of discussion, especially since one is tied to the phenomenological host-parasite interactions 
implemented as part of the current research. As described and discussed in Sections 3.2.2.2.1 & 4.3.4, 
phenomenological inhibition of hepatic transporters, including lactate transport, has a profound effect on 
steady-state lactate concentrations across a range of parasitaemias. The significant negative control displayed 
by the hepatic lactate transporter can thus be interpreted as supporting the notion that reducing the degree of 
microvascular obstruction within the hepatic sinusoids would assist the process of lactate uptake by the liver 
for subsequent gluconeogenic disposal. A possible means whereby this could be accomplished is disruption 
of P. falciparum erythrocyte membrane protein 1 (PfEMP1), the central protein mediating the process of 
microvascular blockage via adherence, rosetting, and aggregation (11). Considering the contribution of 
parasite-mediated microvascular obstruction to not only impaired liver function, but also the appearance of 
multi-organ dysfunction (93), such a targeted intervention would likely yield systemic improvements giving 
a substantially improved clinical outcome. 
As described in Section 2.3, uptake of glucose by the infected erythrocyte is mediated not only by existing 
endogenous mechanisms, but also new permeability pathways (NPPs). These NPPs are non-specific integral 
membrane proteins that mediate the uptake of glucose as well as other nutrients required by the parasite. 
NPPs were not modelled explicitly in the current research, and the contribution made to glucose uptake by 
these pathways would be in addition to the transport mechanisms already mentioned. Considering the 
substantial negative control exhibited by the transporter activity that was included, it could be speculated that 
parasite NPPs would exhibit negative similar control, albeit of an unknown degree. Research assessing 
whether NPPs exert a control high enough to warrant targeted therapy could therefore possibly yield another 




Chapter 5: Recommendations, 
Summary & Conclusion 
5.1 Model Shortcomings and Recommendations for Possible 
Future Research 
Severe P. falciparum malaria is a complex, multi-organ disease that can present with a range of symptoms, 
including that of hyperglycaemia and hyperlactataemia. To date, the causes of HG/HL in severe malaria as 
reported to literature have only been described qualitatively, with a lack of empirical data that can give clear 
indications as to which causes are most responsible for the appearance of hypoglycaemia and 
hyperlactataemia. As stated in the research aims and objectives, one of the core goals of the current research 
was the construction of a whole-body model of glucose and lactate dynamics in both the healthy and infected 
host. This model would subsequently serve as a framework that could be adapted and extended to describe 
the host-parasite interactions that have been reported to give rise to HG/HL. While this aspect of the research 
has been achieved, and has moved us closer towards a means of quantifying the relative contributions of the 
reported causes of HG/HL, the final model still possesses a significant shortcoming, caused by the same 
issue that motivated its inception: a lack of quantitative, empirical data. 
The final meyer1 model contains several phenomenological implementations equipped with estimated 
parameters. These modifications and additions were developed based on how well model outputs of plasma 
glucose and lactate concentrations, as a function of percentage parasitaemia, matched that of clinical 
observations. However, these extensions still contain many unknown factors. These unknowns include both 
the form of the expressions describing host-parasite interactions, as well as the value of the associated 
parameters. Owing to these limitations, the conclusions that can be drawn from the results given by the 
meyer1 model remain relegated to the theoretical realm. However, the model has nevertheless facilitated 
progress towards a quantitative understanding of the aetiology surrounding HG/HL in severe malaria, since 
the modular implementation of host-parasite interactions allows each of these aspects to be developed and 
parameterised independently. The research presented in this thesis is thus best characterised as a pilot study 
demonstrating the types of analyses that can be conducted on a more complete, empirically parameterised 
version of the model.  
A focal point of the current research was the investigation of the role played by gluconeogenesis in cases of 
severe P. falciparum malaria presenting with hypoglycaemia and hyperlactataemia. However, this 




lactate oxidation via lactate dehydrogenase activity. As described in Section 2.6.1 and shown by Fig. 2.6, 
pyruvate and lactate form the bulk of the gluconeogenic substrate pool, but are far from the only materials 
utilized by gluconeogenic metabolism to synthesize glucose in response to hypoglycaemia. Other substrates, 
particularly alanine, glutamine, and to a lesser extent arginine, constitute a sizeable portion of substrates used 
for gluconeogenesis. The contribution of glycerol is also too significant to be ignored. Extension of the 
model to include kinetic descriptions of gluconeogenic metabolism drawing from sources other than 
pyruvate and lactate could thus substantially improve the capacity of the model to describe clinical data. 
Moreover, metabolic disturbances germane to these metabolites have been observed in malaria patients, 
namely impaired rates of alanine clearance (64), increased levels of glycerol (63), and decreased levels of 
arginine (198). Expansion of the model to enable investigation of such metabolic changes associated with 
malaria infection, and subsequently provide insight regarding their aetiology, thus forms an attractive 
possible avenue of future research. 
The extension of the hepatic compartment to include a dynamic system of energy carriers and reducing 
equivalents was judged to be a successful addition to the model, but could be further improved. As explained 
in Section 3.1.3.1, the implementation of this system was necessitated due to the integral role that these 
molecules play in dictating balance of hepatic glycolysis and gluconeogenesis in response to hypoglycaemia 
and metabolic acidosis. While the addition of dynamic variables was made expedient by the existing, 
clamped expressions present in the original model, kinetic descriptions of transport of these molecules 
between the hepatic mitochondria and cytosol, as well as oxidative phosphorylation activity, had to be 
obtained from a separate model. These ‘foreign’ components were effectively introduced verbatim from their 
original model, with little modification of parameter values. While this implementation has yielded 
satisfactory results and plausible model simulation outputs, it remains an attractive candidate for replacement 
with more suitable kinetic descriptions that have been specifically modelled and validated within the context 
of reducing equivalent and adenosine phosphate metabolism within the hepatocyte. 
Another shortcoming related to the model’s depiction of gluconeogenesis is the description of renal function. 
After the liver, the kidneys form the second most significant site of gluconeogenesis. Additionally, renal 
excretion of lactate has been observed under conditions of sufficiently high lactataemia (Section 2.6.2.3). 
Inclusion of a kinetic description of renal function can potentially be implemented in a manner similar to that 
used for the hepatic compartment, i.e. adaption and incorporation of an independently published model 
featuring descriptions of glycolysis and gluconeogenesis, with further possible inclusion of renal lactate 
excretion functionality. A cursory search for such a model was conducted during model development, but the 
lack of models published that were appropriate to this task, as well as the complexity that another detailed 
compartment would add to the model, led to the decision to not pursue this venture. Nevertheless, the 
contribution of renal metabolism to whole-body glucose and lactate metabolism, as well as the marked 
incidence of kidney injury in cases of severe malaria (106), makes the renal compartment a suitable 




While the extension of the model to include a more comprehensive kinetic description of gluconeogenesis 
was not included, modulation and scaling of the model as a function of age was implemented (Section 3.1). 
However, due to time constraints, this was not utilized functionally in the current research. The clinical 
presentations of severe P. falciparum malaria, including the relative incidence of metabolic acidosis and 
hypoglycaemia, vary significantly with age (Section 2.4, Fig. 2.4, Fig. 4.4). This phenomenon lead to the 
implementation of a model architecture that allows the size and metabolic contribution of the individual 
compartments to whole-body glucose and lactate metabolism to be scaled independently. The ability to 
further modulate model structure and properties as a function of age in an enzyme-specific manner was also 
planned, but was not pursued upon the realization of the amount of time that would be required for data 
collection, programmatic implementation, testing and validation that such a feature would require. Future 
allocation of time and resources to the development of this feature could well lead to greater insights and 
understanding with regards to the differential metabolic abnormalities associated with the age at which an 
individual suffers from malaria infection. 
As stated in the beginning of this section, the host-parasite interactions introduced as part of the current 
model development were rudimentary, phenomenological functions that were not necessarily accurate 
mathematical representations of the interactions taking place. A notable example of this is the 
implementation of decreasing hepatic transporter substrate affinity as a function of increasing parasitaemia 
(Section 3.2.2.2.1). Statements from scientific literature relating the deleterious effect of parasite 
sequestration within the hepatic microvasculature to lactate clearance by the liver were interpreted 
mathematically as a hyperbolic increase in the KM values for the hepatic glucose, lactate and pyruvate 
transporters, a relatively straightforward implementation. While use of this function substantially improved 
the descriptive capacity of the model with regards to plasma lactate concentration (Section 4.2), the 
expressions used to relate parasitaemia and transporter affinity were not derived mechanistically, nor 
parameterised with quantitative data obtained from experimental studies. Without a detailed description of 
the specific molecular entities and reactions that mediate the development of microvascular obstruction, 
more in-depth analysis cannot be carried out. For example, as described in Section 2.6.4, the process of 
cytoadherence, sequestration, and microvascular occlusion is mediated by a number of known protein 
ligands, including ICAM-1, CD36, and PfEMP1. A mechanistic description of the interactions between these 
ligands, present on the infected erythrocyte membrane and intraluminal capillary surface, would enable 
methodologies such as metabolic control analysis to identify which ligands, or possibly enzymatic 
components mediating their expression, would be most vulnerable to novel chemotherapeutic interventions. 
It is thus specifically recommended that future studies collect, at minimum, the following measurements in 
patients suffering from severe P. falciparum malaria: plasma glucose and lactate concentration, 
microvascular obstruction (percentage of blocked capillaries, in as many organs as is viable), and parasite 
burden (parasite count, parasite biomass). Such data would allow the empirical development of expressions 
describing two crucial relationships: that between the parasite burden, sequestration and microvascular 
blockage, and that between the degree of microvascular obstruction and plasma glucose and lactate 




represent known biochemical entities (such as the mediators of cytoadherence mentioned previously) 
involved in the process of parasite-mediated microvascular occlusion, thereby removing the theoretical, 
phenomenological limitations present in the current model. Further development and expansion of the model 
to include such detailed mechanistic descriptions thus presents a promising and exciting avenue for future 
research.  
Should the model undergo further development, the process will be expedited by the custom software 
routines (as presented in Appendix A) that are already in place and specifically suited towards analysis of 
meyer1. The MCA and parameter scanning (assessing the changes in model outputs as a function of 
iteratively varying the value of a single parameter) functionality is particularly ideal for evaluating the 
changes in model outputs (of the form of those presented in Chapter 4) as new and existing modules are 
introduced and improved.  
5.2 Summary & Conclusion 
Malaria is the most prominent parasitic disease capable of infecting humans. Despite continued advances in 
science and medicine for over a century, the disease is yet to be fully eradicated, and continues to levy a 
substantial health burden in countries where the disease is endemic. Malaria caused by Plasmodium 
falciparum is particularly dangerous, and is responsible for a high mortality rate in children where the 
infection has progressed to severe disease. While effective medicines exist to halt and reverse the 
progression of severe P. falciparum malaria, the need for novel chemotherapeutics is necessitated by the 
continued threat of drug resistance by the parasite. To this end, novel drug targets must be identified that can 
be exploited to circumvent resistance while maintaining favourable clinical outcomes. However, the 
development of new drugs is marred by the complexity of the disease, the variation in clinical presentation, 
and an incomplete understanding of malaria pathogenesis. 
One such aspect of P. falciparum malaria that remains unclear is the paradoxical co-presentation of 
hypoglycaemia and hyperlactataemia (HG/HL) in patients suffering from severe disease, with these 
symptoms predicting a high risk of mortality. Though the appearance of these symptoms has been 
qualitatively attributed to a number of factors in the scientific literature, a thorough mechanistic 
understanding complete with robust quantitative evidence has yet to be established. It is this gap in 
understanding that the current research aimed to help rectify.  
At the outset of this research, we posed the research question of what causes of HG/HL in cases of severe P. 
falciparum malaria can be discovered using a kinetic modelling approach. In order to answer this, we aimed 
to construct a whole-body model of glucose and lactate metabolism that could describe changes in metabolic 
behaviour at both the level of organ compartments and individual reactions. Another aim that guided the 
research was to use this whole-body model as a platform to implement the possible host-parasite interactions 
contributing to the development of hypoglycaemia and hyperlactataemia, and provide quantitative evidence 




These aims were translated into six research objectives, which, once achieved, would provide an answer to 
the research question, as well as insights into malaria pathophysiology that contribute to the discovery and 
development of novel chemotherapeutics designed to prevent and reverse the course of the disease. 
With these research goals in place, we proceeded to review literature regarding which metabolic aspects of 
malaria pathophysiology would be most likely to yield insights into the development of HG/HL once 
described in silico using a kinetic modelling approach. These aspects were identified as glucose consumption 
by the parasite, hepatic gluconeogenesis, and the effects of parasite sequestration within the peripheral 
microcirculation. We also discussed the applicability of metabolic modelling and control analysis to 
investigating the relative contribution of these pathophysiological features to the appearance of HG/HL in 
severe disease. 
Chapters 3 and 4 describe the process of how research objectives 2 (model construction), 3 (model 
validation), 4 (parasite glycolysis alone as a cause of hypoglycaemia) and 5 (introduction of host-parasite 
interactions to account for hyperlactataemia) were achieved. Once the whole-body model had been 
constructed, its simulation outputs were compared with both those published for the original constituent 
models, and clinical data of plasma glucose and lactate concentrations in patients suffering from malaria. 
These results indicated that the model was capable giving reasonable descriptions in both the healthy and 
infected state over a range of parasitaemias. To produce these outputs, the model had undergone several 
modifications and extensions to include the most important pathophysiological features pertinent to HG/HL 
mentioned previously. Simulation and analysis results obtained from this final version of the model allowed 
both parts of the research question to be addressed. It was determined that parasite metabolism alone was a 
likely candidate for the appearance of hypoglycaemia in severe malaria, but could not account for 
hyperlactataemia. Reasonable descriptions of increasing plasma lactate concentration as a function of rising 
parasitaemia was achieved only once host-parasite interactions were implemented in the model. Of these 
interactions, the effect of microcirculatory obstruction within the hepatic compartment emerged as the most 
significant interaction giving rise to dangerously high plasma lactate concentrations.  
Several important conclusions can be drawn from the present work. First, following the completion of the 
whole-body meyer1 model, it was demonstrated through a process of reproduction and comparison that 
independently published models originally constructed to serve distinct research purposes could be adapted 
and combined into a newer, larger model that could be used to answer novel research questions, while still 
maintaining the functionality of the original constituent models. Attention was also given as to how these 
models could be made mutually compatible despite their varying levels of detail through techniques such as 
the clamping of plasma metabolites (e.g. alanine, FFAs) and the implementation of a uniform description of 
hormonal control between compartments. Furthermore, it was also shown that components of the substituent 
models could be extended to allow more biochemically realistic behaviour, as was the case for the dynamic 
implementation of energy carriers and reducing equivalents in the hepatic compartment. The demonstration 
of the validity of this approach substantiates the rationale for continued use of this methodology when 




furthering our understanding of the metabolic pathophysiology involved in the appearance of HG/HL in 
severe P. falciparum malaria.  
Simulation results allowed conclusions to be drawn regarding which components of infected host glucose 
and lactate metabolism were most responsible for the appearance of HG/HL. It was shown that parasite 
glycolysis alone could account for the appearance of hypoglycaemia, albeit only at heavier parasite burdens 
(Section 4.2). Metabolic control analysis results indicated that the degree of hypoglycaemia in severe 
malaria could be substantially ameliorated with drugs targeted towards inhibiting glucose uptake by the 
infected erythrocyte (NPPs), transport of glucose into the parasite cytosol (non-selective high capacity 
channel, PHT1), and the initial enzymes catalysing glycolysis within the parasite (HK & PFK)(Section 4.4). 
These results thus place more emphasis on the parasite’s prolific glucose consumption as a primary cause of 
low blood sugar, as opposed to other causes reported in the literature, such as a global shift in host 
metabolism towards anaerobic glycolysis. The finding that parasite lactate production would be unable to 
overwhelm the host’s capacity for lactate clearance was, however, in keeping with previous published 
statements. It was shown that the host’s rate of lactate uptake, as mediated by the liver and other organs, 
would comfortably exceed the rate of lactate production by the parasite, even in severe disease. 
Given the liver’s central role in the conversion of lactate to glucose, the gluconeogenic function of the 
hepatic compartment was investigated, and it was readily concluded that hepatic gluconeogenesis was not 
impaired to any appreciable degree in the presence of the changes in blood glucose and lactate 
concentrations brought on by P. falciparum infection (Sections 4.3.1-4.3.3). Hepatic substrate cycle 
function, redox state and net conversion of lactate to glucose all gave a definitive indication of functional 
hepatic gluconeogenesis. The results collected up to this point strongly suggested that parasite metabolism 
alone could not account for the appearance of metabolic acidosis in severe P. falciparum malaria.  
Consultation of scientific literature indicated that host-parasite interactions, specifically modulation of host 
metabolism by the parasite, could be an important cause of high plasma lactate in cases of severe infection. 
Of the interactions mediating a significant influence over the steady-state plasma lactate concentration over a 
range of parasitaemias, the degree to which hepatic perfusion was phenomenologically inhibited by 
increasing parasite burden was found to be the most significant (Section 4.3.4, Appendix C). Thus, with 
regards to novel chemotherapeutic interventions slowing or reversing the development of hyperlactataemia, 
MCA results indicate that restoration of hepatic lactate uptake and gluconeogenic utilisation of lactate, via 
inhibition of parasite sequestration, would likely yield a substantial improvement for this clinical outcome. 
This finding is supported by numerous references in the scientific literature concerning the importance of 
hepatic microvascular obstruction in mediating the appearance of hyperlactataemia in severe P. falciparum 
malaria. This strongly encourages further research into targeting of the protein ligands mediating the process 
of infected erythrocyte cytoadherence and sequestration to prevent hyperlactataemia and improve clinical 
outcomes. 
In addition to the body of work presented here, another product of this research is the software written during 




this research, does not possess built-in functionality specifically geared towards kinetic modelling of 
biological systems. Instead, the wide range of existing functionality can be utilised as part of user-defined 
functions that can be written to accomplish specific tasks. Thus, as the size and the complexity of the model 
grew, so too did the scope and functionality of the functions written alongside it. This has culminated in a 
collection of functions that can process large models in order to expedite the process of inspecting model 
structure, viewing simulation outputs, and efficiently processing large amounts of data during large-scale 
metabolic control analysis. An overview of this software, as well as example outputs, is shown in Appendix 
A. Given the lack of an existing, continually updated software package geared towards kinetic modelling on 
the Mathematica platform, and the certainty that the aforementioned custom software would be re-used and 
further developed as part of possible future research, there exists an attractive prospect of formally 
combining and packaging the various functions into a coherent suite suitable for use by other researchers in 
future.  
In conclusion, this work presents a multi-compartmental, whole-body model of glucose and lactate 
metabolism in the P. falciparum-infected human host, providing a quantitative means for assessing the 
relative contributions of pathways, compartments and phenomenological host-parasite interactions to the 
appearance of hyperglycaemia and hyperlactataemia in severe disease. By combining independently 
published models relevant to whole-body glucose and lactate metabolism, an in silico platform has been 
constructed that has the potential to reveal which metabolic components of parasite and host metabolism 
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Appendix A: Software Used 
Wolfram Mathematica 11.3 was used as the software platform to construct and analyse all iterations of the 
model. COPASI 4.25 was used to view the original specifications of XML-based models prior to import into 
Mathematica, and for viewing the original, unedited versions of models for validation purposes. These 
models were obtained in SBML-XML format through personal correspondence, or reproduced manually in 
Mathematica using published supplemental material and appendices. 
A.1 PARVIO: The Common Structure of a Model 
During the course of this thesis, a pattern was observed with regards to model structure that could be applied 
to any models that were to be incorporated into the final mathematical framework. This common pattern was 
termed ‘PARVIO’, an abbreviation of a series of components that consisted of parameters, assignments, rates 





Figure A.1: Diagrammatical flowchart illustrating PARVIO structure. A simple model pathway (top) 
is described mathematically (middle), with the output plots shown (bottom). The components of 
PARVIO are all shown in list (curly bracketed) format: parameters, assignments, rates, initial values, 
and ODEs. Arrows indicate the order of substitution, whereby the components of complex expressions 
are replaced by their respective assignments or values as defined in the rates, assignments, and 
parameters (see text). The PARVIO is combined and passed as input to the NDSolve function (not 
shown), which finds a numerical solution to the equations specified in the ODEs. Finally, the output of 




This format was based on the template given as output by JWS Online’s Mathematica notebook output 
feature, which gives the same components, albeit in a different order. The PARVIO format is mentioned and 
described here due to its ubiquity in the custom software written during model development, with all 
functions dealing with the model as a whole being programmed to recognise this specific, logical ordering of 
components.  
Below, a brief explanation will be allotted to each PARVIO component. 
A.1.1 Parameters 
A parameter can be defined as a rule the replacement value of which is purely numeric, consists of a single 
entity, and does not require further substitution to achieve a numerical value. 
The vast majority of parameters are used to provide the basic constants inherent in rate equations, 
particularly those describing enzyme kinetics. Common examples include values for parameters such as Vmax, 
Km, Keq, Ki, Ka and the Hill coefficient n. Parameter rules can also be used to specify the initial concentration 
of a particular metabolite within a given compartment, from which its initial mass can be derived. Finally, 
parameters can also be used to specify important quantities that have substantial effects on the entire model, 
such as the percentage parasitaemia present in the blood, or the age or weight of an individual being 
simulated. 
A.1.2 Assignments 
An assignment falls in the grey area between parameters and rates. An arbitrary guideline used in the current 
research is that the right-hand side of an assignment expression can neither express a purely numerical 
quantity, nor a rate equation, enzymatic or otherwise. However, assignments fulfil an essential role by acting 
as aliases for frequently repeated, often complex expressions, or providing a logical chain of substitution 
rules that can make the structure of an otherwise complicated expression much easier to discern. The 
example below will be used to illustrate the utility of assignments. 
First, let us consider the expression used to denote the molar concentration of glyceraldehyde 3-phosphate 




At first glance, this appears to be a simple expression describing the concentration of a metabolite as its 
molar mass (RBCi_gap[t]) divided by the volume of its enclosing compartment (RBCi_VOLUME). 
However, while the variable RBCi_gap[t] requires no further substitution, the value of RBCi_VOLUME is 
dependent on a number of subexpressions and parameters. 
The volume of the infected red blood cell compartment RBCi_VOLUME denotes the total cytosolic volume 





!"#$_&01234 → 	!"#$_#411_&01234_5!'#6708	 ⋅ 	!"#$_&01234_5!'#6708 
Where RBCi_CELL_VOLUME_FRACTION denotes the volumetric fraction of an infected red blood cell that 
is not taken up by the trophozoite 
!"#$_#411_&01234_5!'#6708 → 	1 −
<5_37=#_>?@<56A?*ℎ
!"#C_37=#_>?@!"#DEF)C@. 
And RBCi_VOLUME_FRACTION denotes the infected fraction of the total erythrocyte cytosolic volume 
!"#$_&01234_5!'#6708	 → 	<5_'2G_<=	 ⋅ 	!"#_#H60=01 
Where PF_AUX_PS indicates percentage parasitaemia. In turn, the total erythrocyte cytosolic volume 
RBC_CYTOSOL is derived from the subfraction of the blood plasma volume 
!"#_#H60=01 → 	!"#C_37=#_'@*ℎ)#E@@I).EA5A)J.$?K ⋅ 	<1'=3'_L'43'60#!76 ⋅ 	<1'=3'_6?.&?@M1	 
Finally, the term PLASMA_TotVolmL is itself an assignment determined by a chain of assignment rules 
which ultimately depend on the age of the individual being simulated: 
<1'=3'_6?.&?@M1 → 	1000 ⋅ 	<1'=3'_#03<'!63486_&01234_1764!= 
	<1'=3'_#03<'!63486_&01234_1764!= → F'(EIE$(ℎ."&[<1'=3'_'2G_'O4] 
This description is intended to show how the use of assignments can be used to delineate complex compound 
expressions into concise, logical, and easy-to-follow chains of components. Furthermore, while the list of 
assignments laid out above may seem exceedingly verbose, their necessity is perhaps best illustrated by how 
RBCi_VAR_gap would be expressed had only parameters been used: 
!"#$_()*[.]
P1 − <5_37=#_>?@<56A?*ℎ!"#C_37=#_>?@!"#DEF)C@.Q	 ⋅ 	 (<5_'2G_<=	 ⋅ 	 [!"#C_37=#_'@*ℎ)#E@@I).EA5A)J.$?K ⋅ 	<1'=3'_L'43'60#!76 ⋅ 	(1000 ⋅ [F'(EIE$(ℎ."&[<1'=3'_'2G_'O4]])	])
 
In effort to preserve a modicum of brevity and legibility, the body of the function fAgeWeightBV is not 
included here. 
Thus, the use of assignments to organise complex rate equations facilitates comprehension, expedites 
troubleshooting, and improves the ease of editing or modification. 
A.1.3 Rates 
The initial intuitive definition of a rate equation is an equation describing the kinetics of a single enzyme, as 
shown above. The left-hand side of the rate equation will subsequently be used to denote the derivative 
governing the turnover of the relevant metabolites as part of their respective ODE, for example: 
 
(Note that transaldolase catalyzes the reaction sedoheptulose 7-phosphate + glyceraldehyde 3-phosphate ↔ erythrose 4-phosphate + 




A ‘rate’ can therefore be defined as any expression that appears on the right-hand side of an ODE equation, 
usually with a stoichiometric coefficient attached. Consider the following ODE equation for plasma glucose: 
 
While most of the rate names refer to the activities of the transport proteins of their separate compartments, 
the terms v_ENZ_PLASMA_GLUCOSE_FEED and v_ENZ_PLASMA_GLUCOSE_UTILIZATION refer to 
broader processes which may not necessarily involve enzymatic activity, such as the rate of an intravenous 
glucose infusion or the combined activity of several organs which, while not under study, still have an 
important role in mediating plasma glucose turnover. 
Each rate name will have a corresponding rule providing its matching rate equation, the latter of which is 
composed of a combination of assignments and parameters, as outlined above. 
A.1.4 Variables 
Variables constitute the least complex component of PARVIO. From a biochemical perspective, their utility 
is limited to simply listing the metabolites or species in the model that are subject to change. However, they 
form a compulsory argument of NDSolve, as the variables are the ‘functions’ that NDSolve computes a 
numerical solution for e.g. x[t] being a function of time. 
A.1.5 Initial Values 
As the name suggests, the initial values specify the numerical quantity that a variable assumes at the start of 
the computation when t = tstart (more often when t = 0). While this may at first seem straightforward, the 
utility that can be extracted from different forms of the right-hand side of initial value equations should not 
be underestimated.  
In simpler models where the values of variable are expressed in terms of concentration, the initial value of a 
metabolite can simply be equated to a number. 
 
For ease of use, or when the procedural variation of the initial value is desired, a parameter value can be used 
instead. 
 
Consider a multi-compartmental model whereby the numeric value of variables is expressed in millimoles, 
initial concentrations are specified in millimolar, and the volumes of the respective compartments are subject 




These changes can be easily accommodated via the use of assignment rules, which scale the initial mass of 
the metabolite as a function of the volume of its enclosing compartment, e.g. 
 
A.1.6 ODEs 
The final part of the PARVIO is composed of ordinary differential equations, or ODEs. This involves one or 
more equations each of which specifies the time derivative of variable on the left-hand side, and one or more 
terms on the right. Within the context of PARVIO, each right-hand side term represents a rate, usually with a 
stoichiometric coefficient attached. While the stoichiometric coefficient can be safely omitted when its value 
is one, it is usually helpful to add a coefficient of 1.0 for the sake of consistency and readability.  
A.2 Software Tools 
A.2.1 Rate Visualisation 
Models used in systems biology are written in code, whether this be in the form of standardised XML (e.g. 
Systems Biology Markup Language) that requires interpretation prior to simlation, or code that can be 
directly simulated in languages such as Python, MATLAB or Mathematica. Unfortunately, the programmatic 
depiction of mathematical expressions does not lend itself well to legibility, as the combination of forward 
slashes, asterisks, and nested parentheses can quickly accumulate to render previously elegant expressions 
almost indecipherable to the human eye. This problem is most often encountered when dealing with rate 
equations, which will typically contain the bulk of mathematical expressions used in a model. 
A Graphical User Interface (GUI) based approach to viewing the structure of a model’s rate equations 
becomes increasingly desirable as the size and complexity of the model grows. This is due to several reasons. 
i. Comprehension and legibility. As described above, the programmatic implementation of 
mathematical expressions, especially intricate and complex expressions, can produce illegible lines 
of code that lend themselves more to misinterpretation and confusion than insight and understanding. 
Furthermore, attempting to edit and modify such code can quickly and easily lead to a frustrating 
experience attempting to find an obscure variable or a missing parenthesis. Fortunately, Mathematica 
has some built-in features that facilitate the neat expression of mathematical code, such as use of a 
division bar or superscript notation for exponents. With more lengthy expressions, however, these 
formatting measures are automatically abandoned by the program as it attempts to fit the entire 
expression within the limits of the display window. 
ii. Accessibility. Model source code, especially that which has been recently imported from an online 
database or converted from another format, is usually not formatted or organised in such a way that 
particular parts of the model can be found in an easy or intuitive manner. For example, a new model 




separate components. Another difficulty is the lack of sorting or organisation, whereby lists of 
variables, rates and parameters are not sorted alphabetically (or according to any other ordering 
schema), making the identification of a particular variable a frustrating exercise in chance as one 
hopes that it lies close to wherever one chooses to start reading. 
iii. Troubleshooting. The occurrence of human error becomes virtually unavoidable as the size and 
complexity of a model grows. This becomes especially problematic when the error is relatively 
minor and difficult to spot, such as accidentally entering a stoichiometric coefficient as negative 
instead of positive. Additionally, such missteps may not be readily apparent upon simulation, and 
can produce apparently sane outputs that are only identified as erroneous upon later, more detailed 
analysis. Unless the structure and composition of the model is presented in a clear, unambiguous 
manner, finding the error can become an intensely frustrating and laborious exercise. 
With this rationale in mind, and considering the standardised PARVIO model structure described above, a 
GUI-based interface for viewing model rate equations should ideally have the following features: 
i. Standard mathematical format. The mathematical expressions of the model should be parsed in 
such a way that the output resembles the notation used in scientific publications as closely as 
possible. This includes the use of fraction bars, superscript notation for exponents, and appropriate 
use of parenthesis. Additionally, redundant information should be omitted for brevity and 
conciseness. For example, should all of the variables and terms of a given rate equation begin with 
the same prefix, the prefix should be truncated to minimise the use of space. 
ii. Display of substrate, product and modifier stoichiometry. Each rate equation will have at least 
one substrate or product with its associated stoichiometric coefficient. Most rate equations will have 
at least one substrate and one product, each with its own corresponding stoichiometric coefficient. 
However, some rate equations may have several substrates, several products, as well as modifiers 
mediating inhibition or activation. Thus, all of these variables should be presented in a way that 
clearly states their stoichiometric relationship with the rate in question. 
iii. Display of relevant assignments. Owing to the essential and ubiquitous use of assignment 
expressions in the construction of rate equations, any assignment rules that form part of a rate 
equation should be presented alongside the information listed above. The right-hand side of the 
assignment rules should also be expressed in the same clear mathematical notation as that used for 
the rate equation. Additionally, since these assignments could be composed of their own sub-
assignments, any and all relevant sub-assignments should also be included. 
iv. Display of relevant parameters. Apart from stoichiometric coefficients, the quantitative properties 




Thus, the name and value of every relevant parameter should be displayed. This includes any 
parameters that form part of the rate equation’s assignments. 
v. Display of indexes. Every non-numeric entity that forms part of a rate equation can be identified by 
its index, i.e. its sequential position in the model’s source code once that latter has been sorted 
alphabetically. For example, the index of B in the sequence A, B, C will be 2.  
vi. Ease of navigation. Navigating between different rate equations and/or compartments should be 
facilitated by use of a drop-down menu, a tab-based interface, or a combination thereof. 
vii. Efficient parsing and rendering. As the model may contain hundreds of rate equations and 
assignments, each of which has to be processed individually, the process can become 
computationally expensive and slow. Thus, code should be optimised to minimise the time and 
resources spent. 
Instead of showing the several hundred lines of code used to produce the GUI output shown in Fig. A.3, a 
terse, conceptual explanation will be given here, using Fig. A.2 as an aid. First, since model development 
often involves small, iterative changes to a larger model, it is more expedient to check an existing, previously 
parsed array for changes, than to process an entirely new object from the beginning. Thus, the program first 
checks to see if any changes that would affect the final output are present. If an array already exists, and no 
changes are present, the program immediately provides the existing output. If changes are present, the 
program parses the input PARVIO into its irreducible components, and compares each of these with the 
existing array to detect any modifications, additions, or removals. These changes are recorded, and used as 
input for another function that makes the necessary changes to the existing array to produce an updated array 
that is subsequently submitted for rendering and output. In the case where no previous array is present, the 
program defaults to a routine involving the parsing and rendering of the relevant assignment and rate 





Figure A.2: Program flowchart for rate visualisation functions 
The process of parsing and rendering individual assignment and rate expression involves converting the 
clear, legible mathematical format of the expression to an image file, which is subsequently viewed in the 
GUI interface. Furthermore, the parameters that form part of each expression, as well as their respective 
values, are parsed and displayed alongside the appropriate expression. Finally, the program also checks for 
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Figure A.3: Example output of the rate visualisation GUI. Label 
numbers are according to features listed above for a GUI-based interface 





A.2.2 Timecourse Visualisation 
An integral part of computational systems biology is being able to view how variables change over time, 
whether these variables be concentrations of metabolites, the relative rates of fluxes, or the state of terms 
controlling rates dynamically as a function of other rate components. Practical examples would include 
examining how the concentration of glycogen within a system decreases over time in response to fasting; 
how the flux of a bidirectional transporter could change between positive and negative as the relative 
compartmental concentrations of its substrate change, and how plasma insulin levels rise as a result of 
increasing blood glucose concentrations.  
The most common approach with regards to timecourse visualisation is the use of a variable vs time plot, a 
line graph depicting how the value of a given variable changes as a function of time. While this sounds 
straightforward, and is indeed relatively simple to implement in Mathematica, it comes with multiple caveats 
and nuances that, unless considered and addressed, will quickly frustrate the process of examining the model 
visually, especially once it starts to grow in size and complexity.  
These issues became apparent early in the modelling process. As the number of metabolites, fluxes, and 
other dynamic entities grew, it was decided that the best course of action would be to code a rudimentary set 
of functions that could automatically discern the best way to present model components, while still being 
configurable by user input via a GUI. These functions have been modified and developed over time to form a 
suite of utilities that can effectively address the needs of routine model simulation. 
It was found that the most suitable method for plotting simulation outputs was to do this on a per-species 
basis. In other words, for every dynamic variable, the corresponding output would include information 
regarding its identity, initial values, and plots of its change in magnitude over time, after which other 
elements would be parsed and displayed, specifically the fluxes responsible for dictating the turnover of that 
particular entity. 
During the course of this thesis, several features were identified that would be useful in viewing the outputs 
of model simulations as part of a GUI-based approach. They are listed below: 
i. Easy identification of plotted variables. Unless less than a handful of variables are being plotted, 
either on the same or separate graphs, it will be extremely difficult to discern which plot corresponds 
to which entity. While this concern may sound obvious, it can nevertheless quickly and unexpectedly 
emerge when visualising multiple entities, such as the concentrations of metabolites in a pathway. 
Thus, each plot should be accompanied by at least the name of the dependent variable, preferably 
accompanied by further information such as its index and compartment (if applicable). Furthermore, 
the minimum value of the y-axis should be defined as zero, since the magnitude of a given chemical 
species becoming negative indicates a fault or error in the model, and can be quickly discerned by 




ii. Concise display of relevant fluxes. Similar to the utility of having the relevant substrates, products 
and modifiers shown as part of rate display, the ability to view the names, indexes and stoichiometry 
of the set of rates governing the turnover of a particular metabolite at a glance is similarly useful. 
The value of stoichiometric coefficients is particularly important, since this is not readily apparent as 
part of a plot. 
iii. Plotting species mass and concentration. In cases where chemical species are not defined 
exclusively in terms of concentration, it is useful to be able to view plots of both the change in mass 
and concentration of a variable over time. 
iv. Plots of relevant fluxes. The magnitude of each variable over time is a function of its associated 
inputs or outputs, or, in the case of biochemical models, the rates at which it is produced and 
consumed. Thus, the activity of the associated rates should be shown, complete with their indexes, 
names, and a means by which their relationship with the variable (i.e. positive or negative 
stoichiometric coefficients) can be discerned. Furthermore, since reversable reactions can freely 
change between positive and negative values, the range of the y-axis should be automatically 
configured to accommodate this, while still showing the position of the x-axis to discern the relative 
degree to which the rate becomes positive or negative. 
v. Ease of navigation. Models can involve dozens, and sometimes hundreds of variables, some of 
which can be the same chemical species present in different compartments. Thus, the ability to 
quickly and easily navigate to a desired variable is essential. 
vi. Efficient computation and rendering. Since multiple variables can depend on the same rate with 
the same stoichiometry, identical rate plots can potentially be produced repeatedly if outputs are 
generated on a per-variable basis. Therefore, when processing a list of variables, the code should 
render each unique rate plot only once, and then produce copies for each relevant variable. This 
optimisation becomes especially important with large, complex models, and can significantly reduce 
computation time. 
As in Section A.2.1, a conceptual explanation of the programmatic implementation of timecourse 
visualisation will be given here, using Fig. A.5 as a visual aid and Fig. A.6 as an example output. 
Computation begins with the submission of a multi-level, nested array with three major components: the 
PARVIO, the numeric solutions for the ODEs specified in the PARVIO, and the upper bound of the time for 
which the solutions were obtained. Thereafter, the ODEs are parsed to identify all unique pairs of 
stoichiometric coefficients with their accompanying rates, since each of these pairs will be plotted at least 
once as part of the final output. This identification of unique pairs is part of the optimisation process 




To illustrate, let us consider the case of v2 in Fig. A.1. This rate affects the amount of metabolites A and B, 
thus the respective GUI output for each of these variables will both contain a plot of v2. In the case of 
metabolite A, v2 has a negative stoichiometric coefficient, and a positive one in the case of metabolite B. 
This will thus produce two different plots of the same rate each with the appropriate stoichiometric 
coefficient. However, let us consider a situation with a hypothetical metabolite D, that is also formed by v2, 
uses metabolite A as substrate, and has the same set of stoichiometric coefficients (Fig. A.4). A practical 
example of this would be the reaction catalysed by aldolase (shown in Fig. 3.3). In this case, the same 
coefficient and rate pair would appear in the ODE equations for both metabolites B and D. If optimisation 
were not implemented, v2 would be parsed and plotted twice, producing two plot objects, one each for the 
GUI outputs of metabolites B and D. However, if this duplication were detected beforehand, as has been 
implemented in code, then the coefficient-rate pair would only need to be parsed and rendered once, thus 
saving on computational burden and time. A similar process is also applied when parsing the numerical 
values of the rates themselves before multiplication with the stoichiometric coefficient, but this will not be 
discussed here. Thus, when working with large, complex models with many branch points, such optimisation 
can significantly reduce the time taken to render simulation results and expedite analysis.   
 
Figure A.4: Example schema of a branched pathway with rate duplication. 
Once all unique coefficient-rate pairs have been identified, they are each parsed, rendered and plotted once, 
and allocated to an array. Thereafter, the plotting process is repeated for the mass and concentration 
timecourses of all dynamic variables, which are allocated to their own, separate array. With these two arrays 
in place, the GUI output can be constructed for each dynamic variable, with the relevant rate plots being 
accessed from the previously constructed array. These GUI outputs are grouped by the compartment the 





Figure A.5: Program flowchart for 
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The process of carrying out large scale metabolic control analysis (MCA) was a challenging one, and it is 




programming proficiency was at its highest. The primary source of difficulty was not necessarily the 
calculation of the sensitivity coefficients themselves, indeed, this could be accomplished with a simple, terse 
function: 
 
This function first checks to see if the wild-type denominator is zero, 
in which case it returns zero as output. Otherwise, it returns a 
sensitivity coefficient as described in Section 2.7.2 
For analysing the control coefficient of a single rate expression, or the response coefficient of a single 
parameter, the process is fairly straightforward: 
i. Provide a wild-type PARVIO, solved timecourse, and tend as input. This will usually already be 
present during the course of routine model simulations. 
ii. Determine the wild-type steady-state values for all rate expressions and chemical species. This is 
usually a quick and easy task, accomplished by simply substituting the relevant expressions with the 
variable masses obtained at t = tend. 
iii. Construction of a base argument containing all components that are not subject to perturbation. Since 
only a single model entity is to be perturbed, the set of ODEs and initial conditions can be 
substituted with the remainder of the replacement rules, thereby leaving only a single entity to be 
replaced prior to each analysis. 
iv. Pre-allocation of steady-state flux and variable arrays. For each dependent entity (for example, a flux 
or variable concentration), an array is allocated with the following elements: 




The index, name, and steady-state wild type value will already be supplied from step 2, the 
remainder of the array elements will be set to 0 by default. This sub-array forms the elements of two 
larger arrays, one for all rate expressions, and one for all variables.  
v. Computation of numerical solutions of steady-state values for variables following perturbation. 
Using the double perturbation method, two arguments are created from the base argument, each 
supplied with a fractionally increased and decreased model entity, respectively. These arguments are 




vi. Retrieval of steady-state flux and variable values. The third and fourth array elements of the sub-
array shown in step 4 are stored in memory, their values derived from substitution of the relevant 
entities by the steady-state variable masses obtained in step 5. 
vii. Computation of sensitivity coefficients. With all of the requisite elements present, the final element 
of the sub-array, the control or response coefficient, can be calculated for each flux or variable. 
However, this is only the computation required for a single perturbed rate or parameter. Should one wish, for 
example, to carry out MCA on all the rates or parameters of a model, the computational burden becomes 
substantially heavier. To illustrate, the current model at the time of writing has the following dimensions: 
 
Obtaining a numerical solution for the wild-type model takes approximately 1.5 seconds to complete: 
 
Note that this does not include any other processes, such as argument substitution or determination of steady-
state values of model entities. 
Since computation of a numerical solution usually takes up the bulk of computation time, let us assume a 
conservative estimate of 2.5 seconds for completion of steps 1-7 described above, doubling this value to 5 
seconds to account for the double perturbation. Therefore, using these values, we can calculate the length of 
time required to sequentially conduct MCA by perturbing all 266 rates of the model, which comes out to 22 
minutes and 10 seconds. 
 
Furthermore, assuming that the list of parameters selected for response analysis was reduced to a more 
reasonable length of 900, computation would be of the order of 75 minutes. 
 
While such computation times may seem acceptable, and even reasonable when compared to the amount of 
time effort required by some laboratory processes, they nevertheless remain very undesirable, for two 
important reasons. First, Mathematica does not permit more than one evaluation on the same kernel, meaning 
that one could not proceed with other work while the computation is running. Secondly, and perhaps most 
importantly, these computations are done at a single percentage parasitaemia. Since this thesis is interested in 
the metabolic dynamics across a range of parasitaemias, the multiplicative total time required would be 




Fortunately, however, this issue can be mostly overcome using parallel computation. Mathematica possesses 
built-in functionality for use of multi-core central processing units, whereby computations can be evaluated 
in parallel across multiple CPUs. The combination of CPUs can provide a platform of multiple kernels, with 
each kernel being able to process one evaluation at a time. On the machine used to conduct most of the 
analysis, 16 kernels were available. Thus, using parallel computation, the time required for obtaining 
numerical solutions could be reduced by a factor of 16.  
To implement this, during computation the program was instructed to pre-allocate a m by n array, with m 
being the number of entities perturbed and n representing the number of perturbations per entity, usually two 
(one increase, one decrease). This array, as well as the base argument, list of perturbations, and other data 
required for computation, was distributed across all kernels. Each kernel was then instructed to obtain a 
numeric solution for a perturbed model with perturbed entity i and perturbation (up or down) j, 
independently of the other kernels, and store this solution at array address (i, j). The possibility of two 
different kernels parsing the same element was eliminated by the distribution (sharing) of the array across all 
kernels simultaneously. Additional code was also written to be able to monitor the progress of the 
computation on each kernel and as a whole, in case any errors occurred during computation (Fig. A.7).  
 
Figure A.7: Example dynamic output monitoring the progress of control coefficient 
calculation 
Once the numerical solutions had been obtained, the program proceeded to obtain the perturbed, steady-state 
values of fluxes and chemical species concentrations, perform the relevant sensitivity calculations, and return 
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B.1 Rank-based Metabolic Control Analysis 
Considering the size of the model, in particular the large number of rates and parameters, a rank-based 
approach was implemented when identifying the most significant sensitivity coefficients with regards to 
steady-state concentrations of plasma glucose and lactate. This involved calculation of both control and 
response coefficients for all rates and parameters at regular percentage parasitaemia intervals. For each 
percentage parasitaemia, the control and response coefficients were ranked in descending order according to 
their absolute value. Thereafter, coefficients were selected with the criteria that they each appeared at least 
once in the top ten highest ranked coefficients for any of the percentage parasitaemias simulated. Using this 
method, 19 and 24 rates were selected as having significant control over steady-state glucose and lactate 
concentrations, respectively. For response coefficients, 32 parameters were found as having significant 
response coefficients with regards to the steady-state concentration of plasma glucose, and 34 for the steady-
state concentration of plasma lactate.  
Each set of control or response coefficients for plasma glucose or lactate were then ranked again, based on 
the area under the curve when plotting the coefficient against the percentage parasitaemia at which it is 
obtained; plots of the hepatic rates exhibiting significant control on plasma glucose and lactate concentration 
are shown below. For each plot, the alphabetical position of the rate is shown in the title on the left, with its 
ranking in parenthesis on the right. The plot markers themselves indicate whether the coefficient obtained at 
the relevant percentage parasitaemia is positive (green) or negative (red). This visual representation shows 
how the magnitude of a particular coefficient changes as a function of parasite burden.  
B.1.1 MCA of the Hepatic Compartment 
As shown by the results presented below, the hepatic lactate transporter displayed strong positive and 
negative control over steady-state plasma glucose and lactate concentrations, respectively. The hepatic 
compartment yielded two rates with significant control coefficients across all data sets: the lactate 
transporter, ranked 13th, and glucokinase, ranked 19th (Fig B.1). Lactate transport exerted generally 
increasing positive control over plasma glucose as parasitaemia increased. Glucokinase activity showed a 





Figure B.1: Significant plasma glucose control coefficients obtained from rate expressions in the hepatic 
compartment. Green markers indicate positive control, red markers indicate negative control 
The hepatic compartment yielded a single significant control coefficient on plasma lactate, specifically that 
relating to the rate of transport of lactate into and out of the hepatic compartment (Fig. B.2). The control 
exhibited by this rate has an initial maximum in the uninfected state, which declines and reaches a second, 
lower peak at approximately 1% parasitaemia, thereafter decreasing rapidly. 
 
Figure B.2: Significant plasma lactate control coefficients obtained from rate 
expressions in the hepatic compartment. Red markers indicate negative control 
B.2 Metabolic Contribution of Other Organs 
The concomitant presence of both hypoglycaemia and hyperlactataemia in patients with severe P. falciparum 
malaria appears paradoxical at first. Considering the fact that lactate usually accounts for over half of all 
gluconeogenic substrates in the healthy individual (43), the occurrence of low blood sugar despite the 
overabundance of this precursor points to a fault in the host’s gluconeogenic capacity. Indeed, the most 
intuitive and elegant situation in this regard would be to rectify the host’s limited capacity to convert lactate 
to glucose, thereby solving both problems at once. Since the liver is known to carry out the majority of 
gluconeogenesis under normal circumstances, it was initially hypothesized that both the cause of, and 
solution to, simultaneous hypoglycaemia and lactic acidosis would be explained by aberrations of hepatic 




the presence of phenomenological parasite inhibition mechanisms, it is still capable of maintaining 
considerable levels of gluconeogenesis, we now turn to examination of the remaining compartments. 
B.2.1 Brain Metabolism 
 




The relative contributions of the various compartments to plasma lactate turnover are shown in Figure B.4. 
The graph for infected erythrocyte lactate flux appears similar to that of glucose, with export of lactate into 
plasma increasing as what would appear to be a slightly hyperbolic function of percentage parasitaemia. 
Removal of lactate from plasma by the liver appears to remain almost static at 20% across all significant 
parasitaemia values. Renal excretion of lactate shows a sigmoid relationship with increasing parasitaemia, 
reaching a plateau of approximately 13% at around 10% parasitaemia. The respective graphs for lactate 
export and import by the muscle and brain compartments appear roughly equal and opposite, with initial 
values of 30-35% declining to around 20% at maximal parasitaemia. At lower levels of parasitaemia, these 
results place the brain ahead of the liver in terms of the contribution to plasma lactate uptake. 
 
Figure B.4: Relative contributions of fluxes to plasma lactate concentration at steady state. 
Calculations and colour schemes are identical to Fig. 4.5. 
The discovery that the brain was not only a net importer of lactate, but accounted for the majority of lactate 
clearance upon infection (Fig. B.4), was very unexpected. As stated in the literature review, the 
contemporary consensus surrounding whole-body lactate clearance attributes the overwhelming majority 
thereof to the two major gluconeogenic organs, the liver and kidney, with the heart a distant third. However, 
while this is generally the case under typical, resting conditions, the brain is capable of importing lactate 
when its plasma concentration becomes substantially elevated; this influx of lactate can provide up to 30% of 
cerebral energy requirements via eventual oxidation through the TCA cycle (199–202). The dearth of 
discussion regarding cerebral lactate uptake is likely due to both its characterization as an organ that 
exclusively prefers oxidative carbohydrate catabolism, and the uncertainty and debate surrounding the exact 




To further investigate the influence of brain metabolism on plasma glucose and lactate concentrations, we 
can consider the results obtained from metabolic control analysis. 
Four rates from the brain compartment produced control coefficients that were deemed significant with 
regards to plasma glucose. Three rates exerted negative control over plasma glucose, namely hexokinase, 
phosphocreatine hydrolysis and ATPase activity, ranking 4th, 11th, and 14th, respectively (Fig. B.5). The 
remaining rate, denoting phosphocreatine synthesis, exhibited positive control, and was ranked 12th.  
 
Figure B.5: Significant plasma glucose control coefficients obtained from rate expressions 
in the brain compartment 
Six rates from the brain compartment were identified as having significant control over plasma lactate, with 
brain ATP hydrolysis and hexokinase ranking first and third for highest control overall (Fig B.6). 
Furthermore, all six rates featured ATP as either substrate or product; whether ATP was produced or 
consumed as part of the reaction did not appear to predict whether the resultant control would be positive or 
negative. A notable feature of these trends is the 6-8% percentage parasitaemia at which a minimal plateau is 
reached; the control coefficients obtained for plasma glucose for the corresponding rates initiate a steep 
upwards slope at this approximately this same interval. Of interest is the change in sign of response at 
approximately 11% parasitaemia for the two reactions mediating phosphocreatine turnover. 
In addition to the flux observations, the significance of brain metabolism in mediating plasma glucose and 
lactate levels can be inferred from MCA results. Brain hexokinase activity displayed significant negative and 
positive control over steady-state plasma glucose and lactate levels, respectively (Figs. B.6 & B7). These 
findings underscore the brain’s continued reliance on glucose as a metabolic fuel, despite the metabolic 





Figure B.6: Significant plasma lactate control coefficients obtained from rate expressions 
in the brain compartment. Note the switch from positive to negative response at 
approximately 11% parasitaemia for phosphocreatine flux. 
When examining the sensitivity of plasma lactate to model components in the brain compartment, a pattern 
emerges that points towards the importance of the brain’s use of lactate as a supplemental fuel. Oxidative 
phosphorylation exerts negative control over plasma lactate, while TCA cycle activity shows positive control 
(Fig. B.6). Additionally, substrate affinity parameter responses for plasma lactate are positive in the case of 
phosphate in oxidative phosphorylation, and negative for phosphate and acetyl-CoA in TCA cycle activity 
(Fig. B.7).  
Response coefficients obtained from brain parameters with regards to lactate share an early peak at low 
levels of parasitaemia (Fig. B.7). The substrate affinity constant for ATP in cerebral ATPase activity ranks 
particularly high, showing positive response. The remainder of the positive response coefficients are 
relegated to phosphate’s Michaelis-Menten constants of ATP for oxidative phosphorylation and creatine for 
phosphocreatine synthesis. Negative response coefficients all rank lower in comparison, particularly with 





Figure B.7: Significant plasma lactate response coefficients with regards to parameters comprising 
kinetic expressions located in the brain compartment.  
Affinity constants, in this case the KM values for phosphate and acetyl-CoA, having a negative response 
coefficient with respect to plasma lactate indicate that the brain TCA cycle activity is proportional to steady-
state plasma lactate concentrations. These findings agree with the positive control coefficient of TCA cycle 
activity, since an increased KM translates to reduced substrate affinity, which results in decreased reaction 
velocity. How do these results translate to an increased steady-concentration of plasma lactate as TCA cycle 
activity increases? For an irreversible reaction at steady state, the substrate concentration is inversely 
proportional to the maximal rate velocity, since as VMAX increases, the amount of substrate required to 
produce a flux equal to adjacent reactions decreases. Thus, as the steady-state concentration of acetyl-CoA 
decreases with increasing steady-state TCA cycle flux, so, too, does the amount of pyruvate. Therefore, the 
dependence of TCA cycle activity on pyruvate decreases, and the system becomes less reliant on the import 




The negative control coefficients of the ATP hydrolysis and oxidative phosphorylation reactions for both 
glucose and lactate support this line of evidence. ATP hydrolysis activity produces ADP and phosphate, two 
substrates required for TCA cycle activity. Thus, as the activity of these two processes increases, the demand 
for acetyl-CoA, pyruvate, and lactate increases, resulting in increased lactate uptake from the plasma 
compartment. Oxidative phosphorylation activity’s negative control coefficient could likely be due to its 
provision of ATP for subsequent hydrolysis; its lower rank (19th vs 1st for ATP hydrolysis) supports the 
notion of its indirect negative control. 
Besides net lactate import, another unexpected behaviour was observed during model simulations: net 
pyruvate export by the brain. Simulations show that, in the infected state, pyruvate export from the brain into 
the plasma compartment accounts for approximately 30% of negative pyruvate flux at steady state. This 
behaviour could perhaps be explained by the system attempting to favour the oxidative component of LDH 
activity by mass action, thereby providing additional NAD+ that can be used as part of TCA cycle activity. 
The results obtained from this model therefore indicate that the brain plays a significant function in limiting 
the rise of plasma lactate to pathologically high levels, through its use of lactate as a supplemental fuel 
during hypoglycaemia. This result was unexpected, and could possibly be a result of how the model was 
structured, rather than a physiological reality. Nevertheless, further investigation determining the 
significance and validity of these results is certainly warranted. 
B.2.2 The Involvement of Skeletal Muscle 
Skeletal muscle proved to be a difficult compartment to model within the context of this thesis. Even within 
the generalized, simplified framework of Kim et al.’s (16) description, carbohydrate, protein, and lipid 
metabolism are included (Fig. B.8). As explained in the methods section, only pathways directly involving 
glucose catabolism could be included, thereby precluding the model from analysing the dynamic behaviour 
and effect of noncarbohydrate metabolism in skeletal muscle. The possible dynamic interactions of muscular 
protein and lipid metabolism with the altered levels of plasma glucose and lactate would have been 
interesting to determine. However, having recognized these limitations, several conclusions can still be 





Figure B.8: Pathway diagram of muscle carbohydrate metabolism as described in the 
model. Grey species and rates denote clamped variables and processes. 
Skeletal muscle is a metabolically complex organ capable of utilizing numerous pathways for free energy 
production under different physiological states. A comprehensive review of the endpoints of muscular 
glucose metabolism can unfortunately not be included here, and therefore it was considered reasonable to 
assume here the reductionist view that, in both healthy and diseased states, skeletal muscle is generally a net 
exporter of lactate, exhibiting a preference for anaerobic glycolysis over oxidative catabolism. 
Use of such a simplified view is indeed propitious when considering the observations showing skeletal 
muscle’s substantial contribution to plasma lactate levels, particularly in response to increasing parasitaemia. 
Simulations show an approximate 15% increase in skeletal muscle’s contribution to plasma lactate flux from 
the healthy state to nascent infection (Fig. B.4, 0.1% parasitaemia).  
As a whole, the simulation results for the skeletal muscle compartment indicate a strong preference for 




muscle exhibits net import of glucose and pyruvate, and net lactate export, demonstrating lactate to be the 
favoured metabolic terminus. Hexokinase activity, the process responsible for committing glucose to muscle 
compartment metabolism, shows strong negative and positive control over plasma glucose and lactate, 
respectively (Figs. B.9 & B.10).  
 
Figure B.9: Significant plasma glucose control coefficients obtained from rate expressions 
in the skeletal muscle compartment 
The collection of rates in skeletal muscle exerting significant control over plasma glucose appeared to cover 
the entirety of oxidative glucose catabolism, and showed particularly similar trends, with the shapes of the 
graphs becoming near identical above 6% parasitaemia (Fig B.9).  Negative control was observed for initial 
glucose phosphorylation and the lumped oxidative phosphorylation and TCA cycle pathways; ATPase 
activity showed positive control over steady-state plasma glucose concentration, with a shallow trough 





Figure B.10: Significant plasma lactate control coefficients obtained from rate expressions 
in the skeletal muscle compartment 
Six rates from the skeletal muscle compartment showed significant control over steady-state lactate 
concentration. Four of these six rates comprised the entirety of fluxes mediating significant control over 
plasma glucose, namely ATPase activity, phenomenological hexokinase activity, and the lumped oxidative 
phosphorylation and TCA cycle pathways (Fig B.10). Of these, only one has changed sign; ATP hydrolysis, 
oxidative phosphorylation, and the lumped TCA cycle appear to exert negative control on the steady-state 
plasma concentrations of both glucose and lactate, albeit with differing magnitudes and distributions across 
the parasitaemia datasets. Similar to the graphs obtained for plasma glucose, plots of plasma lactate control 
coefficients appear remarkably similar in shape across the differing rates, regardless of sign. A peak in 
absolute magnitude is reached at approximately 1% parasitaemia, which then declines hyperbolically with an 
inflection point situated at approximately 3.5%. A change in sign is observed for the lumped TCA cycle and 
hexokinase activity, occurring at relatively high parasitaemias.  
Furthermore, a greater portion of G6P, the product of hexokinase activity, undergoes glycolysis instead of 




glycogen storage (Fig. B.11). Muscle glycogen content decreases rapidly from an initial 1534 mM to 400 
mM at approximately 1.5% parasitaemia, after the graph assumes a less steep slope, which proceeds roughly 
linearly to a final minimum of 103 mM. The ratio of glycogenolysis to glycogenesis exhibits an inverted 
trend with regards to muscle glycogen concentration, rapidly increasing from 0.233 to 0.800 at 
approximately 1.5%, after which it gradually increases to a final maximum of 0.973. 
 
Figure B.11: Components of skeletal muscle glycogen metabolism simulated at varying 
parasitaemias, measured at steady-state. (A) Muscle glycogen concentration (B) The rate of 
glycogenesis (GGS) (C) The rate of glycogenolysis (GGL) (D) Ratio of glycogenolysis to 
glycogenesis 
Increased partitioning of glucose utilization to glycolysis rather than gluconeogenesis is thus illustrated by 
the steady-state muscle glycogen concentration declining rapidly with increasing parasitaemia, particularly at 
parasitaemias leading up to 1.5%; and the negative control that glycogenesis exerts over plasma lactate. 
Further indirect evidence for increased catabolism vs storage is the positive control displayed by the 
irreversible conversion of G6P to GAP over plasma lactate, which irrevocably removes G6P from the 
potential glycogenic substrate pool. 
Besides glucose, another important metabolic node representing a crossroads between anaerobic glycolysis 
and other forms of oxidation is pyruvate. The steady-state concentration of pyruvate within the skeletal 
muscle compartment is determined by the activity of several fluxes, both direct and indirect (Fig. B.8). 
Positive fluxes consist of synthesis from GAP, oxidation of lactate, or import from the circulation. Oxidation 
to acetyl-CoA, reduction to form lactate, or transamination to alanine form the negative fluxes. Simulations 
show pyruvate reduction to lactate making up the majority of all negative pyruvate flux across the complete 
range of parasitaemia values (Fig. B.12). Consumption of pyruvate increases rapidly upon initial infection, 
reaching near-maximal levels at approximately 1% parasitaemia with a plateau thereafter. Pyruvate 




90% of all pyruvate catabolism across all parasitaemias. Additionally, the conversion of pyruvate to acetyl-
CoA is also upregulated, increasing the relative contribution that it makes to cellular acetyl-CoA when 
compared with production of acetyl-CoA from free fatty acids. 
 
Figure B.12: Relative contributions and fractions of fluxes mediating a decrease in muscle 
pyruvate; the flux of fatty acid oxidation (FFA→ACoA) together with its fraction with 
regards to PYR→ACoA is also shown 
Four parameters from the muscle compartment were identified as having significant response coefficients 
(Fig B.13). Two are constants mediating the control of the cellular redox state on reactions utilising 
NAD+/NADH (the separate value of ν for the oxidative phosphorylation reaction is due to a distinct 
specification by the original authors), with the constant for ATP synthesis having positive response, and the 
constant governing the remainder of the reactions displaying negative response coefficients. The parameter 
specifying the maximum degree of skeletal ATP hydrolysis upregulation by the parasite displayed a positive 
response coefficient across all parasitaemias, sharply increasing between 0% and 1.5% parasitaemia. The 
Michaelis-Menten constant for ATP in the ATP hydrolysis reaction yielded negative response coefficients 
across all parasitaemias. The significant response with regards to plasma glucose displayed by the parameter 





Figure B.13: Significant plasma glucose response coefficients with regards to parameters 
comprising kinetic expressions belonging to the skeletal muscle compartment.  
Recall that this parameter is a phenomenological affinity constant for the redox state controller, denoting the 
ratio of NADH/NAD+ required for a controller value of half. Thus, an increase in this parameter will drive 
the system towards an increased NADH/NAD+ ratio, which in this case would translate to increased lactate 
oxidation vs pyruvate reduction. This parameter shows a negative response with regards to steady-state 
plasma concentrations of both glucose and lactate (Figs. B.13 & B.14).  
The significant response coefficients for plasma lactate in the skeletal muscle compartment primarily involve 
energy- and reducing-equivalent metabolism (Fig B.14). The affinity constant of ATP for the ATP 
hydrolysis reaction shows strong negative response at early parasitaemias. The redox state controller 
constants show early peaks, with positive and negative values for the oxidative phosphorylation-specific and 
general constants, respectively. Similar to its effect on plasma glucose, the parameter determining the 
maximal degree of parasite-mediated ATP hydrolysis stimulation also shows positive responses across all 
datasets, also peaking at approximately 1.5%. However, it does not maintain this behaviour, and decreases 





Figure B.14: Significant plasma lactate response coefficients with regards to parameters 
comprising kinetic expressions belonging to the skeletal muscle compartment.  
The negative response with regards to lactate can be readily explained by diminished lactate oxidation 
activity; negative response concerning plasma glucose is likely due to the system upregulating glucose 




The remainder of the results obtained from MCA lend further credence to the notion of anaerobic glycolysis 
being the dominant pathway in skeletal muscle in the presence of severe malarial infection. The negative 
control exerted by TCA cycle and oxidative phosphorylation activity over both steady-state plasma glucose 
and lactate concentrations, together with the associated response coefficients, indicate that the muscle 
compartment responds to a decreased flux of pyruvate to lactate by increasing its uptake of glucose as a 
mass-action compensatory mechanism, to sustain pyruvate oxidation through LDH and offset the subsequent 
decreased release of lactate.  
By contrast, the positive control displayed by ATP hydrolysis activity over plasma glucose and lactate could 
demonstrate an inversion of the processes described above. The increased production of ADP provides 
additional substrate for TCA cycle and oxidative phosphorylation activity, thereby upregulating these 
processes through mass action. Furthermore, the lumped TCA cycle reaction produces NADH, which can 
subsequently be utilized by oxidative phosphorylation for synthesis of ATP and NAD+. Therefore, the 
concomitant upregulation of these processes will result in a greater flux of pyruvate through the aerobic 
pathway, thereby lessening the need for glucose uptake, and reducing the fraction of pyruvate reduced to 
lactate. The positive response exhibited by the parameter denoting maximum parasite-mediated ATPase 
stimulation (MUSCLE_PF_MOD_MAX) further supports this explanation. 
It should be noted that, in contrast to the brain compartment, the skeletal muscle includes a description of 
fatty acid oxidation, which provides acetyl-CoA, ADP, and NADH. The relatively large amount of acetyl-
CoA provided by this reaction in comparison to that produced by pyruvate oxidation (Fig. B.12) was noted 
early in the analysis stage. It stands to reason that this reaction frees up a considerable amount of pyruvate 
that can instead be oxidized to lactate, and is likely a major contributor to the preference for anaerobic 
glycolysis exhibited by the skeletal muscle compartment in this model. As mentioned previously, the 
clamped free fatty acid concentration provides an effectively constant, unlimited supply of substrate for this 
reaction, thereby precluding the useful observations that could be made with a dynamic pool of free fatty 
acids and distal metabolites. It therefore feels appropriate to reiterate the utility of unclamping these 
variables as part of possible future research. 
The findings and assertions discussed above should, however, be considered together with the limitations of 
this particular compartment as portrayed in the current model. As noted by the authors of K1 in their original 
paper, the lack of distinction between cytosolic and mitochondrial compartments substantially limits the 
predictive capacity of the model (16). This is particularly important when considering the separate 
subcellular compartments in which the reactions catalysed by lactate dehydrogenase (cytosol) and oxidative 
phosphorylation (mitochondria) take place. The absence of such a distinction also precludes the model from 
being able to accommodate separate compartments for the different skeletal muscle fibre types, each having 
their own capacity for aerobic versus anaerobic glycolytic metabolism. While the resolution of these 
limitations was judged to lie well beyond the scope of the current research, they should nonetheless be 




In summary, skeletal muscle is not capable of appreciable net glucose export or complete gluconeogenesis, 
but it has been consistently described as an important organ with regards to maintaining blood glucose 
homeostasis. This has been due to its ability to switch between net lactate export and import, and its 
contribution of alanine, a major gluconeogenic precursor, during times of catabolic stress. However, its role 
within this model has been limited to that of a major lactate exporter, theoretically exacerbated by the 
increase in anaerobic glycolysis during convulsions. Furthermore, the absence of a dynamic system of 
alanine exchange with the circulation likely hampers the descriptive power of the model, especially given the 
observations from clinical data noting disturbed amino acid metabolism (64, 198). 
B.2.3 The Role of the Kidney 
The kidney has two possible means of plasma lactate disposal: uptake for use as a gluconeogenic substrate 
(88), or excretion into the urine (106). Though this model does not feature a detailed renal compartment with 
kinetic descriptions for gluconeogenesis, a phenomenological function for renal lactate excretion was 
included. This function was implemented in such a way that renal lactate excretion only became significant 
once plasma lactate exceeded a certain threshold. This threshold was set to 6.8 mM, slightly higher than 5-6 
mM reported in literature (88). This approach appeared to work as intended (Fig. B.15), with renal lactate 
excretion remaining largely inactive below the threshold, but constituting a maximum of approximately 13% 
of plasma lactate flux once the threshold had been exceeded (Fig. B.4).  
 
Figure B.15: Renal lactate excretion flux vs steady-state 
plasma lactate concentration in the meyer1 model. 
Due to the lack of clinical data, this phenomenologically modelled renal lactate excretion was parameterized 
to fit the data, and not based on quantitative measurements of renal lactate excretion kinetics, as would 
ideally be the case. Furthermore, a committed renal compartment complete with kinetic descriptions of 
gluconeogenesis was not included. However, the single function that was implemented, though approximate, 




Parasitized erythrocytes have a particular propensity to sequester within the renal microvasculature (106), 
and the development of renal pathology, particularly malaria-associated acute renal failure, contributes to 
kidney failure as one of the three most common causes of death in severe malaria (137). Since it has been 
successfully demonstrated in the current work that the effects of microvascular obstruction can be integrated 
into existing models of organ-specific function and metabolism, the kidney is an ideal candidate for 
incorporation as part of possible future development of the model.  
In summary, within the context of metabolic acidosis, contemporary literature has often cited the kidney’s 
significant ability to carry out gluconeogenesis; the capacity of the kidney to excrete lactate during severe 
metabolic acidosis has only rarely been mentioned. Therefore, while the inclusion of a simple first-order 
renal lactate excretion function has comparatively little support in literature, within the scope of this model it 






C.1 Parasite-Mediated Changes in Host Metabolism 
In order to model the effects that P. falciparum might have on host metabolism, several terms were 
introduced into the model to inhibit or accelerate specific metabolic processes in certain compartments. 
These terms generally took on the form of Michaelis-Menten type functions, with associated values dictating 
the maximum degree of effect and the ‘affinity’ that these effects had for percentage parasitaemia. However, 
due to the lack of quantitative data with which to parameterise these functions, values were chosen 
arbitrarily, and subsequently adjusted based on visual inspection and comparison with the clinical data 
described in Section 4.1.3. Each parasite modulation parameter was varied across a range of values the 
boundaries of which were chosen based on their plausibility. Numerical solutions were obtained for each of 
these values across a range of parasitaemias encompassing the percentages described in the collated clinical 
data. Since plasma glucose and lactate concentrations comprise the only dependent variables against which 
the model outputs could be validated, plots of the steady-state values of these metabolites were produced for 
each parasite modulation parameter value and superimposed on scatter plots of clinical data. Each parameter 
value was assigned a different colour to facilitate comparison. 
The ‘default value’ specifies the parameter value used in the final model. 
C.1.1 Brain 
The percentage parasitaemia at which half-maximal cerebral perfusion would be present appeared to have 
little effect on model outputs, showing virtually no change as the parameter was varied from its default value 





Figure C.1: Changes in selected model outputs with variation of parasite-mediated 
perfusion affinity modulation parameter in the brain compartment, details presented in 
information box, top-left. The colour of each curve corresponds to simulations conducted 
with the matching parameter value. From top-right panel, left-to-right, top-to-bottom: 
plasma glucose concentration, plasma lactate concentration, glucose influx into the brain 
compartment, lactate influx into the brain compartment and pyruvate efflux out of the brain 
compartment 
By contrast, the parameter denoting the maximum degree of perfusion inhibition showed substantial changes 
in model outputs once the default value of 0.3 was increased above 0.6. Values of 0.75 and 0.9 showed 
particularly drastic alterations, though their inclusion here is mostly for the sake of interest, since it seems 





Figure C.2: Changes in selected model outputs with variation of parasite-mediated 
perfusion velocity modulation parameter. From top-right panel, left-to-right, top-to-
bottom: plasma glucose concentration, plasma lactate concentration, glucose influx into 
the brain compartment, lactate influx into the brain compartment and pyruvate efflux out 







Two parasite-mediated inhibition terms were introduced into the hepatic compartment, each having two 
parameters specifying the percentage parasitaemia producing half-maximal effect (KM), and the maximum 
magnitude of effect (MAX). As described in the Methods section, these terms were applied to rate 
expressions mediating aspects of mitochondrial metabolism and transport between the hepatic and plasma 
compartments. 
A 100-fold increase in the phenomenological KM value of parasite-mediated inhibition of selected fluxes in 
the hepatic mitochondrial compartment showed virtually no effect on the steady-state plasma concentrations 
of glucose and lactate. However, some minor shifts were seen for the plots showing the steady-state flux of 
the affected reactions. 
 
Figure C.3: Changes in selected model outputs with variation of parasite-mediated 
hypoxia ‘affinity’ modulation parameter, details presented in information box, top-left. 
Abbreviations: Trnsp Pyr Mito, mitochondrial pyruvate transporter; PDH, pyruvate 
dehydrogenase; PC, pyruvate carboxylase; O2→H2O, oxidative phosphorylation activity. 
All rates are of the hepatic compartment, influx/efflux denotes transport into/out of 






Figure C.3 (contd.): Changes in selected model outputs with variation of parasite-
mediated hypoxia ‘affinity’ modulation parameter. Abbreviations as in above. 
Variation of the maximal degree of inhibition showed more pronounced changes, although these were only 
noticeable for plasma glucose and lactate at values above 0.6. More drastic shifts were however observed for 
the affected reactions, as well as the fluxes of glucose export and pyruvate import. PDH flux, in particular, 






Figure C.4: Changes in selected model outputs with variation of parasite-mediated 





Figure C.4 (contd.): Changes in selected model outputs with variation of parasite-
mediated hypoxia maximum degree modulation parameter. Abbreviations as in Fig C.3. 
 
Increasing the KM value for parasite-mediated hepatic perfusion inhibition by a factor of 100 over several 
increments yielded a shift towards in the right for the plots of steady-state plasma concentrations of glucose 
and lactate, with the emergence of lactic acidosis in particular being delayed substantially until higher 
parasitaemias had been reached. Furthermore, the maximum fluxes of glucose, lactate and pyruvate transport 





Figure C.5: Changes in selected model outputs with variation of parasite-mediated 
perfusion affinity modulation parameter in the liver compartment. Rates are as Fig C.3. 
To ascertain the effects of varying degrees of maximum parasite-mediated perfusion inhibition, the value of 
the MAX parameter was varied between 0 (no inhibition) to 50 (its default value). The absence of perfusion 
inhibition prevented the appearance of lactic acidosis entirely, while delaying the onset of hypoglycaemia. 





Figure C.6: Changes in selected model outputs with variation of parasite-mediated 
perfusion velocity modulation parameter in the liver compartment. Rates are as in Fig. C.3. 
C.1.3 Muscle 
In contrast to the other compartments, modulation of skeletal muscle metabolism was implemented in such a 
way that the activity of a single rate expression, that describing the rate of ATP hydrolysis, would be 
accelerated in response to increasing percentage parasitaemias. 
A 25-fold increase in the phenomenological KM value of parasite-mediated upregulation of ATPase activity 
showed small, albeit noticeable, changes in the curves for plasma glucose and lactate. A value of 0.05 
(corresponding to 5% parasitaemia) appeared to eliminate the initial rise in plasma glucose concentrations at 
early parasitaemias, while simultaneously delaying the onset of hyperlactataemia. ATPase activity declined 
in response to increases in this parameter. Furthermore, a slight upwards shift was observed for glucose 





Figure C.7: Changes in selected model outputs with variation of parasite-modulation 
parameter. From top-right panel, left-to-right, top-to-bottom: plasma glucose 
concentration, plasma lactate concentration, skeletal muscle ATPase flux, glucose influx 
into the skeletal muscle compartment, lactate efflux out of the skeletal muscle 
compartment and pyruvate influx into the skeletal muscle compartment 
 
The maximum degree of parasite-mediated ATPase acceleration was varied between values of 0 (no 
upregulation) and 2 (twice the default value). With no upregulation, a downward shift is observed for both 
plasma glucose and lactate, indicating hastened onset of hypoglycaemia with a marginal decrease in the 




this parameter, with an increase of 0.5 yielding a concomitant 5 mmol/min increase in flux. Steady-state 
fluxes of glucose uptake and lactate release show approximately negative and positive proportionality with 
regards to this parameter, respectively. 
 
Figure C.8: Changes in selected model outputs with variation of parasite-mediated 
‘affinity’ modulation parameter for ATPase activity in the muscle compartment. Rates are 





C.1.4 Uninfected Erythrocytes 
Variation of the KM parameter of parasite-mediated inhibition of uninfected erythrocyte phosphofructokinase 
and pyruvate kinase activity showed little appreciable effect on plasma glucose and lactate concentrations. 
However, as the value of this parameter was increased, the slopes of the flux vs. percentage parasitaemia 
graphs could be seen to increase for not only PFK and PK, but also the rate of glucose import. 
 
Figure C.9: Changes in selected model outputs with variation of parasite-modulation term parameter, 
details presented in information box, top-left. Abbreviations: PFK, phosphofructokinase; PK, pyruvate 
kinase. From top, left-to-right, top-to-bottom: plasma glucose concentration, plasma lactate concentration, 
PFK flux, PK flux, glucose influx into the uninfected erythrocyte compartment, lactate efflux out of 
uninfected erythrocyte compartment and pyruvate efflux out of the uninfected erythrocyte compartment 
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